Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16369821,systemic clearance,"The mean irinotecan systemic clearance and steady-state volume of distribution values were 14.3 l/h/m(2) and 211 l/m(2), respectively.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),[h·l] / [m(2],14.3,1034,DB00762,Irinotecan
,16369821,steady-state volume of distribution,"The mean irinotecan systemic clearance and steady-state volume of distribution values were 14.3 l/h/m(2) and 211 l/m(2), respectively.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),[l] / [m(2],211,1035,DB00762,Irinotecan
,16369821,saliva/plasma AUC ratios,"The saliva/plasma AUC ratios averaged 1 for irinotecan, 0.3 for SN-38, 0.17 for APC and 0.27 for NPC.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),,1,1036,DB00762,Irinotecan
,16369821,saliva/plasma AUC ratios,"The saliva/plasma AUC ratios averaged 1 for irinotecan, 0.3 for SN-38, 0.17 for APC and 0.27 for NPC.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),,0.3,1037,DB00762,Irinotecan
,16369821,saliva/plasma AUC ratios,"The saliva/plasma AUC ratios averaged 1 for irinotecan, 0.3 for SN-38, 0.17 for APC and 0.27 for NPC.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),,0.17,1038,DB00762,Irinotecan
,16369821,saliva/plasma AUC ratios,"The saliva/plasma AUC ratios averaged 1 for irinotecan, 0.3 for SN-38, 0.17 for APC and 0.27 for NPC.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),,0.27,1039,DB00762,Irinotecan
,12712460,time to tumor progression (TTP),Median survival was 24 weeks; median time to tumor progression (TTP) was 6 weeks.,Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12712460/),weeks,6,1294,DB00762,Irinotecan
,12712460,TTP,"Median TTP was 2.7 months, and median survival was 8.5 months.",Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12712460/),month,2.7,1295,DB00762,Irinotecan
,17185998,clearance,The haplotype ABCC2*2 was associated with lower irinotecan clearance (28.3 versus 31.6 l/h; P=0.020).,Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185998/),[l] / [h],28.3,3593,DB00762,Irinotecan
,17185998,clearance,The haplotype ABCC2*2 was associated with lower irinotecan clearance (28.3 versus 31.6 l/h; P=0.020).,Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185998/),[l] / [h],31.6,3594,DB00762,Irinotecan
,23595344,maximum tolerated dose,"The maximum tolerated dose of irinotecan was 350 mg/m(2) for the 0 and 1 DA groups, and 200 mg/m(2) for the 2 DA group.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,350,4242,DB00762,Irinotecan
,23595344,maximum tolerated dose,"The maximum tolerated dose of irinotecan was 350 mg/m(2) for the 0 and 1 DA groups, and 200 mg/m(2) for the 2 DA group.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,200,4243,DB00762,Irinotecan
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,7.72,4244,DB00762,Irinotecan
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,5.71,4245,DB00762,Irinotecan
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,2.72,4246,DB00762,Irinotecan
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,85,4247,DB00762,Irinotecan
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,83,4248,DB00762,Irinotecan
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,97,4249,DB00762,Irinotecan
,16369746,maximum tolerable dose,"The maximum tolerable dose was 50 mg/m(2) of irinotecan, and the dose-limiting toxicity was esophagitis.",Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369746/),[mg] / [m(2],50,4587,DB00762,Irinotecan
,16369746,survival time,"Tumor response was observed in 50% of cases, and the median survival time of the 12 patients enrolled was 10.1 months, including two patients with 5-year disease-free survival.",Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369746/),month,10.1,4588,DB00762,Irinotecan
,19135530,area under the plasma concentration-time curve (AUC),"After oral irinotecan dosing, the mean area under the plasma concentration-time curve (AUC) was found to be 14.03+/-2.18 microgh/ml which was increased significantly, i.e. 61.71+/-15.0 microgh/ml when verapamil was co-administered (P<0.05).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μgh] / [ml],14.03,4808,DB00762,Irinotecan
,19135530,area under the plasma concentration-time curve (AUC),"After oral irinotecan dosing, the mean area under the plasma concentration-time curve (AUC) was found to be 14.03+/-2.18 microgh/ml which was increased significantly, i.e. 61.71+/-15.0 microgh/ml when verapamil was co-administered (P<0.05).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μgh] / [ml],61.71,4809,DB00762,Irinotecan
,19135530,maximum plasma concentration,"Similarly, the mean maximum plasma concentration of irinotecan increased from 2.93+/-0.37 microg/ml (without verapamil) to 10.75+/-1.0 microg/ml (with verapamil) (P<0.05).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μg] / [ml],2.93,4810,DB00762,Irinotecan
,19135530,maximum plasma concentration,"Similarly, the mean maximum plasma concentration of irinotecan increased from 2.93+/-0.37 microg/ml (without verapamil) to 10.75+/-1.0 microg/ml (with verapamil) (P<0.05).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μg] / [ml],10.75,4811,DB00762,Irinotecan
,19135530,AUC,"On the other hand, the intravenous irinotecan administration with verapamil resulted in small but statistically significant effect on AUC (10.76+/-2.0 to 23.3+/-3.8 microgh/ml; P<0.05) and systemic clearance (1206.4+/-159.7 to 713.5+/-78.2 ml/(hkg)).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μgh] / [ml],10.76,4812,DB00762,Irinotecan
,19135530,AUC,"On the other hand, the intravenous irinotecan administration with verapamil resulted in small but statistically significant effect on AUC (10.76+/-2.0 to 23.3+/-3.8 microgh/ml; P<0.05) and systemic clearance (1206.4+/-159.7 to 713.5+/-78.2 ml/(hkg)).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μgh] / [ml],23.3,4813,DB00762,Irinotecan
,19135530,systemic clearance,"On the other hand, the intravenous irinotecan administration with verapamil resulted in small but statistically significant effect on AUC (10.76+/-2.0 to 23.3+/-3.8 microgh/ml; P<0.05) and systemic clearance (1206.4+/-159.7 to 713.5+/-78.2 ml/(hkg)).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[ml] / [hkg],1206.4,4814,DB00762,Irinotecan
,19135530,systemic clearance,"On the other hand, the intravenous irinotecan administration with verapamil resulted in small but statistically significant effect on AUC (10.76+/-2.0 to 23.3+/-3.8 microgh/ml; P<0.05) and systemic clearance (1206.4+/-159.7 to 713.5+/-78.2 ml/(hkg)).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[ml] / [hkg],713.5,4815,DB00762,Irinotecan
,19135530,percent,"The mean percent of irinotecan excreted into bile over 5h following intravenous and oral administration was found to be 8% and 1%, respectively, which was further reduced to half when treated with verapamil.","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),%,8,4816,DB00762,Irinotecan
,19135530,percent,"The mean percent of irinotecan excreted into bile over 5h following intravenous and oral administration was found to be 8% and 1%, respectively, which was further reduced to half when treated with verapamil.","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),%,1,4817,DB00762,Irinotecan
,24820348,RD,The RD for the phase II study was thus determined to be 90 mg/m(2).,A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with anthracyclines and taxanes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24820348/),[mg] / [m],90,5602,DB00762,Irinotecan
,24820348,response rate,The response rate was 41.7%.,A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with anthracyclines and taxanes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24820348/),%,41.7,5603,DB00762,Irinotecan
,32474564,OS,"The median PFS was 10.2 months (95%CI 8.8-14.3) and 10.0 months (95%CI 7.4-11.0), and the median OS was 29.7 months (95%CI 22.9-43.9) and 28.8 months (95%CI 18.4-ND), respectively (p = 0.3758, p = 0.8234).",Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32474564/),month,29.,6333,DB00762,Irinotecan
,32474564,OS,"The median PFS was 10.2 months (95%CI 8.8-14.3) and 10.0 months (95%CI 7.4-11.0), and the median OS was 29.7 months (95%CI 22.9-43.9) and 28.8 months (95%CI 18.4-ND), respectively (p = 0.3758, p = 0.8234).",Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32474564/),month,28.8,6334,DB00762,Irinotecan
,12576438,MTD,The MTD for irinotecan administered in combination with cisplatin (30 mg/m(2)) was 50 mg/m(2).,Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),[mg] / [m],50,7517,DB00762,Irinotecan
,12576438,maximum plasma concentrations (C(max)),"The maximum plasma concentrations (C(max)) for free cisplatin and WR-1065 were 4.5 +/- 1.6 micro M and approximately 89 +/- 10 micro M, respectively.",Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),μM,4.5,7518,DB00762,Irinotecan
,12576438,maximum plasma concentrations (C(max)),"The maximum plasma concentrations (C(max)) for free cisplatin and WR-1065 were 4.5 +/- 1.6 micro M and approximately 89 +/- 10 micro M, respectively.",Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),μM,89,7519,DB00762,Irinotecan
,12576438,half-life (t(1/2)),The half-life (t(1/2)) for free plasma cisplatin was 25.4 +/- 5.4 min.,Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),min,25.4,7520,DB00762,Irinotecan
,12576438,initial t(1/2),The initial t(1/2) for plasma WR-1065 was approximately 7 min and terminal t(1/2) approximately 24 min.,Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),min,7,7521,DB00762,Irinotecan
,12576438,terminal t(1/2),The initial t(1/2) for plasma WR-1065 was approximately 7 min and terminal t(1/2) approximately 24 min.,Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),min,24,7522,DB00762,Irinotecan
,8033091,biliary indexes,"Nine patients with grade 3-4 diarrhea had higher biliary indexes than 12 patients with grade 0-2 diarrhea (median 2228 versus 5499, P = 0.0004).",Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033091/),,2228,7613,DB00762,Irinotecan
,8033091,biliary indexes,"Nine patients with grade 3-4 diarrhea had higher biliary indexes than 12 patients with grade 0-2 diarrhea (median 2228 versus 5499, P = 0.0004).",Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033091/),,5499,7614,DB00762,Irinotecan
,27061418,MTD/RD,"The MTD/RD of a Q21D regimen was determined to be 28 mg/m(2) where the dose-limiting toxicity is myelosuppression, which appears to be cumulative and limits timely subsequent dosing.","A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27061418/),[mg] / [m(2],28,7642,DB00762,Irinotecan
,25577133,MTD,MTD was determined as 120 mg/m(2).,Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25577133/),[mg] / [m(2],120,9087,DB00762,Irinotecan
,25577133,MTD,"The MTD of PEP02 monotherapy at 3-week interval is 120 mg/m(2), which will be the recommended dose for future studies.",Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25577133/),[mg] / [m],120,9088,DB00762,Irinotecan
,19060478,progression-free survival,"Median survival was 16.6 months, while median progression-free survival was 6.2 months.",A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19060478/),month,6.2,9310,DB00762,Irinotecan
,29216585,Total analytical run time,Total analytical run time was 17min.,Determination of irinotecan and its metabolite SN-38 in dried blood spots using high-performance liquid-chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29216585/),min,17,9528,DB00762,Irinotecan
,18414865,AUC,"Among patients treated with a constant capecitabine dose of 450 mg bid, there was a higher mean AUC of 5-FU in women than in men (mean +/- SD: 892 +/- 287 nM h vs. 537 +/- 182 nM h; Mann-Whitney two-tailed, P = 0.02).","Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18414865/),h·nM,892,10721,DB00762,Irinotecan
,18414865,AUC,"Among patients treated with a constant capecitabine dose of 450 mg bid, there was a higher mean AUC of 5-FU in women than in men (mean +/- SD: 892 +/- 287 nM h vs. 537 +/- 182 nM h; Mann-Whitney two-tailed, P = 0.02).","Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18414865/),h·nM,537,10722,DB00762,Irinotecan
,14997342,distribution half-life,Disappearance of the lactone form from the plasma was biexponential with a mean distribution half-life of 57.5 min (CV +/-33%) and an elimination half-life of 457 min (CV +/-24%).,Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14997342/),min,57.5,10905,DB00762,Irinotecan
,14997342,elimination half-life,Disappearance of the lactone form from the plasma was biexponential with a mean distribution half-life of 57.5 min (CV +/-33%) and an elimination half-life of 457 min (CV +/-24%).,Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14997342/),min,457,10906,DB00762,Irinotecan
,14997342,volume of distribution for the central compartment,The volume of distribution for the central compartment was 1.36 l/kg (CV +/-27%) and clearance from the central compartment was 10.6 ml/kg per minute (CV +/-28%).,Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14997342/),[l] / [kg],1.36,10907,DB00762,Irinotecan
,14997342,clearance from the central compartment,The volume of distribution for the central compartment was 1.36 l/kg (CV +/-27%) and clearance from the central compartment was 10.6 ml/kg per minute (CV +/-28%).,Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14997342/),[ml] / [kg·min],10.6,10908,DB00762,Irinotecan
,14997342,peripheral compartment volume of distribution,The peripheral compartment volume of distribution was 1.96 l/kg (CV +/-8.4%).,Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14997342/),[l] / [kg],1.96,10909,DB00762,Irinotecan
,14997342,Peak CSF lactone concentration,"Peak CSF lactone concentration, which occurred at 12 to 25 min after the end of the infusion, was 0.33 n M (CV +/-71%).",Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14997342/),M·n,0.33,10910,DB00762,Irinotecan
,19147776,progression-free survival,"Among 15 colorectal cancer patients (10 with prior irinotecan), the calculated median progression-free survival was 5.4 months; 11 patients (72.7%) achieved disease control and 2 patients (13%) had partial response.","Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19147776/),month,5.4,12099,DB00762,Irinotecan
,15014016,steady-state concentration,"Indeed, the steady-state concentration of irinotecan, SN-38, and SN-38glu were 42.7 +/- 25.2, 14.9 +/- 1.9, and 31.7 +/- 3.5 nmol/liter, respectively, and the area under the time-concentration curves of irinotecan, SN-38, and SN-38glu were 6.94 +/- 0.41, 1.92 +/- 0.30, and 4.23 +/- 0.52 hx micro mol/liter, respectively.",A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014016/),[nM] / [l],42.7,12481,DB00762,Irinotecan
,15014016,steady-state concentration,"Indeed, the steady-state concentration of irinotecan, SN-38, and SN-38glu were 42.7 +/- 25.2, 14.9 +/- 1.9, and 31.7 +/- 3.5 nmol/liter, respectively, and the area under the time-concentration curves of irinotecan, SN-38, and SN-38glu were 6.94 +/- 0.41, 1.92 +/- 0.30, and 4.23 +/- 0.52 hx micro mol/liter, respectively.",A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014016/),[nM] / [l],14.9,12482,DB00762,Irinotecan
,15014016,steady-state concentration,"Indeed, the steady-state concentration of irinotecan, SN-38, and SN-38glu were 42.7 +/- 25.2, 14.9 +/- 1.9, and 31.7 +/- 3.5 nmol/liter, respectively, and the area under the time-concentration curves of irinotecan, SN-38, and SN-38glu were 6.94 +/- 0.41, 1.92 +/- 0.30, and 4.23 +/- 0.52 hx micro mol/liter, respectively.",A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014016/),[nM] / [l],31.7,12483,DB00762,Irinotecan
,15014016,area under the time-concentration curves,"Indeed, the steady-state concentration of irinotecan, SN-38, and SN-38glu were 42.7 +/- 25.2, 14.9 +/- 1.9, and 31.7 +/- 3.5 nmol/liter, respectively, and the area under the time-concentration curves of irinotecan, SN-38, and SN-38glu were 6.94 +/- 0.41, 1.92 +/- 0.30, and 4.23 +/- 0.52 hx micro mol/liter, respectively.",A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014016/),[h·μmol] / [l],6.94,12484,DB00762,Irinotecan
,15014016,area under the time-concentration curves,"Indeed, the steady-state concentration of irinotecan, SN-38, and SN-38glu were 42.7 +/- 25.2, 14.9 +/- 1.9, and 31.7 +/- 3.5 nmol/liter, respectively, and the area under the time-concentration curves of irinotecan, SN-38, and SN-38glu were 6.94 +/- 0.41, 1.92 +/- 0.30, and 4.23 +/- 0.52 hx micro mol/liter, respectively.",A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014016/),[h·μmol] / [l],1.92,12485,DB00762,Irinotecan
,15014016,area under the time-concentration curves,"Indeed, the steady-state concentration of irinotecan, SN-38, and SN-38glu were 42.7 +/- 25.2, 14.9 +/- 1.9, and 31.7 +/- 3.5 nmol/liter, respectively, and the area under the time-concentration curves of irinotecan, SN-38, and SN-38glu were 6.94 +/- 0.41, 1.92 +/- 0.30, and 4.23 +/- 0.52 hx micro mol/liter, respectively.",A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014016/),[h·μmol] / [l],4.23,12486,DB00762,Irinotecan
,23136196,MTD,The MTD was 115 mg/m(2) for the w × 3q4w schedule and 145 mg/m(2) for both the q14d and q21d schedules.,"A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136196/),[mg] / [m(2],115,14184,DB00762,Irinotecan
,23136196,MTD,The MTD was 115 mg/m(2) for the w × 3q4w schedule and 145 mg/m(2) for both the q14d and q21d schedules.,"A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136196/),[mg] / [m(2],145,14185,DB00762,Irinotecan
,23136196,half-life,"Etirinotecan pegol administration resulted in sustained and controlled systemic exposure to SN-38, which had a mean half-life of approximately 50 days.","A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136196/),d,50,14186,DB00762,Irinotecan
,23136196,MTD,The MTD recommended for phase II clinical trials is 145 mg/m(2) q14d or q21d.,"A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136196/),[mg] / [m],145,14187,DB00762,Irinotecan
,22882086,Ki,"The MBLI87 Ki was estimated to 141 nm for Mit, 289 nm for CPT11, and 1160 nm for SN38.",A template model for studying anticancer drug efflux transporter inhibitors in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22882086/),nm,141,14354,DB00762,Irinotecan
,22882086,Ki,"The MBLI87 Ki was estimated to 141 nm for Mit, 289 nm for CPT11, and 1160 nm for SN38.",A template model for studying anticancer drug efflux transporter inhibitors in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22882086/),nm,289,14355,DB00762,Irinotecan
,22882086,Ki,"The MBLI87 Ki was estimated to 141 nm for Mit, 289 nm for CPT11, and 1160 nm for SN38.",A template model for studying anticancer drug efflux transporter inhibitors in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22882086/),nm,1160,14356,DB00762,Irinotecan
,22882086,ratio of intrinsic transport clearance divided by diffusion clearance,"The ratio of intrinsic transport clearance divided by diffusion clearance was estimated to 2.5 for Mit, 1.01 for CPT11, and 5.4 for SN38.",A template model for studying anticancer drug efflux transporter inhibitors in vitro. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22882086/),,2.5,14357,DB00762,Irinotecan
,22882086,ratio of intrinsic transport clearance divided by diffusion clearance,"The ratio of intrinsic transport clearance divided by diffusion clearance was estimated to 2.5 for Mit, 1.01 for CPT11, and 5.4 for SN38.",A template model for studying anticancer drug efflux transporter inhibitors in vitro. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22882086/),,1.01,14358,DB00762,Irinotecan
,22882086,ratio of intrinsic transport clearance divided by diffusion clearance,"The ratio of intrinsic transport clearance divided by diffusion clearance was estimated to 2.5 for Mit, 1.01 for CPT11, and 5.4 for SN38.",A template model for studying anticancer drug efflux transporter inhibitors in vitro. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22882086/),,5,14359,DB00762,Irinotecan
,9619758,area under the curve (AUC),Pharmacokinetic analysis of free platinum from CDDP demonstrated that the area under the curve (AUC) from 33 mg/m2 CDDP was 0.92 +/- 0.29 microg/ml h.,Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9619758/),[μg] / [h·ml],0.92,15012,DB00762,Irinotecan
,9619758,response rate,"In 13 patients evaluated for response, the response rate was 54%.",Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9619758/),%,54,15013,DB00762,Irinotecan
,21750645,plasma concentrations,"The plasma concentrations of 5-FU at 24 hr after the start of treatment were 27.4 ng/mL and 9.4 ng/mL in the patients with and without the bolus injection, respectively.",Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750645/),[ng] / [ml],27.4,15050,DB00762,Irinotecan
,21750645,plasma concentrations,"The plasma concentrations of 5-FU at 24 hr after the start of treatment were 27.4 ng/mL and 9.4 ng/mL in the patients with and without the bolus injection, respectively.",Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750645/),[ng] / [ml],9.4,15051,DB00762,Irinotecan
,21750645,AUC(0-48),"At 48 hr, they were 31.3 ng/mL and 10.4 ng/mL with the AUC(0-48) values of 22.16 mg h/L and 0.65 mg h/L, respectively.",Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750645/),[h·mg] / [l],22.16,15052,DB00762,Irinotecan
,21750645,AUC(0-48),"At 48 hr, they were 31.3 ng/mL and 10.4 ng/mL with the AUC(0-48) values of 22.16 mg h/L and 0.65 mg h/L, respectively.",Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750645/),[h·mg] / [l],0.65,15053,DB00762,Irinotecan
,16680463,area under the time-concentration curve (AUC),"Indeed, area under the time-concentration curve (AUC) of SN-38 was significantly lower at the first cycle than the second cycle (0.99+/-0.45 hxmicrog/ml vs 1.34+/-0.65, respectively, P=0.027) whereas AUC of irinotecan and SN-38-glucuronide were higher at first cycle than second cycle (34.53+/-11.38 hxmicrog/ml vs. 28.42+/-12.23 hxmicrog/ml, P=0.064 and 2.39+/-1.21 h(microg/ml vs. 1.86+/-1.11 hxmicrog/ml, P=0.018, respectively).",Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680463/),[h·μg] / [ml],0.99,15965,DB00762,Irinotecan
,16680463,area under the time-concentration curve (AUC),"Indeed, area under the time-concentration curve (AUC) of SN-38 was significantly lower at the first cycle than the second cycle (0.99+/-0.45 hxmicrog/ml vs 1.34+/-0.65, respectively, P=0.027) whereas AUC of irinotecan and SN-38-glucuronide were higher at first cycle than second cycle (34.53+/-11.38 hxmicrog/ml vs. 28.42+/-12.23 hxmicrog/ml, P=0.064 and 2.39+/-1.21 h(microg/ml vs. 1.86+/-1.11 hxmicrog/ml, P=0.018, respectively).",Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680463/),,1.34,15966,DB00762,Irinotecan
,16680463,AUC,"Indeed, area under the time-concentration curve (AUC) of SN-38 was significantly lower at the first cycle than the second cycle (0.99+/-0.45 hxmicrog/ml vs 1.34+/-0.65, respectively, P=0.027) whereas AUC of irinotecan and SN-38-glucuronide were higher at first cycle than second cycle (34.53+/-11.38 hxmicrog/ml vs. 28.42+/-12.23 hxmicrog/ml, P=0.064 and 2.39+/-1.21 h(microg/ml vs. 1.86+/-1.11 hxmicrog/ml, P=0.018, respectively).",Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680463/),[h·μg] / [ml],34.53,15967,DB00762,Irinotecan
,16680463,AUC,"Indeed, area under the time-concentration curve (AUC) of SN-38 was significantly lower at the first cycle than the second cycle (0.99+/-0.45 hxmicrog/ml vs 1.34+/-0.65, respectively, P=0.027) whereas AUC of irinotecan and SN-38-glucuronide were higher at first cycle than second cycle (34.53+/-11.38 hxmicrog/ml vs. 28.42+/-12.23 hxmicrog/ml, P=0.064 and 2.39+/-1.21 h(microg/ml vs. 1.86+/-1.11 hxmicrog/ml, P=0.018, respectively).",Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680463/),[h·μg] / [ml],28.42,15968,DB00762,Irinotecan
,16680463,AUC,"Indeed, area under the time-concentration curve (AUC) of SN-38 was significantly lower at the first cycle than the second cycle (0.99+/-0.45 hxmicrog/ml vs 1.34+/-0.65, respectively, P=0.027) whereas AUC of irinotecan and SN-38-glucuronide were higher at first cycle than second cycle (34.53+/-11.38 hxmicrog/ml vs. 28.42+/-12.23 hxmicrog/ml, P=0.064 and 2.39+/-1.21 h(microg/ml vs. 1.86+/-1.11 hxmicrog/ml, P=0.018, respectively).",Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680463/),[h(μg] / [ml],2.39,15969,DB00762,Irinotecan
,16680463,AUC,"Indeed, area under the time-concentration curve (AUC) of SN-38 was significantly lower at the first cycle than the second cycle (0.99+/-0.45 hxmicrog/ml vs 1.34+/-0.65, respectively, P=0.027) whereas AUC of irinotecan and SN-38-glucuronide were higher at first cycle than second cycle (34.53+/-11.38 hxmicrog/ml vs. 28.42+/-12.23 hxmicrog/ml, P=0.064 and 2.39+/-1.21 h(microg/ml vs. 1.86+/-1.11 hxmicrog/ml, P=0.018, respectively).",Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680463/),[h·μg] / [ml],1.86,15970,DB00762,Irinotecan
,10873073,MTD,"For patients with no prior AP radiation therapy, the MTD was determined to be 320 mg/m2, whereas those with prior AP radiation therapy had a MTD of 290 mg/m2.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[mg] / [m2],320,17617,DB00762,Irinotecan
,10873073,MTD,"For patients with no prior AP radiation therapy, the MTD was determined to be 320 mg/m2, whereas those with prior AP radiation therapy had a MTD of 290 mg/m2.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[mg] / [m2],290,17618,DB00762,Irinotecan
,10873073,terminal phase half-life,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),h,12.4,17619,DB00762,Irinotecan
,10873073,clearance,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [h·m2],13.0,17620,DB00762,Irinotecan
,10873073,clearance,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [m2],234,17621,DB00762,Irinotecan
,10873073,terminal phase volume of distribution,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [h·m2],13.0,17622,DB00762,Irinotecan
,10873073,steady-state volume of distribution,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [m2],123,17623,DB00762,Irinotecan
less,26894853,Recoveries,"Recoveries of irinotecan, SN-38 and SN-38 glucuronide at three different concentrations (low, medium and high) were not less than 85% at three different concentrations in plasma and feces.","Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26894853/),%,85,18824,DB00762,Irinotecan
,18685565,overall response rate,The overall response rate was 8.1%.,Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18685565/),%,8.1,18964,DB00762,Irinotecan
,18685565,survival time,"The median survival time was 441 days, and time to progression was 132 days.",Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18685565/),d,441,18965,DB00762,Irinotecan
,18685565,time to progression,"The median survival time was 441 days, and time to progression was 132 days.",Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18685565/),d,132,18966,DB00762,Irinotecan
,22907396,area under the curve (AUC),"Twenty patients with extensive stage SCLC received intravenous carboplatin at an area under the curve (AUC) of 5 on day 1, and irinotecan in 40-70 mg/m2 dose levels on days 1 and 8, every 21 days, for up to 6 cycles.",A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22907396/),,5,19961,DB00762,Irinotecan
,22907396,objective response rate,The objective response rate was 75% and the median survival was 9.3 months (95% confidence interval 7.5-11.2).,A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22907396/),%,75,19962,DB00762,Irinotecan
,23880820,progression-free survival,"The study met its primary end point with an OS(3-month) of 75%, with median progression-free survival and overall survival of 2.4 and 5.2 months, respectively.","A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23880820/),month,2.,21657,DB00762,Irinotecan
,23880820,overall survival,"The study met its primary end point with an OS(3-month) of 75%, with median progression-free survival and overall survival of 2.4 and 5.2 months, respectively.","A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23880820/),month,5,21658,DB00762,Irinotecan
,15846298,terminal half-life,Pharmacokinetic studies in the mouse following intravenous injection showed that HGS-ETR1 serum concentrations were biphasic with a terminal half-life of 6.9-8.7 days and a steady-state volume of distribution of approximately 60 ml kg(-1).,"HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846298/),d,6.9-8.7,24736,DB00762,Irinotecan
,15846298,steady-state volume of distribution,Pharmacokinetic studies in the mouse following intravenous injection showed that HGS-ETR1 serum concentrations were biphasic with a terminal half-life of 6.9-8.7 days and a steady-state volume of distribution of approximately 60 ml kg(-1).,"HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846298/),[ml] / [kg],60,24737,DB00762,Irinotecan
,15846298,Clearance,Clearance was 3.6-5.7 ml(-1) day(-1) kg(-1).,"HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846298/),1/[day·kg·ml],3.6-5.7,24738,DB00762,Irinotecan
,9829738,total excretion,"Surprisingly, fecal excretion accounted for only 24.4+/-13.3% of the dose, leading to a total excretion of approximately 52%.",Irinotecan (CPT-11) metabolism and disposition in cancer patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829738/),%,52,25064,DB00762,Irinotecan
,20857171,MTD,"The MTD of single-agent oral irinotecan was estimated to be 60 mg/m(2)/day, and DLT included diarrhea, nausea, and neutropenia.",Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20857171/),mg,60,25570,DB00762,Irinotecan
,20857171,MTD,"In an initial group of patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2, the MTD of sequential oral irinotecan/capecitabine was estimated to be 40/1600 mg/m(2)/day with DLT of delayed diarrhea.",Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20857171/),[mg] / [d·m(2)],40,25571,DB00762,Irinotecan
,20857171,MTD,"In an initial group of patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2, the MTD of sequential oral irinotecan/capecitabine was estimated to be 40/1600 mg/m(2)/day with DLT of delayed diarrhea.",Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20857171/),[mg] / [d·m(2)],1600,25572,DB00762,Irinotecan
,7521905,beta half-life,"Elimination of CPT-11 was biphasic, with a mean +/- SD beta half-life of 18.17 +/- 9.09 hours.",Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7521905/),h,18.17,27007,DB00762,Irinotecan
,7521905,terminal half-life,The mean terminal half-life of 7-ethyl-10-hydroxycamptothecin (SN-38; the major metabolite of CPT-11) was 43.40 +/- 37.84 hours.,Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7521905/),h,43.40,27008,DB00762,Irinotecan
,7521905,overall response rate,"There was one complete response (5%) and eight partial responses (38%) among 21 assessable patients, for an overall response rate of 43%.",Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7521905/),%,43,27009,DB00762,Irinotecan
,7521905,response rates,"The response rates for small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) were 58% (seven of 12 patients) and 22% (two of nine patients), respectively.",Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7521905/),%,58,27010,DB00762,Irinotecan
,7521905,response rates,"The response rates for small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) were 58% (seven of 12 patients) and 22% (two of nine patients), respectively.",Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7521905/),%,22,27011,DB00762,Irinotecan
,29798953,PFS,The median PFS at 1 year was 3.83 months in test arm and 4.6 months in reference arm.,"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),month,3.83,30470,DB00762,Irinotecan
,29798953,PFS,The median PFS at 1 year was 3.83 months in test arm and 4.6 months in reference arm.,"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),month,4.6,30471,DB00762,Irinotecan
,29798953,OS,The mean OS was 10.91 months in test arm and 14.68 months in reference arm.,"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),month,10.91,30472,DB00762,Irinotecan
,29798953,OS,The mean OS was 10.91 months in test arm and 14.68 months in reference arm.,"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),month,14.68,30473,DB00762,Irinotecan
,29798953,Tmax,The median Tmaxwas 6.00 h in both the arms.,"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),h,6.00,30474,DB00762,Irinotecan
,29798953,t½,"The median t½ was 330.63 h and 226.14 h, respectively, for test and reference bevacizumab.","Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),h,330.63,30475,DB00762,Irinotecan
,29798953,t½,"The median t½ was 330.63 h and 226.14 h, respectively, for test and reference bevacizumab.","Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),h,226.14,30476,DB00762,Irinotecan
,16203781,activation ratio,"Patients with CES2 mRNA expression above the median cutoff value presented an activation ratio higher (median, 0.25; range, 0.15-0.42) than those with CES2 mRNA below the median (median, 0.20; range, 0.10-0.40; P = 0.013).",Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203781/),,0.25,30569,DB00762,Irinotecan
,16203781,activation ratio,"Patients with CES2 mRNA expression above the median cutoff value presented an activation ratio higher (median, 0.25; range, 0.15-0.42) than those with CES2 mRNA below the median (median, 0.20; range, 0.10-0.40; P = 0.013).",Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203781/),,0,30570,DB00762,Irinotecan
,16203781,AUC,"This was associated with a nonsignificant trend of 1.34-fold increase of SN38 AUC in the group of patients with high CES2 mRNA expression (mean, 1.03 +/- 0.62 versus 0.77 +/- 0.32 micromol/L hour).",Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203781/),[μM] / [h·l],1.03,30571,DB00762,Irinotecan
,16203781,AUC,"This was associated with a nonsignificant trend of 1.34-fold increase of SN38 AUC in the group of patients with high CES2 mRNA expression (mean, 1.03 +/- 0.62 versus 0.77 +/- 0.32 micromol/L hour).",Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203781/),[μM] / [h·l],0.77,30572,DB00762,Irinotecan
,10647495,m/z,"Selected reaction monitoring with the mass transitions m/z 169.2 --> 84.2 and 139.2 --> 98.1 was used for the detection of 4PP and the internal standard (IS), 1-piperidineproprionitrile, respectively.",Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647495/),,169.2,30961,DB00762,Irinotecan
,10647495,m/z,"Selected reaction monitoring with the mass transitions m/z 169.2 --> 84.2 and 139.2 --> 98.1 was used for the detection of 4PP and the internal standard (IS), 1-piperidineproprionitrile, respectively.",Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647495/),,84.2,30962,DB00762,Irinotecan
,10647495,m/z,"Selected reaction monitoring with the mass transitions m/z 169.2 --> 84.2 and 139.2 --> 98.1 was used for the detection of 4PP and the internal standard (IS), 1-piperidineproprionitrile, respectively.",Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647495/),,139.2,30963,DB00762,Irinotecan
,10647495,m/z,"Selected reaction monitoring with the mass transitions m/z 169.2 --> 84.2 and 139.2 --> 98.1 was used for the detection of 4PP and the internal standard (IS), 1-piperidineproprionitrile, respectively.",Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647495/),,98.1,30964,DB00762,Irinotecan
,10647495,absolute recoveries,"The assay was linear from 14.8 to 591.0 nM with absolute recoveries of 4PP (59.1 nM) and IS (143.7 nM) of 85.7% (n = 10) and 86.7% (n = 10), respectively.",Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647495/),nM,59.1,30965,DB00762,Irinotecan
,10647495,absolute recoveries,"The assay was linear from 14.8 to 591.0 nM with absolute recoveries of 4PP (59.1 nM) and IS (143.7 nM) of 85.7% (n = 10) and 86.7% (n = 10), respectively.",Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647495/),nM,143.7,30966,DB00762,Irinotecan
,10647495,absolute recoveries,"The assay was linear from 14.8 to 591.0 nM with absolute recoveries of 4PP (59.1 nM) and IS (143.7 nM) of 85.7% (n = 10) and 86.7% (n = 10), respectively.",Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647495/),%,85.7,30967,DB00762,Irinotecan
,10647495,absolute recoveries,"The assay was linear from 14.8 to 591.0 nM with absolute recoveries of 4PP (59.1 nM) and IS (143.7 nM) of 85.7% (n = 10) and 86.7% (n = 10), respectively.",Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647495/),%,86.7,30968,DB00762,Irinotecan
,10647495,terminal half-life,Plasma concentrations of 4PP declined slowly with a long terminal half-life (33.4 +/- 17.1 h).,Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647495/),h,33.4,30969,DB00762,Irinotecan
,12235447,clearance,"The population estimate of clearance for irinotecan was 31.6 L/h, and the volume of distribution at steady-state (V(SS)) was 263 L.",Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235447/),[l] / [h],31.6,31333,DB00762,Irinotecan
,12235447,volume of distribution at steady-state (V(SS)),"The population estimate of clearance for irinotecan was 31.6 L/h, and the volume of distribution at steady-state (V(SS)) was 263 L.",Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235447/),l,263,31334,DB00762,Irinotecan
,12235447,clearance divided by formation fraction (F(m)),"The clearance divided by formation fraction (F(m)) was 712 L/h and 66.8 L/h for SN-38 and SN-38G, respectively.",Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235447/),[l] / [h],712,31335,DB00762,Irinotecan
,12235447,clearance divided by formation fraction (F(m)),"The clearance divided by formation fraction (F(m)) was 712 L/h and 66.8 L/h for SN-38 and SN-38G, respectively.",Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235447/),[l] / [h],66.8,31336,DB00762,Irinotecan
,12235447,V(SS)/F(m),"The V(SS)/F(m) was 72,000 L for SN-38 and 85.4 L for SN-38G.",Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235447/),l,"72,000",31337,DB00762,Irinotecan
,12235447,V(SS)/F(m),"The V(SS)/F(m) was 72,000 L for SN-38 and 85.4 L for SN-38G.",Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235447/),l,85.4,31338,DB00762,Irinotecan
,29131533,PFS,"Among 29 patients treated at level 2, PFS was longer for UGT1A1 wt/*6 and wt/*28 patients than for wt/wt patients (12 vs. 8 months, P = 0.06).",A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29131533/),month,12,31541,DB00762,Irinotecan
,29131533,PFS,"Among 29 patients treated at level 2, PFS was longer for UGT1A1 wt/*6 and wt/*28 patients than for wt/wt patients (12 vs. 8 months, P = 0.06).",A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29131533/),month,8,31542,DB00762,Irinotecan
,24379067,zeta potential,The zeta potential of PEG-coated irinotecan cationic liposomes was approximately 23 mV.,PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24379067/),mv,23,31648,DB00762,Irinotecan
,9832373,lambda ex,"CPT-11 and SN-38 derivatives were detected at lambda ex=362 nm/lambda em=425 nm and lambda ex=375 nm/lambda em =560 nm, respectively.",Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832373/),nm,362,32098,DB00762,Irinotecan
,9832373,lambda ex,"CPT-11 and SN-38 derivatives were detected at lambda ex=362 nm/lambda em=425 nm and lambda ex=375 nm/lambda em =560 nm, respectively.",Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832373/),nm,375,32099,DB00762,Irinotecan
,28395759,objective response rate,"The objective response rate was 25.8% among the 85 patients, 57.3% in patients with tumors wild type (WT) for KRAS, and 25% in those whose tumor harbored a mutant-KRAS.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),%,25.8,32507,DB00762,Irinotecan
,28395759,objective response rate,"The objective response rate was 25.8% among the 85 patients, 57.3% in patients with tumors wild type (WT) for KRAS, and 25% in those whose tumor harbored a mutant-KRAS.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),%,57.3,32508,DB00762,Irinotecan
,28395759,objective response rate,"The objective response rate was 25.8% among the 85 patients, 57.3% in patients with tumors wild type (WT) for KRAS, and 25% in those whose tumor harbored a mutant-KRAS.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),%,25,32509,DB00762,Irinotecan
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,181,32510,DB00762,Irinotecan
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,200,32511,DB00762,Irinotecan
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,132,32512,DB00762,Irinotecan
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,121,32513,DB00762,Irinotecan
,15634630,time to progression,"Median time to progression was 6 months, and median survival was 8.4 months.","A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634630/),month,6,32870,DB00762,Irinotecan
,15634630,survival,"Median time to progression was 6 months, and median survival was 8.4 months.","A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634630/),month,8.4,32871,DB00762,Irinotecan
,24382596,Response rate,Response rate was 65%; median progression-free survival 16.4 months.,"Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24382596/),%,65,33960,DB00762,Irinotecan
,24382596,progression-free survival,Response rate was 65%; median progression-free survival 16.4 months.,"Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24382596/),month,16.4,33961,DB00762,Irinotecan
,22551773,Limits of,Limits of quantification were 5 ng/mL for CPT-11 and SN-38 in plasma samples and 1.25 ng/g in brain.,A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22551773/),[ng] / [ml],5,36243,DB00762,Irinotecan
,22551773,Limits of,Limits of quantification were 5 ng/mL for CPT-11 and SN-38 in plasma samples and 1.25 ng/g in brain.,A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22551773/),[ng] / [g],1.25,36244,DB00762,Irinotecan
,16257855,t1/2,"Irinotecan and 5-FU were observed to be rapidly eliminated (t1/2 = 1 h and 0.5 h, respectively).","Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16257855/),h,1,36707,DB00762,Irinotecan
,16257855,t1/2,"Irinotecan and 5-FU were observed to be rapidly eliminated (t1/2 = 1 h and 0.5 h, respectively).","Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16257855/),h,0.5,36708,DB00762,Irinotecan
,21512394,response rate,"The response rate of the primary tumor (Japanese criteria) was 25.0% in arm A (12 of 48 patients) and 14.9% in arm B (seven of 47 patients), whereas the response rates according to Response Evaluation Criteria In Solid Tumors were 27.8% (10 of 36) versus 21.9% (seven of 32).",Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21512394/),%,25.0,38016,DB00762,Irinotecan
,21512394,response rate,"The response rate of the primary tumor (Japanese criteria) was 25.0% in arm A (12 of 48 patients) and 14.9% in arm B (seven of 47 patients), whereas the response rates according to Response Evaluation Criteria In Solid Tumors were 27.8% (10 of 36) versus 21.9% (seven of 32).",Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21512394/),%,14.9,38017,DB00762,Irinotecan
,21512394,response rates,"The response rate of the primary tumor (Japanese criteria) was 25.0% in arm A (12 of 48 patients) and 14.9% in arm B (seven of 47 patients), whereas the response rates according to Response Evaluation Criteria In Solid Tumors were 27.8% (10 of 36) versus 21.9% (seven of 32).",Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21512394/),%,27.8,38018,DB00762,Irinotecan
,21512394,response rates,"The response rate of the primary tumor (Japanese criteria) was 25.0% in arm A (12 of 48 patients) and 14.9% in arm B (seven of 47 patients), whereas the response rates according to Response Evaluation Criteria In Solid Tumors were 27.8% (10 of 36) versus 21.9% (seven of 32).",Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21512394/),%,21.9,38019,DB00762,Irinotecan
,31982558,IC50,"Compared with single and mixture drugs administration, the nanoformulated VES-Ir NPs codelivered both VES and Ir with different anticancer mechanisms to induce the highest suppress proliferation of MCF-7 (IC50 0.18 μM) and A549 (IC50 0.29 μM) cells in a synergistic way (CI < 1).",Vitamin E-based prodrug self-delivery for nanoformulated irinotecan with synergistic antitumor therapeutics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31982558/),μM,0.18,38664,DB00762,Irinotecan
,31982558,IC50,"Compared with single and mixture drugs administration, the nanoformulated VES-Ir NPs codelivered both VES and Ir with different anticancer mechanisms to induce the highest suppress proliferation of MCF-7 (IC50 0.18 μM) and A549 (IC50 0.29 μM) cells in a synergistic way (CI < 1).",Vitamin E-based prodrug self-delivery for nanoformulated irinotecan with synergistic antitumor therapeutics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31982558/),μM,0.29,38665,DB00762,Irinotecan
,31982558,tumor inhibitory rate (TIR),"Ir is to significantly enhance its bioavailability in vivo with long retention time in bloodstream and thereby, resulting the superior tumor inhibitory rate (TIR) of 85.2% versus controls.",Vitamin E-based prodrug self-delivery for nanoformulated irinotecan with synergistic antitumor therapeutics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31982558/),%,85.2,38666,DB00762,Irinotecan
,15286088,area under the curves (AUCs),"The mean (SD) area under the curves (AUCs) of irinotecan and SN-38 were 20,348 +/- 6466 ng x h/mL and 629 +/- 370 ng x h/mL, respectively, which is in line with earlier findings.",Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286088/),[h·ng] / [ml],"20,348",39401,DB00762,Irinotecan
,15286088,area under the curves (AUCs),"The mean (SD) area under the curves (AUCs) of irinotecan and SN-38 were 20,348 +/- 6466 ng x h/mL and 629 +/- 370 ng x h/mL, respectively, which is in line with earlier findings.",Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286088/),[h·ng] / [ml],629,39402,DB00762,Irinotecan
,15286088,AUC ratio,The median AUC ratio of SN-38G to SN-38 was significantly reduced in carriers of the variant UGT1A1(*)28 allele (7.00 [Wt] vs. 6.26 [Het] vs. 2.51 [Var]; p =.022).,Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286088/),,7.00,39403,DB00762,Irinotecan
,15286088,AUC ratio,The median AUC ratio of SN-38G to SN-38 was significantly reduced in carriers of the variant UGT1A1(*)28 allele (7.00 [Wt] vs. 6.26 [Het] vs. 2.51 [Var]; p =.022).,Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286088/),,6.26,39404,DB00762,Irinotecan
,15286088,AUC ratio,The median AUC ratio of SN-38G to SN-38 was significantly reduced in carriers of the variant UGT1A1(*)28 allele (7.00 [Wt] vs. 6.26 [Het] vs. 2.51 [Var]; p =.022).,Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286088/),,2.51,39405,DB00762,Irinotecan
,18281556,T-Cs,T-Cs ranged from 2 days (LS 180 model) to 18 days (PC-3 model).,Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18281556/),d,2,41699,DB00762,Irinotecan
,18281556,T-Cs,T-Cs ranged from 2 days (LS 180 model) to 18 days (PC-3 model).,Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18281556/),d,18,41700,DB00762,Irinotecan
,18281556,T-Cs,Irinophore C (40 mg/kg) engendered T-Cs ranging from 14 days (LS 180 model) to 87 days (Capan-1 model).,Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18281556/),d,14,41701,DB00762,Irinotecan
,18281556,T-Cs,Irinophore C (40 mg/kg) engendered T-Cs ranging from 14 days (LS 180 model) to 87 days (Capan-1 model).,Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18281556/),d,87,41702,DB00762,Irinotecan
,9789606,Biliary index,"Biliary index was 6980 versus 2180 +/- 1110 (range 840-3730) in patients with 7/7 versus 6/6 genotypes, respectively.","UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789606/),,6980,42249,DB00762,Irinotecan
,9789606,Biliary index,"Biliary index was 6980 versus 2180 +/- 1110 (range 840-3730) in patients with 7/7 versus 6/6 genotypes, respectively.","UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789606/),,2180,42250,DB00762,Irinotecan
,14578322,recoveries,Assay recoveries ranged from 92.8% to 111.2% for plasma and 100.1% to 104.1% for saliva.,Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578322/),%,92.8,44847,DB00762,Irinotecan
,14578322,recoveries,Assay recoveries ranged from 92.8% to 111.2% for plasma and 100.1% to 104.1% for saliva.,Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578322/),%,111.2,44848,DB00762,Irinotecan
,14578322,recoveries,Assay recoveries ranged from 92.8% to 111.2% for plasma and 100.1% to 104.1% for saliva.,Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578322/),%,100.1,44849,DB00762,Irinotecan
,14578322,recoveries,Assay recoveries ranged from 92.8% to 111.2% for plasma and 100.1% to 104.1% for saliva.,Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578322/),%,104.1,44850,DB00762,Irinotecan
,14578322,extraction recovery,Mean extraction recovery from plasma or saliva was 90%.,Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578322/),%,90,44851,DB00762,Irinotecan
,23781580,RD,"The RD of irinotecan was determined as 50 mg/m2 for the patients with wild-type, 40 mg/m2 for those with heterotype, and 30 mg/m2 for homotype UGT IAl genotype.",UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23781580/),[mg] / [m2],50,45385,DB00762,Irinotecan
,23781580,RD,"The RD of irinotecan was determined as 50 mg/m2 for the patients with wild-type, 40 mg/m2 for those with heterotype, and 30 mg/m2 for homotype UGT IAl genotype.",UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23781580/),[mg] / [m],40,45386,DB00762,Irinotecan
,16047343,MTD,The MTD of the irinotecan/carboplatin combination was 60 mg/m(2)/5 . mg mL/minute.,A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047343/),[mg] / [m(2],60,46324,DB00762,Irinotecan
,16047343,MTD,The MTD of the irinotecan/carboplatin combination was 60 mg/m(2)/5 . mg mL/minute.,A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047343/),,5 .,46325,DB00762,Irinotecan
,26101915,drug:antibody ratio (DAR),"IMMU-132 is most efficacious at a high drug:antibody ratio (DAR) of 7.6:1, which does not affect binding and pharmacokinetics.","Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26101915/),,7.6:1,46719,DB00762,Irinotecan
,16906022,clearance,Genotypic-phenotypic correlates showed the clearance of irinotecan to be 3-fold lower in patients carrying the *15 haplotype than cancer patients with the reference genotype *1a/*1a (9.57+/-3.15 vs. 28.86+/-10.97 l/h/m; P=0.001).,Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16906022/),[l] / [h·m],9.57,47420,DB00762,Irinotecan
,16906022,clearance,Genotypic-phenotypic correlates showed the clearance of irinotecan to be 3-fold lower in patients carrying the *15 haplotype than cancer patients with the reference genotype *1a/*1a (9.57+/-3.15 vs. 28.86+/-10.97 l/h/m; P=0.001).,Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16906022/),[l] / [h·m],28.86,47421,DB00762,Irinotecan
,16906022,area under the plasma concentration-time curve from zero to infinity,The area under the plasma concentration-time curve from zero to infinity and normalized by dose and body surface area (AUC0-nf/dose/BSA) were significantly higher in patients harbouring the *15 haplotype than patients with the reference genotype for irinotecan (39.27+/-15.17 vs. 17.32+/-6.30 h/m; P=0.003) and 7-ethyl-10-hydroxycamptothecin (1.28+/-0.53 vs. 0.69+/-0.32 h/m; P=0.021).,Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16906022/),[h] / [m],39.27,47422,DB00762,Irinotecan
,16906022,area under the plasma concentration-time curve from zero to infinity,The area under the plasma concentration-time curve from zero to infinity and normalized by dose and body surface area (AUC0-nf/dose/BSA) were significantly higher in patients harbouring the *15 haplotype than patients with the reference genotype for irinotecan (39.27+/-15.17 vs. 17.32+/-6.30 h/m; P=0.003) and 7-ethyl-10-hydroxycamptothecin (1.28+/-0.53 vs. 0.69+/-0.32 h/m; P=0.021).,Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16906022/),[h] / [m],17.32,47423,DB00762,Irinotecan
,16906022,area under the plasma concentration-time curve from zero to infinity,The area under the plasma concentration-time curve from zero to infinity and normalized by dose and body surface area (AUC0-nf/dose/BSA) were significantly higher in patients harbouring the *15 haplotype than patients with the reference genotype for irinotecan (39.27+/-15.17 vs. 17.32+/-6.30 h/m; P=0.003) and 7-ethyl-10-hydroxycamptothecin (1.28+/-0.53 vs. 0.69+/-0.32 h/m; P=0.021).,Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16906022/),[h] / [m],1.28,47424,DB00762,Irinotecan
,16906022,area under the plasma concentration-time curve from zero to infinity,The area under the plasma concentration-time curve from zero to infinity and normalized by dose and body surface area (AUC0-nf/dose/BSA) were significantly higher in patients harbouring the *15 haplotype than patients with the reference genotype for irinotecan (39.27+/-15.17 vs. 17.32+/-6.30 h/m; P=0.003) and 7-ethyl-10-hydroxycamptothecin (1.28+/-0.53 vs. 0.69+/-0.32 h/m; P=0.021).,Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16906022/),[h] / [m],0.69,47425,DB00762,Irinotecan
,27507617,MTD,Conclusions: The MTD of irinotecan in FOLFIRI plus bevacizumab is 310 mg/m2 for UGT1A1 *1/*1 patients and 260 mg/m2 for *1/*28 patients.,Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27507617/),[mg] / [m2],310,47547,DB00762,Irinotecan
,27507617,MTD,Conclusions: The MTD of irinotecan in FOLFIRI plus bevacizumab is 310 mg/m2 for UGT1A1 *1/*1 patients and 260 mg/m2 for *1/*28 patients.,Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27507617/),[mg] / [m2],260,47548,DB00762,Irinotecan
more,33092063,area under the curve,Tumor responses and prolonged stable disease were associated with a mean irinotecan area under the curve of more than 400 min.,SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33092063/),min,400,47983,DB00762,Irinotecan
,21325073,IC(50),"In vitro, PKI-587 potently inhibited class I PI3Ks (IC(50) vs. PI3K-α = 0.4 nmol/L), PI3K-α mutants, and mTOR.","Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21325073/),[nM] / [l],0.4,49560,DB00762,Irinotecan
less,21325073,IC(50),"PKI-587 inhibited growth of 50 diverse human tumor cell lines at IC(50) values of less than 100 nmol/L. PKI-587 suppressed phosphorylation of PI3K/mTOR effectors (e.g., Akt), and induced apoptosis in human tumor cell lines with elevated PI3K/mTOR signaling.","Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21325073/),[nM] / [l],100,49561,DB00762,Irinotecan
,16855842,overall response rate,"A partial response was obtained in 10 patients, giving an overall response rate of 27.0% (95% confidence interval 13.8-44.1%).",A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855842/),%,27.0,49723,DB00762,Irinotecan
,16855842,overall survival,The median overall survival was 7.3 months with a 1-year survival rate of 29.5%.,A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855842/),month,7.3,49724,DB00762,Irinotecan
,28817371,progression-free survival,"Median progression-free survival and overall survival were 3.6 and 6.9 months, respectively.",Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28817371/),month,3.6,50217,DB00762,Irinotecan
,28817371,overall survival,"Median progression-free survival and overall survival were 3.6 and 6.9 months, respectively.",Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28817371/),month,6.9,50218,DB00762,Irinotecan
,28817371,half-life,The antibody-drug conjugate's mean half-life was 16.5 hours for the four cohorts.,Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28817371/),h,16.5,50219,DB00762,Irinotecan
,12912940,MTD,The MTD was determined to be 411 mg/m(2)/week in the +EIA cohort and 117 mg/m(2)/week in the -EIA cohort for the weekly x 4 every 6 weeks schedule.,Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12912940/),[mg] / [m(2)·week],411,50397,DB00762,Irinotecan
,12912940,MTD,The MTD was determined to be 411 mg/m(2)/week in the +EIA cohort and 117 mg/m(2)/week in the -EIA cohort for the weekly x 4 every 6 weeks schedule.,Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12912940/),[mg] / [m(2)·week],117,50398,DB00762,Irinotecan
,12912940,CL,"Pharmacokinetic studies showed that the CL of irinotecan was distinctly dose dependent in the patients receiving EIAs, decreasing from approximately 50 liters/h/m(2) at the lower dose levels (125-238 mg/m(2)) to a mean +/- SD value of 29.7 +/- 9.0 liters/h/m(2) (n = 7) at the MTD.",Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12912940/),[h·l] / [m(2],50,50399,DB00762,Irinotecan
,12912940,CL,"Pharmacokinetic studies showed that the CL of irinotecan was distinctly dose dependent in the patients receiving EIAs, decreasing from approximately 50 liters/h/m(2) at the lower dose levels (125-238 mg/m(2)) to a mean +/- SD value of 29.7 +/- 9.0 liters/h/m(2) (n = 7) at the MTD.",Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12912940/),[h·l] / [m(2],29.7,50400,DB00762,Irinotecan
,12912940,CL,"The grand mean CL for a group of 13 patients who were not taking EIAs, 18.8 +/- 10.6 liters/h/m(2), was significantly different from the mean CL at the MTD of the +EIA cohort (P = 0.033).",Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12912940/),[h·l] / [m(2],18.8,50401,DB00762,Irinotecan
,30988612,ζ-potential,The particle size of nano-micelle was 69.41 nm and ζ-potential was -42.01 mV.,One-step mechanochemical preparation and prominent antitumor activity of SN-38 self-micelle solid dispersion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30988612/),m,-,50836,DB00762,Irinotecan
,30988612,ζ-potential,The particle size of nano-micelle was 69.41 nm and ζ-potential was -42.01 mV.,One-step mechanochemical preparation and prominent antitumor activity of SN-38 self-micelle solid dispersion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30988612/),m,42.01,50837,DB00762,Irinotecan
,16044114,AUC,"In particular, the AUC of SN-38 was markedly decreased to 56 from 107 ng.h/mL.",Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044114/),[h·ng] / [ml],56,51211,DB00762,Irinotecan
,16044114,AUC,"In particular, the AUC of SN-38 was markedly decreased to 56 from 107 ng.h/mL.",Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044114/),[h·ng] / [ml],107,51212,DB00762,Irinotecan
,15768380,MTD,Neutropenia and diarrhea were the DLTs in heavily pretreated patients; the MTD was 125 mg/m(2)/day.,A phase I study of irinotecan administered on a weekly schedule in pediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15768380/),mg,125,52826,DB00762,Irinotecan
,15768380,MTD,Neutropenia was the DLT in less-heavily pretreated; the MTD was 160 mg/m(2)/day.,A phase I study of irinotecan administered on a weekly schedule in pediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15768380/),mg,160,52827,DB00762,Irinotecan
,30337148,overall survival,"The median overall survival was 18.14 months, and the 1-year survival was 65%.",Irinotecan-Eluting 75-150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30337148/),month,18.14,54162,DB00762,Irinotecan
,30337148,plasma Cmax,"The average plasma Cmax of the active metabolite was 41.5 ± 26.1 ng/mL, with average Tmax of 1.3 ± 0.5 hours.",Irinotecan-Eluting 75-150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30337148/),[ng] / [ml],41.5,54163,DB00762,Irinotecan
,30337148,Tmax,"The average plasma Cmax of the active metabolite was 41.5 ± 26.1 ng/mL, with average Tmax of 1.3 ± 0.5 hours.",Irinotecan-Eluting 75-150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30337148/),h,1.3,54164,DB00762,Irinotecan
,18172273,time to tumor progression,The median time to tumor progression was 7.7 months.,"Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18172273/),month,7.7,55179,DB00762,Irinotecan
,18172273,RD,The RD of EKB-569 is 25 mg/day when combined with FOLFIRI and results in complete EGFR inhibition.,"Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18172273/),[mg] / [d],25,55180,DB00762,Irinotecan
,12637480,clearance,"Pharmacokinetic studies demonstrated that irinotecan clearance was reduced from 13.4 to 5.8 L/h/m(2) and area under the curve (AUC)(0-tn) was increased 2.2-fold by the coadministration of Cs. Similar significant increases in AUC(0-24h) were seen for both SN38 and SN38G (2.2-fold and 2.3-fold, respectively) in the presence of Cs.",Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637480/),[h·l] / [m(2],13.4 to 5.8,56588,DB00762,Irinotecan
,30657223,progression-free survival,The median progression-free survival was 5.42 months (4.14-6.70 months) and the median overall survival was 15.59 months (11.20-19.81 months).,Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),month,5.42,57848,DB00762,Irinotecan
,30657223,overall survival,The median progression-free survival was 5.42 months (4.14-6.70 months) and the median overall survival was 15.59 months (11.20-19.81 months).,Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),month,15.59,57849,DB00762,Irinotecan
,30657223,maximum concentration,"Free aflibercept had a mean maximum concentration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial growth factor had a clearance of 0.162 L/d (9%) (N = 62).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),[μg] / [ml],73.2,57850,DB00762,Irinotecan
,30657223,clearance,"Free aflibercept had a mean maximum concentration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial growth factor had a clearance of 0.162 L/d (9%) (N = 62).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),[l] / [d],0.805,57851,DB00762,Irinotecan
,30657223,volume of distribution,"Free aflibercept had a mean maximum concentration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial growth factor had a clearance of 0.162 L/d (9%) (N = 62).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),l,6.2,57852,DB00762,Irinotecan
,30657223,clearance,"Free aflibercept had a mean maximum concentration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial growth factor had a clearance of 0.162 L/d (9%) (N = 62).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),[l] / [d],0.162,57853,DB00762,Irinotecan
,30657223,clearance,"Aflibercept did not significantly affect the pharmacokinetics of irinotecan or 5-fluorouracil: The clearance was 11.1 L/h/m2 (28%) for irinotecan and, at steady state, 72.6 L/h/m2 (56%) for 5-fluorouracil (N = 10).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),[l] / [h·m2],11.1,57854,DB00762,Irinotecan
,30657223,clearance,"Aflibercept did not significantly affect the pharmacokinetics of irinotecan or 5-fluorouracil: The clearance was 11.1 L/h/m2 (28%) for irinotecan and, at steady state, 72.6 L/h/m2 (56%) for 5-fluorouracil (N = 10).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),[l] / [h·m2],72.6,57855,DB00762,Irinotecan
,21786211,overall response rate,The overall response rate was 24.0% (6PR/25).,Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21786211/),%,24.0,58771,DB00762,Irinotecan
,10944133,MTD,"The MTD of docetaxel/CPT-11 was 50/60 mg/m(2) (level 5A), or 60/50 mg/m(2) (level 5B).",Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10944133/),mg,50,59017,DB00762,Irinotecan
,19588994,blood circulation half-life,"Polymer-bound CPT was shown to have a long blood circulation half-life of 30.9 +/- 8.8 h and a tumor uptake of 4.2 +/- 2.3% of the injected dose/g of tissue, compared to free CPT in which less than 1% was retained in the blood after 30 min and had a tumor accumulation of 0.29 +/- 0.04% of the injected dose/g of tissue.",Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19588994/),h,30.9,59477,DB00762,Irinotecan
,18056194,maximum tolerated dose,The maximum tolerated dose for irinotecan was determined to be 500 mg/m(2).,Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18056194/),mg,500,61543,DB00762,Irinotecan
,30587986,zeta potential,"The SN38-PA liposomes were characterized as follows: an average particle size of 80.13 nm, an average zeta potential of -33.53 mv, and the entrapment efficiency of 99%.",Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30587986/),mv,-,64055,DB00762,Irinotecan
,30587986,zeta potential,"The SN38-PA liposomes were characterized as follows: an average particle size of 80.13 nm, an average zeta potential of -33.53 mv, and the entrapment efficiency of 99%.",Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30587986/),mv,33.53,64056,DB00762,Irinotecan
,30587986,entra,"The SN38-PA liposomes were characterized as follows: an average particle size of 80.13 nm, an average zeta potential of -33.53 mv, and the entrapment efficiency of 99%.",Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30587986/),,99,64057,DB00762,Irinotecan
,10632326,area under the concentration-time curve (AUC),"Patients with advanced cancer were treated with CPT-11 (days 1, 8, and 15) and carboplatin (day 1) of a fixed-target area under the concentration-time curve (AUC) of 5 mg x min/ml.",Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632326/),[mg·min] / [ml],5,64166,DB00762,Irinotecan
,10632326,AUC,"In 11 patients, the actual AUCs of carboplatin almost achieved the target AUC of 5.",Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632326/),,5,64167,DB00762,Irinotecan
,10632326,AUC,"CPT-11 (50 mg/m2) under the carboplatin target AUC of 5 using the Chatelut formula was the recommended dose for further Phase II study, and this regimen seems to be active for small cell lung cancer.",Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632326/),,5,64168,DB00762,Irinotecan
,9610696,area under the plasma concentration versus the time curve (AUC),"The carboplatin dose was calculated using Calvert's formula, where the target area under the plasma concentration versus the time curve (AUC) was 5 or 6 mg x min/mL.",A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9610696/),[mg·min] / [ml],5,64572,DB00762,Irinotecan
,9610696,area under the plasma concentration versus the time curve (AUC),"The carboplatin dose was calculated using Calvert's formula, where the target area under the plasma concentration versus the time curve (AUC) was 5 or 6 mg x min/mL.",A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9610696/),[mg·min] / [ml],6,64573,DB00762,Irinotecan
,9610696,AUC,"At the 60/6 dose level (n=5), the observed carboplatin AUC after aiming for a target AUC of 6 was 5.9+/-0.9 mg x min/mL, as expected, although the AUCs of both CPT-11 and its active metabolite, SN-38, were lower than expected.",A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9610696/),[mg·min] / [ml],5.9,64574,DB00762,Irinotecan
,9610696,AUC,"The recommended doses for Phase II studies are 60 mg/m2 of CPT-11 and a target AUC of 5 mg x min/mL for carboplatin, plus rhG-CSF.",A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9610696/),[mg·min] / [ml],5,64575,DB00762,Irinotecan
,18362940,steady-state levels (C(ss)),Pharmacokinetic analysis demonstrated that the steady-state levels (C(ss)) of SN-38 were between 1 and 3.3 ng ml(-1).,A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362940/),[ng] / [ml],1 and 3.3,66804,DB00762,Irinotecan
,11352961,response rate,The response rate (complete and partial) among all patients who did not undergo cryosurgery was 74%.,Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352961/),%,74,66844,DB00762,Irinotecan
,11352961,response rate,"Although the main objective of this study was to evaluate the toxicity of the combined regimen, a high response rate (74%) was observed.",Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352961/),%,74,66845,DB00762,Irinotecan
,16001174,systemic clearances,"Median (range) irinotecan and topotecan lactone systemic clearances were 50.3 (16.6-76.2) l/h/m2 and 27.6 (14.7-55.9) l/h/m2, respectively.",Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16001174/),[l] / [h·m2],50.3,68574,DB00762,Irinotecan
,16001174,systemic clearances,"Median (range) irinotecan and topotecan lactone systemic clearances were 50.3 (16.6-76.2) l/h/m2 and 27.6 (14.7-55.9) l/h/m2, respectively.",Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16001174/),[l] / [h·m2],27.6,68575,DB00762,Irinotecan
,17563393,dose-normalized area under the plasma concentration-time curve,"In smokers, the dose-normalized area under the plasma concentration-time curve of irinotecan was significantly lower (median, 28.7 v 33.9 ng x h/mL/mg; P = .001) compared with nonsmokers.",Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17563393/),[h·ng] / [mg·ml],28.7,69930,DB00762,Irinotecan
,17563393,dose-normalized area under the plasma concentration-time curve,"In smokers, the dose-normalized area under the plasma concentration-time curve of irinotecan was significantly lower (median, 28.7 v 33.9 ng x h/mL/mg; P = .001) compared with nonsmokers.",Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17563393/),[h·ng] / [mg·ml],33.9,69931,DB00762,Irinotecan
,21447616,objective response rate,"At the MTD, non-haematologic grade 3/4 adverse events with a frequency of >10% were diarrhoea, vomiting and lethargy, and the objective response rate was 57.9% (95% confidence interval 33.5-79.7).",A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21447616/),%,57.,73220,DB00762,Irinotecan
,21447616,MTD,The MTD of sunitinib combined with FOLFIRI in chemotherapy-naive mCRC was 37.5 mg/day on Schedule 4/2.,A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21447616/),[mg] / [d],37.5,73221,DB00762,Irinotecan
,16778105,number,"The median number of cycles administered per patient was 2.0 (range, 1-12) in part I and 2.0 (range, 1-13) in study part II.",Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778105/),,2.0,73924,DB00762,Irinotecan
,16778105,number,"The median number of cycles administered per patient was 2.0 (range, 1-12) in part I and 2.0 (range, 1-13) in study part II.",Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778105/),,2.0,73925,DB00762,Irinotecan
,16778105,MTD,"The MTD was 30 mg/m(2)/d for irinotecan single agent and 30/1,600 mg/m(2)/d for the combination with capecitabine.",Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778105/),[mg] / [d·m(2)],30,73926,DB00762,Irinotecan
,16778105,MTD,"The MTD was 30 mg/m(2)/d for irinotecan single agent and 30/1,600 mg/m(2)/d for the combination with capecitabine.",Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778105/),[mg] / [d·m(2)],"1,600",73927,DB00762,Irinotecan
,33280996,C0,"Compared to the C0 (5129 ± 757 ng/mL) and AUC0-t (7858 ± 1307 ng h/mL) of CPT-11 in the CPT-11 single administration group, the C0 (4574 ± 371 ng/mL) and AUC0-t (8779 ± 601 ng h/mL) after the separated co-administration remained unchanged, but the pre-mixed co-administration resulted with a significant increased C0 (29,454 ± 12,080 ng/mL) and AUC0-t (15,539 ± 5165 ng h/mL) (p < 0.05).",Pharmacovigilance of herb-drug interactions: A pharmacokinetic study on the combination administration of herbal Kang'ai injection and chemotherapy irinotecan hydrochloride injection by LC-MS/MS. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280996/),[ng] / [ml],5129,75717,DB00762,Irinotecan
,33280996,AUC0-t,"Compared to the C0 (5129 ± 757 ng/mL) and AUC0-t (7858 ± 1307 ng h/mL) of CPT-11 in the CPT-11 single administration group, the C0 (4574 ± 371 ng/mL) and AUC0-t (8779 ± 601 ng h/mL) after the separated co-administration remained unchanged, but the pre-mixed co-administration resulted with a significant increased C0 (29,454 ± 12,080 ng/mL) and AUC0-t (15,539 ± 5165 ng h/mL) (p < 0.05).",Pharmacovigilance of herb-drug interactions: A pharmacokinetic study on the combination administration of herbal Kang'ai injection and chemotherapy irinotecan hydrochloride injection by LC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280996/),[h·ng] / [ml],7858,75718,DB00762,Irinotecan
,33280996,C0,"Compared to the C0 (5129 ± 757 ng/mL) and AUC0-t (7858 ± 1307 ng h/mL) of CPT-11 in the CPT-11 single administration group, the C0 (4574 ± 371 ng/mL) and AUC0-t (8779 ± 601 ng h/mL) after the separated co-administration remained unchanged, but the pre-mixed co-administration resulted with a significant increased C0 (29,454 ± 12,080 ng/mL) and AUC0-t (15,539 ± 5165 ng h/mL) (p < 0.05).",Pharmacovigilance of herb-drug interactions: A pharmacokinetic study on the combination administration of herbal Kang'ai injection and chemotherapy irinotecan hydrochloride injection by LC-MS/MS. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280996/),[ng] / [ml],4574,75719,DB00762,Irinotecan
,33280996,AUC0-t,"Compared to the C0 (5129 ± 757 ng/mL) and AUC0-t (7858 ± 1307 ng h/mL) of CPT-11 in the CPT-11 single administration group, the C0 (4574 ± 371 ng/mL) and AUC0-t (8779 ± 601 ng h/mL) after the separated co-administration remained unchanged, but the pre-mixed co-administration resulted with a significant increased C0 (29,454 ± 12,080 ng/mL) and AUC0-t (15,539 ± 5165 ng h/mL) (p < 0.05).",Pharmacovigilance of herb-drug interactions: A pharmacokinetic study on the combination administration of herbal Kang'ai injection and chemotherapy irinotecan hydrochloride injection by LC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280996/),[h·ng] / [ml],8779,75720,DB00762,Irinotecan
,33280996,C0,"Compared to the C0 (5129 ± 757 ng/mL) and AUC0-t (7858 ± 1307 ng h/mL) of CPT-11 in the CPT-11 single administration group, the C0 (4574 ± 371 ng/mL) and AUC0-t (8779 ± 601 ng h/mL) after the separated co-administration remained unchanged, but the pre-mixed co-administration resulted with a significant increased C0 (29,454 ± 12,080 ng/mL) and AUC0-t (15,539 ± 5165 ng h/mL) (p < 0.05).",Pharmacovigilance of herb-drug interactions: A pharmacokinetic study on the combination administration of herbal Kang'ai injection and chemotherapy irinotecan hydrochloride injection by LC-MS/MS. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280996/),[ng] / [ml],"29,454",75721,DB00762,Irinotecan
,33280996,AUC0-t,"Compared to the C0 (5129 ± 757 ng/mL) and AUC0-t (7858 ± 1307 ng h/mL) of CPT-11 in the CPT-11 single administration group, the C0 (4574 ± 371 ng/mL) and AUC0-t (8779 ± 601 ng h/mL) after the separated co-administration remained unchanged, but the pre-mixed co-administration resulted with a significant increased C0 (29,454 ± 12,080 ng/mL) and AUC0-t (15,539 ± 5165 ng h/mL) (p < 0.05).",Pharmacovigilance of herb-drug interactions: A pharmacokinetic study on the combination administration of herbal Kang'ai injection and chemotherapy irinotecan hydrochloride injection by LC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280996/),[h·ng] / [ml],"15,539",75722,DB00762,Irinotecan
>,23892411,peak concentration,"For the (TA)6/(TA)6 genotype, mPFS of the SN-38 peak concentration >43.2 ng/ml subgroup was significantly longer than that of ≤43.2 ng/ml subgroup (8.0 ± 0.35 vs.","Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23892411/),[ng] / [ml],43.2,77584,DB00762,Irinotecan
≤,23892411,peak concentration,"For the (TA)6/(TA)6 genotype, mPFS of the SN-38 peak concentration >43.2 ng/ml subgroup was significantly longer than that of ≤43.2 ng/ml subgroup (8.0 ± 0.35 vs.","Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23892411/),[ng] / [ml],43.2,77585,DB00762,Irinotecan
≤,23892411,peak concentration,"For the (TA)6/(TA)6 genotype, CPT-11 dosage can be increased gradually to improve efficacy for patients with SN-38 peak concentration ≤43.2 ng/ml after CPT-11 infusion; and for (TA)6/(TA)7 genotype patients, CPT-11 dosage may be lowered appropriately to reduce serious adverse effects such as bone marrow suppression and delayed diarrhea without affecting the efficacy for those with SN-38 valley concentration >16.83 ng/ml.","Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23892411/),[ng] / [ml],43.2,77586,DB00762,Irinotecan
>,23892411,valley concentration,"For the (TA)6/(TA)6 genotype, CPT-11 dosage can be increased gradually to improve efficacy for patients with SN-38 peak concentration ≤43.2 ng/ml after CPT-11 infusion; and for (TA)6/(TA)7 genotype patients, CPT-11 dosage may be lowered appropriately to reduce serious adverse effects such as bone marrow suppression and delayed diarrhea without affecting the efficacy for those with SN-38 valley concentration >16.83 ng/ml.","Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23892411/),[ng] / [ml],16.83,77587,DB00762,Irinotecan
,32537847,trough concentrations,"Geometric mean trough concentrations at cycle 1, day 15, were ramucirumab, 24.8 μg/mL; merestinib, 130 ng/mL.","Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32537847/),[μg] / [ml],24.8,78646,DB00762,Irinotecan
,32537847,trough concentrations,"Geometric mean trough concentrations at cycle 1, day 15, were ramucirumab, 24.8 μg/mL; merestinib, 130 ng/mL.","Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32537847/),[ng] / [ml],130,78647,DB00762,Irinotecan
,32537847,progression-free survival,Median progression-free survival was 3.3 months (95% confidence interval [CI]: 1.6-4.4).,"Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32537847/),month,3.3,78648,DB00762,Irinotecan
,32537847,overall survival,Median overall survival was 8.9 months (95% CI: 3.5-12.7).,"Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32537847/),month,8.9,78649,DB00762,Irinotecan
,10999728,half-life,"The half-life and area under the plasma concentration-time curve of SN-38 were 47+/-7.9 h and 2.0+/-0.79 microM x h, respectively, both representing a 2-fold increase as compared with earlier reported estimates (A. Sparreboom et al, Clin. Cancer Res., 4: 2747-2754, 1998).",Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999728/),h,47,80327,DB00762,Irinotecan
,10999728,area under the plasma concentration-time curve,"The half-life and area under the plasma concentration-time curve of SN-38 were 47+/-7.9 h and 2.0+/-0.79 microM x h, respectively, both representing a 2-fold increase as compared with earlier reported estimates (A. Sparreboom et al, Clin. Cancer Res., 4: 2747-2754, 1998).",Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999728/),h·μM,2.0,80328,DB00762,Irinotecan
,10999728,plasma concentration ratios,"We have also found, in contrast to earlier data, that SN-38G/SN-38 plasma concentration ratios decrease over time from approximately 7 (up to 50 h) to approximately 1 (at 500 h).",Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999728/),,7,80329,DB00762,Irinotecan
,10999728,plasma concentration ratios,"We have also found, in contrast to earlier data, that SN-38G/SN-38 plasma concentration ratios decrease over time from approximately 7 (up to 50 h) to approximately 1 (at 500 h).",Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999728/),,1,80330,DB00762,Irinotecan
,9443622,Maximum plasma concentrations,"Maximum plasma concentrations at 25 mg/kg reached around 10000 ng/ml, and dropped to 500 ng/ml in 8 h.",Pharmacokinetics of CPT-11 in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443622/),[ng] / [ml],10000,80719,DB00762,Irinotecan
,9443622,Maximum plasma concentrations,"Maximum plasma concentrations at 25 mg/kg reached around 10000 ng/ml, and dropped to 500 ng/ml in 8 h.",Pharmacokinetics of CPT-11 in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443622/),[ng] / [ml],500,80720,DB00762,Irinotecan
,9443622,Plasma concentrations,Plasma concentrations of SN-38 remained between 2 and 10 ng/ml.,Pharmacokinetics of CPT-11 in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443622/),[ng] / [ml],2 and 10,80721,DB00762,Irinotecan
,9443622,systemic clearance,"Mean values of systemic clearance, mean residence time and distribution volume at steady state, the major pharmacokinetic parameters for CPT-11, were 13.3 (ml/min per kg), 192 (min) and 2553 (ml/kg), respectively.",Pharmacokinetics of CPT-11 in rhesus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443622/),[ml] / [kg·min],13.3,80722,DB00762,Irinotecan
,9443622,mean residence time,"Mean values of systemic clearance, mean residence time and distribution volume at steady state, the major pharmacokinetic parameters for CPT-11, were 13.3 (ml/min per kg), 192 (min) and 2553 (ml/kg), respectively.",Pharmacokinetics of CPT-11 in rhesus monkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443622/),min,192,80723,DB00762,Irinotecan
,9443622,distribution volume at steady state,"Mean values of systemic clearance, mean residence time and distribution volume at steady state, the major pharmacokinetic parameters for CPT-11, were 13.3 (ml/min per kg), 192 (min) and 2553 (ml/kg), respectively.",Pharmacokinetics of CPT-11 in rhesus monkeys. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443622/),[ml] / [kg],2553,80724,DB00762,Irinotecan
,30128072,IC50,"Optimization of this series focusing on potency and physicochemical properties (especially permeability) led to the identification of compound 21, a highly potent ATM inhibitor (ATM cell IC50 0.0028 μM) with excellent kinase selectivity and favorable physicochemical and pharmacokinetics properties.","Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30128072/),μM,0.0028,80985,DB00762,Irinotecan
,11822765,terminal half-lives,"The harmonic mean terminal half-lives for CPT-11, SN-38, and SN-38G were 7.1 hours, 13.4 hours, and 12.7 hours, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822765/),h,7.1,81659,DB00762,Irinotecan
,11822765,terminal half-lives,"The harmonic mean terminal half-lives for CPT-11, SN-38, and SN-38G were 7.1 hours, 13.4 hours, and 12.7 hours, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822765/),h,13.4,81660,DB00762,Irinotecan
,11822765,terminal half-lives,"The harmonic mean terminal half-lives for CPT-11, SN-38, and SN-38G were 7.1 hours, 13.4 hours, and 12.7 hours, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822765/),h,12.7,81661,DB00762,Irinotecan
,11822765,clearance,"Across the range of doses studied, mean CPT-11 clearance was 14.0 +/- 4.0 l/h/m2 and volume of distribution was 146 +/- 45.9 l/m2.",Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822765/),[l] / [h·m2],14.0,81662,DB00762,Irinotecan
,11822765,volume of distribution,"Across the range of doses studied, mean CPT-11 clearance was 14.0 +/- 4.0 l/h/m2 and volume of distribution was 146 +/- 45.9 l/m2.",Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822765/),[l] / [m2],146,81663,DB00762,Irinotecan
,29873288,zeta potential,"Developed formulation revealed particle size, 166.9 ± 13.63 nm, zeta potential, 14.67 ± 1.08 mV and drug content (42.69 ± 1.97 µg/mg), with spherical shape and smooth surface.",Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29873288/),mv,14.67,82149,DB00762,Irinotecan
,7799022,recovery time,"Dose-dependent, reversible, noncumulative granulocytopenia was the dose-limiting toxicity (nadir, days 6 to 9; median recovery time, 5 days).",Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),d,5,83116,DB00762,Irinotecan
,7799022,terminal half-life,"CPT-11 plasma disposition was bi- or triphasic, with a mean terminal half-life of 14.2 +/- 0.9 hours (mean +/- SEM).",Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),h,14.2,83117,DB00762,Irinotecan
,7799022,volume of distribution (Vdss),"The mean volume of distribution (Vdss) was 157 +/- 8 L/m2, and total-body clearance was 15 +/- 1 L/m2/h.",Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),[l] / [m2],157,83118,DB00762,Irinotecan
,7799022,total-body clearance,"The mean volume of distribution (Vdss) was 157 +/- 8 L/m2, and total-body clearance was 15 +/- 1 L/m2/h.",Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),[l] / [h·m2],15,83119,DB00762,Irinotecan
,7799022,apparent half-life,SN-38 plasma decay had an apparent half-life of 13.8 +/- 1.4 hours.,Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),h,13.8,83120,DB00762,Irinotecan
,7799022,MTD,"The MTD of CPT-11 administered as a 30-minute IV infusion every 3 weeks is 600 mg/m2, with granulocytopenia being dose-limiting.",Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),,600,83121,DB00762,Irinotecan
,14569845,response rate,The combination of docetaxel and irinotecan resulted in a response rate of 30%.,Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14569845/),%,30,83549,DB00762,Irinotecan
,11193895,Vmax,"The transport of CPT in Caco-2 cell lines (validated model of intestinal drug transport) was concentration dependent and saturable (Vmax: 34 x 10(-5) cm/sec and Km: 20 microM), and was temperature dependent with an activation energy (Ea) of 11.7 kcal/mole.",Pharmacokinetics of orally administered camptothecins. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),[cm] / [s],34 x 10(-5),85169,DB00762,Irinotecan
,11193895,Km,"The transport of CPT in Caco-2 cell lines (validated model of intestinal drug transport) was concentration dependent and saturable (Vmax: 34 x 10(-5) cm/sec and Km: 20 microM), and was temperature dependent with an activation energy (Ea) of 11.7 kcal/mole.",Pharmacokinetics of orally administered camptothecins. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),μM,20,85170,DB00762,Irinotecan
,11193895,activation energy (Ea),"The transport of CPT in Caco-2 cell lines (validated model of intestinal drug transport) was concentration dependent and saturable (Vmax: 34 x 10(-5) cm/sec and Km: 20 microM), and was temperature dependent with an activation energy (Ea) of 11.7 kcal/mole.",Pharmacokinetics of orally administered camptothecins. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),[kcal] / [mole],11.7,85171,DB00762,Irinotecan
,11193895,specific activities,"The mean (+/- SD) specific activities (pmoles/min/mg) were: liver (8.57 +/- 10.4, n = 8), duodenum (5.06 +/- 3.7, n = 4), jejunum (6.44 +/- 2.8, n = 5), ileum (4.81 +/- 2.4, n = 5), colon (1.93 +/- 1.5, n = 6), and rectum (0.82, n = 1).",Pharmacokinetics of orally administered camptothecins. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),[pmoles] / [mg·min],8.57,85172,DB00762,Irinotecan
,11193895,specific activities,"The mean (+/- SD) specific activities (pmoles/min/mg) were: liver (8.57 +/- 10.4, n = 8), duodenum (5.06 +/- 3.7, n = 4), jejunum (6.44 +/- 2.8, n = 5), ileum (4.81 +/- 2.4, n = 5), colon (1.93 +/- 1.5, n = 6), and rectum (0.82, n = 1).",Pharmacokinetics of orally administered camptothecins. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),[pmoles] / [mg·min],5.06,85173,DB00762,Irinotecan
,11193895,specific activities,"The mean (+/- SD) specific activities (pmoles/min/mg) were: liver (8.57 +/- 10.4, n = 8), duodenum (5.06 +/- 3.7, n = 4), jejunum (6.44 +/- 2.8, n = 5), ileum (4.81 +/- 2.4, n = 5), colon (1.93 +/- 1.5, n = 6), and rectum (0.82, n = 1).",Pharmacokinetics of orally administered camptothecins. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),[pmoles] / [mg·min],6.44,85174,DB00762,Irinotecan
,11193895,specific activities,"The mean (+/- SD) specific activities (pmoles/min/mg) were: liver (8.57 +/- 10.4, n = 8), duodenum (5.06 +/- 3.7, n = 4), jejunum (6.44 +/- 2.8, n = 5), ileum (4.81 +/- 2.4, n = 5), colon (1.93 +/- 1.5, n = 6), and rectum (0.82, n = 1).",Pharmacokinetics of orally administered camptothecins. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),[pmoles] / [mg·min],4.81,85175,DB00762,Irinotecan
,11193895,specific activities,"The mean (+/- SD) specific activities (pmoles/min/mg) were: liver (8.57 +/- 10.4, n = 8), duodenum (5.06 +/- 3.7, n = 4), jejunum (6.44 +/- 2.8, n = 5), ileum (4.81 +/- 2.4, n = 5), colon (1.93 +/- 1.5, n = 6), and rectum (0.82, n = 1).",Pharmacokinetics of orally administered camptothecins. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),[pmoles] / [mg·min],1.93,85176,DB00762,Irinotecan
,21953502,central volume of distribution V(1),"Estimated pharmacokinetic parameters (% standard error) were as follows: central volume of distribution V(1) = 2.96 L (4%), peripheral volume of distribution V(2) = 4.65 L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836 L/d (8%), and zero-order elimination rate k(0) = 8.71 mg/d (10%).",Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),l,2.96,86539,DB00762,Irinotecan
,21953502,peripheral volume of distribution V(2),"Estimated pharmacokinetic parameters (% standard error) were as follows: central volume of distribution V(1) = 2.96 L (4%), peripheral volume of distribution V(2) = 4.65 L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836 L/d (8%), and zero-order elimination rate k(0) = 8.71 mg/d (10%).",Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),l,4.65,86540,DB00762,Irinotecan
,21953502,elimination clearance CL,"Estimated pharmacokinetic parameters (% standard error) were as follows: central volume of distribution V(1) = 2.96 L (4%), peripheral volume of distribution V(2) = 4.65 L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836 L/d (8%), and zero-order elimination rate k(0) = 8.71 mg/d (10%).",Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),[l] / [d],0.497,86541,DB00762,Irinotecan
,21953502,distribution clearance Q,"Estimated pharmacokinetic parameters (% standard error) were as follows: central volume of distribution V(1) = 2.96 L (4%), peripheral volume of distribution V(2) = 4.65 L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836 L/d (8%), and zero-order elimination rate k(0) = 8.71 mg/d (10%).",Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),[l] / [d],0.836,86542,DB00762,Irinotecan
,21953502,zero-order elimination rate k(0),"Estimated pharmacokinetic parameters (% standard error) were as follows: central volume of distribution V(1) = 2.96 L (4%), peripheral volume of distribution V(2) = 4.65 L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836 L/d (8%), and zero-order elimination rate k(0) = 8.71 mg/d (10%).",Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),[mg] / [d],8.71,86543,DB00762,Irinotecan
,21953502,PFS,Median PFS of patients with a cetuximab residual concentration on day 14 below median value was 3.3 months as compared with 7.8 months for the other patients (P = 0.004).,Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),month,3,86544,DB00762,Irinotecan
,21953502,PFS,Median PFS of patients with a cetuximab residual concentration on day 14 below median value was 3.3 months as compared with 7.8 months for the other patients (P = 0.004).,Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),month,7.8,86545,DB00762,Irinotecan
,2306725,50% effective doses,"The 50% effective doses of CPT-11 against KB and L1210 cells were 1100 and 5500 ng/ml, respectively.",Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2306725/),[ng] / [ml],1100,86616,DB00762,Irinotecan
,2306725,50% effective doses,"The 50% effective doses of CPT-11 against KB and L1210 cells were 1100 and 5500 ng/ml, respectively.",Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2306725/),[ng] / [ml],5500,86617,DB00762,Irinotecan
,2306725,biological half-life,The plasma CPT-11 concentration decreased biexponentially after i.v. administration of CPT-11 into mice with a biological half-life of 0.8 to 1.1 h.,Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2306725/),h,0.8 to 1.1,86618,DB00762,Irinotecan
,2306725,half-life,The SN-38 concentration decreased for the first 30 min after administration and was then maintained for a few hours at about 0.1 microgram/ml after i.v. administration of 20 and 40 mg/kg of CPT-11 followed by the log-linear terminal phase with a half-life of about 2 h which was independent of the dose.,Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2306725/),h,2,86619,DB00762,Irinotecan
,27194579,time of disease control,The median time of disease control was 22.1 weeks.,Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194579/),weeks,22.1,88504,DB00762,Irinotecan
,17095207,K(i),"In vitro, sorafenib strongly inhibited SN38 glucuronidation in human liver microsomes as indicated by a K(i) value of 2.7 micromol/l.",Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17095207/),[μM] / [l],2.7,89198,DB00762,Irinotecan
,32156785,progression-free,"At the recommended phase II dose, 3 of 6 patients (50%) had a partial response; the median progression-free and overall survival (PFS, OS) were 65.6 weeks and 25.1 months, respectively.",Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32156785/),weeks,65.6,91775,DB00762,Irinotecan
,32156785,"overall survival (PFS, OS)","At the recommended phase II dose, 3 of 6 patients (50%) had a partial response; the median progression-free and overall survival (PFS, OS) were 65.6 weeks and 25.1 months, respectively.",Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32156785/),month,25.1,91776,DB00762,Irinotecan
,16284918,K(a),"Capecitabine oral absorption was characterized by a rapid first order input (K(a)=2.1 +/- 0.3 hr(-1)) with a lag time (0.28 +/- 0.11 hr), but related inter-occasion (IOV) and inter-subject (ISV) variabilities for these parameters, 167% and 110%, indicated that this oral absorption was highly variable.",Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284918/),1/[hr],2.1,92790,DB00762,Irinotecan
,16284918,lag time,"Capecitabine oral absorption was characterized by a rapid first order input (K(a)=2.1 +/- 0.3 hr(-1)) with a lag time (0.28 +/- 0.11 hr), but related inter-occasion (IOV) and inter-subject (ISV) variabilities for these parameters, 167% and 110%, indicated that this oral absorption was highly variable.",Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284918/),h,0.28,92791,DB00762,Irinotecan
,16284918,CL (CL10,"The capecitabine CL (CL10 = 218+/- 18 L/hr, ISV = 18%) and 5'-DFUR elimination rate constant (K34 = 5.3 +/- 2.0 hr(-1), ISV = 25%) were influenced by total bilirubin (BILT).",Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284918/),[l] / [h],218,92792,DB00762,Irinotecan
,16284918,elimination rate constant (K34,"The capecitabine CL (CL10 = 218+/- 18 L/hr, ISV = 18%) and 5'-DFUR elimination rate constant (K34 = 5.3 +/- 2.0 hr(-1), ISV = 25%) were influenced by total bilirubin (BILT).",Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284918/),1/[hr],5.3,92793,DB00762,Irinotecan
,16284918,elimination rate constant of plasma 5-FU (K40),The elimination rate constant of plasma 5-FU (K40) was 66 +/- 24 hr(-1) (ISV = 34%).,Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284918/),1/[hr],66,92794,DB00762,Irinotecan
,15523087,exposure,"In addition, the presence of a UGT1A1 variant with a (TA)7 repeat in the promoter (UGT1A1*28) was associated with increased exposure to SN-38 (435 ng x h/mL, 95% confidence interval [CI] = 339 to 531 ng x h/mL in patients who are homozygous for wild-type UGT1A1; 631 ng x h/mL, 95% CI = 499 to 762 ng .",Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15523087/),[h·ng] / [ml],435,93629,DB00762,Irinotecan
,15523087,exposure,"In addition, the presence of a UGT1A1 variant with a (TA)7 repeat in the promoter (UGT1A1*28) was associated with increased exposure to SN-38 (435 ng x h/mL, 95% confidence interval [CI] = 339 to 531 ng x h/mL in patients who are homozygous for wild-type UGT1A1; 631 ng x h/mL, 95% CI = 499 to 762 ng .",Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15523087/),[h·ng] / [ml],631,93630,DB00762,Irinotecan
,18761148,lambda(max),"A new, simple, sensitive and specific reversed-phase high performance liquid chromatographic (HPLC) method using ultraviolet detection was developed and validated for the analysis of CPT-11 (lambda(max)=254 nm, 365 nm) and its major active metabolite, SN-38 (lambda(max)=380 nm) in rat plasma and bile.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),,254,94652,DB00762,Irinotecan
,18761148,lambda(max),"A new, simple, sensitive and specific reversed-phase high performance liquid chromatographic (HPLC) method using ultraviolet detection was developed and validated for the analysis of CPT-11 (lambda(max)=254 nm, 365 nm) and its major active metabolite, SN-38 (lambda(max)=380 nm) in rat plasma and bile.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),nm,380,94653,DB00762,Irinotecan
,18761148,flow rate,The chromatographic separation was achieved by gradient elution consisting of acetonitrile and water (pH 3.0 adjusted with 20% o-phosphoric acid) at a flow rate of 1.0 ml/min.,"Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),[ml] / [min],1.0,94654,DB00762,Irinotecan
,18761148,Total run time,Total run time for each sample was 30 min.,"Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),min,30,94655,DB00762,Irinotecan
,18761148,retention times,"All the analytes viz. topotecan, CPT-11, SN-38 were well separated with retention times of 11.4, 13.4 and 15.5 min, respectively.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),min,11.4,94656,DB00762,Irinotecan
,18761148,retention times,"All the analytes viz. topotecan, CPT-11, SN-38 were well separated with retention times of 11.4, 13.4 and 15.5 min, respectively.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),min,13.4,94657,DB00762,Irinotecan
,18761148,retention times,"All the analytes viz. topotecan, CPT-11, SN-38 were well separated with retention times of 11.4, 13.4 and 15.5 min, respectively.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),min,15.5,94658,DB00762,Irinotecan
,18761148,percent extraction efficiency,"The percent extraction efficiency was approximately 97% for CPT-11 and SN-38 from plasma while extraction recovery of CPT-11 and SN-38 from bile was approximately 70% and approximately 60%, respectively.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),%,97,94659,DB00762,Irinotecan
,18761148,extraction recovery,"The percent extraction efficiency was approximately 97% for CPT-11 and SN-38 from plasma while extraction recovery of CPT-11 and SN-38 from bile was approximately 70% and approximately 60%, respectively.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),%,70,94660,DB00762,Irinotecan
,18761148,extraction recovery,"The percent extraction efficiency was approximately 97% for CPT-11 and SN-38 from plasma while extraction recovery of CPT-11 and SN-38 from bile was approximately 70% and approximately 60%, respectively.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),%,60,94661,DB00762,Irinotecan
,18761148,absolute bioavailability,"In the present study, irinotecan showed an absolute bioavailability of 30% as calculated from the pharmacokinetic data.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),%,30,94662,DB00762,Irinotecan
,18441330,confirmed response rate,"The confirmed response rate for patients receiving 5-FU at standard 2000 mg/m(2) (N = 41) was 56%, with a median duration of 9.3 months.",Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18441330/),%,56,95589,DB00762,Irinotecan
,18441330,progression-free,"Median progression-free and overall survival times including all 49 patients were 8.1 (95% confidence interval 6.0-9.7) and 28.2 months, respectively.",Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18441330/),month,8.1,95590,DB00762,Irinotecan
,18441330,overall survival times,"Median progression-free and overall survival times including all 49 patients were 8.1 (95% confidence interval 6.0-9.7) and 28.2 months, respectively.",Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18441330/),month,28.2,95591,DB00762,Irinotecan
,11773157,clearance,"The mean (+/- SD) CPT-11 clearance was 33.6 +/- 10.8 L/h, with an interindividual variability (IIV) of 32.1%.",Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11773157/),[l] / [h],33.6,96270,DB00762,Irinotecan
,8826613,peak plasma concentrations (Cmax),Pharmacokinetic evaluations performed i.v. at the highest non-toxic dosage in mice bearing P03 tumors revealed CPT-11 peak plasma concentrations (Cmax) of 8.9 micrograms/ml and a terminal half-life of 0.6 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),[μg] / [ml],8.9,96648,DB00762,Irinotecan
,8826613,terminal half-life,Pharmacokinetic evaluations performed i.v. at the highest non-toxic dosage in mice bearing P03 tumors revealed CPT-11 peak plasma concentrations (Cmax) of 8.9 micrograms/ml and a terminal half-life of 0.6 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,0.6,96649,DB00762,Irinotecan
,8826613,Cmax,The metabolite SN-38 plasma concentrations presented a Cmax of 1.6 micrograms/ml and a terminal half-life of 7.4 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),[μg] / [ml],1.6,96650,DB00762,Irinotecan
,8826613,terminal half-life,The metabolite SN-38 plasma concentrations presented a Cmax of 1.6 micrograms/ml and a terminal half-life of 7.4 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,7.4,96651,DB00762,Irinotecan
,8826613,half-life,"Although the CPT-11 tumor levels were similar to the plasma concentrations for early time points, drug levels decreased more slowly in the tumor compared to plasma (half-life, 5.0 h).",Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,5.0,96652,DB00762,Irinotecan
,8826613,half-life,SN-38 tumor levels reached concentrations in the range of 0.32-0.34 micrograms/g and decayed with a half-life of 6.9 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,6.9,96653,DB00762,Irinotecan
,33993383,MTD,The MTD of alisertib combined with weekly irinotecan was 20 mg twice per day on days 1-3 and 8-10.,Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33993383/),mg,20,96916,DB00762,Irinotecan
,21509928,systemic exposure,Median (range) systemic exposure to SN-38 at the MTD (30 mg/m(2) /dose) was 67 ng-h/mL (36 to 111 ng-h/mL).,Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21509928/),[ng-h] / [ml],67,97467,DB00762,Irinotecan
,34031756,MTD,"The DLTs included vomiting and febrile neutropenia, and the MTD was 90 mg/m2.",Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34031756/),mg,90,97557,DB00762,Irinotecan
,32534159,maximum conjugation yield,The folic acid was conjugated with gelatin through the formation of amide linkage with a maximum conjugation yield of ~69%.,Tuning the pharmacokinetics and efficacy of irinotecan (IRI) loaded gelatin nanoparticles through folate conjugation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32534159/),%,69,97752,DB00762,Irinotecan
,32534159,-,The irinotecan (IRI)-loading efficiency estimated for IRI-GNP and IRI-GNP-F was 6.6 ± 0.42% and 11.2 ± 0.73% respectively and both formulations showed faster release of IRI at acidic pH (~5) than at physiological pH (~7).,Tuning the pharmacokinetics and efficacy of irinotecan (IRI) loaded gelatin nanoparticles through folate conjugation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32534159/),%,6.6,97753,DB00762,Irinotecan
,32534159,loading efficiency,The irinotecan (IRI)-loading efficiency estimated for IRI-GNP and IRI-GNP-F was 6.6 ± 0.42% and 11.2 ± 0.73% respectively and both formulations showed faster release of IRI at acidic pH (~5) than at physiological pH (~7).,Tuning the pharmacokinetics and efficacy of irinotecan (IRI) loaded gelatin nanoparticles through folate conjugation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32534159/),%,6.6,97754,DB00762,Irinotecan
,32534159,loading efficiency,The irinotecan (IRI)-loading efficiency estimated for IRI-GNP and IRI-GNP-F was 6.6 ± 0.42% and 11.2 ± 0.73% respectively and both formulations showed faster release of IRI at acidic pH (~5) than at physiological pH (~7).,Tuning the pharmacokinetics and efficacy of irinotecan (IRI) loaded gelatin nanoparticles through folate conjugation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32534159/),%,11.2,97755,DB00762,Irinotecan
,9932079,terminal half-life,"The clinical pharmacokinetics of irinotecan (CPT11) can be described by a 2 or 3 compartment model, a mean terminal half-life of 12 hours, a volume of distribution at steady state of 168 l/m2 and a total body clearance of 15 l/m2/h.",[Irinotecan pharmacokinetics]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932079/),h,12,98308,DB00762,Irinotecan
,9932079,volume of distribution at steady state,"The clinical pharmacokinetics of irinotecan (CPT11) can be described by a 2 or 3 compartment model, a mean terminal half-life of 12 hours, a volume of distribution at steady state of 168 l/m2 and a total body clearance of 15 l/m2/h.",[Irinotecan pharmacokinetics]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932079/),[l] / [m2],168,98309,DB00762,Irinotecan
,9932079,total body clearance,"The clinical pharmacokinetics of irinotecan (CPT11) can be described by a 2 or 3 compartment model, a mean terminal half-life of 12 hours, a volume of distribution at steady state of 168 l/m2 and a total body clearance of 15 l/m2/h.",[Irinotecan pharmacokinetics]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932079/),[l] / [h·m2],15,98310,DB00762,Irinotecan
,9932079,u,"The mean 24 h irinotecan urinary excretion represents 17-25% of the administered dose, whereas SN38 and its glucuronide recovery in urine is minimal (0.5 and 6%, respectively).",[Irinotecan pharmacokinetics]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932079/),%,0.5,98311,DB00762,Irinotecan
,9219511,terminal half-life,Irinotecan lactone showed biphasic plasma disposition following intravenous dosing with a terminal half-life ranging between 1.1 to 3 h.,Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219511/),h,1.1 to 3,99147,DB00762,Irinotecan
,9219511,steady-state volume of distribution,The steady-state volume of distribution ranged from 19.1 to 48.1 l/m2.,Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219511/),[l] / [m2],19.1 to 48.1,99148,DB00762,Irinotecan
,9219511,bioavailability,"After oral dosing, peak irinotecan and SN-38 lactone concentrations occurred within 1 h, and the irinotecan lactone bioavailability was 0.12 at 10 mg/kg and 0.21 at 40 mg/kg.",Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219511/),,0.12,99149,DB00762,Irinotecan
,9219511,bioavailability,"After oral dosing, peak irinotecan and SN-38 lactone concentrations occurred within 1 h, and the irinotecan lactone bioavailability was 0.12 at 10 mg/kg and 0.21 at 40 mg/kg.",Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219511/),,0.21,99150,DB00762,Irinotecan
,9219511,percent unbound,"The percent unbound SN-38 lactone in murine plasma at 1000 ng/ml was 3.4 +/- 0.67%, whereas at 100 ng/ml the percent unbound was 1.18 +/- 0.14%.",Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219511/),%,3.4,99151,DB00762,Irinotecan
,9219511,percent unbound,"The percent unbound SN-38 lactone in murine plasma at 1000 ng/ml was 3.4 +/- 0.67%, whereas at 100 ng/ml the percent unbound was 1.18 +/- 0.14%.",Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219511/),%,1.18,99152,DB00762,Irinotecan
,9219511,exposure,"Systemic exposure to unbound SN-38 lactone in nontumor-bearing animals after a single oral irinotecan dose of 40, 10, and 5 mg/kg was 28.3, 8.6, and 2.9 ng h/ml, respectively.",Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219511/),[h·ng] / [ml],28.3,99153,DB00762,Irinotecan
,9219511,exposure,"Systemic exposure to unbound SN-38 lactone in nontumor-bearing animals after a single oral irinotecan dose of 40, 10, and 5 mg/kg was 28.3, 8.6, and 2.9 ng h/ml, respectively.",Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219511/),[h·ng] / [ml],8.6,99154,DB00762,Irinotecan
,9219511,exposure,"Systemic exposure to unbound SN-38 lactone in nontumor-bearing animals after a single oral irinotecan dose of 40, 10, and 5 mg/kg was 28.3, 8.6, and 2.9 ng h/ml, respectively.",Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219511/),[h·ng] / [ml],2.9,99155,DB00762,Irinotecan
,12931014,areas under the curve (AUC,"Following CPT-11 administration, the mean areas under the curve (AUC; ng.h/ml) of SN-38 were 0.11 at 50 mg/m(2) and 0.17 at 60 mg/m(2).",Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12931014/),[h·ng] / [ml],0.11,99756,DB00762,Irinotecan
,12931014,areas under the curve (AUC,"Following CPT-11 administration, the mean areas under the curve (AUC; ng.h/ml) of SN-38 were 0.11 at 50 mg/m(2) and 0.17 at 60 mg/m(2).",Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12931014/),[h·ng] / [ml],0.17,99757,DB00762,Irinotecan
,12931014,AUCs,"Following nedaplatin administration, the mean AUCs (microg x h/ml) of filterable platinum were 6.0 at 50 mg/m(2), and 6.0 at 60 mg/m(2).",Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12931014/),[h·μg] / [ml],6.0,99758,DB00762,Irinotecan
,12931014,response rate,The response rate was 50% (2 complete responses and 2 partial responses).,Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12931014/),%,50,99759,DB00762,Irinotecan
,8622015,response duration,"The median response duration was 8.1 months (range, 4.0 to 16.0) and the median survival time was 12.1 months (range, 2.1 to 21.7) for all 41 patients.",Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622015/),month,8.1,100300,DB00762,Irinotecan
,8622015,survival time,"The median response duration was 8.1 months (range, 4.0 to 16.0) and the median survival time was 12.1 months (range, 2.1 to 21.7) for all 41 patients.",Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622015/),month,12.1,100301,DB00762,Irinotecan
,11357175,half-lives,"After injection of a bolus dose of 5 micromol in the reservoir, irinotecan lactone disappeared from the perfusate following a two-exponential decay with half-lives of 3.5 and 120 min and a total clearance of 1.54 +/- 0.07 mL/min per gram of liver.","Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11357175/),min,3.5,101715,DB00762,Irinotecan
,11357175,half-lives,"After injection of a bolus dose of 5 micromol in the reservoir, irinotecan lactone disappeared from the perfusate following a two-exponential decay with half-lives of 3.5 and 120 min and a total clearance of 1.54 +/- 0.07 mL/min per gram of liver.","Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11357175/),min,120,101716,DB00762,Irinotecan
,11357175,total clearance,"After injection of a bolus dose of 5 micromol in the reservoir, irinotecan lactone disappeared from the perfusate following a two-exponential decay with half-lives of 3.5 and 120 min and a total clearance of 1.54 +/- 0.07 mL/min per gram of liver.","Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11357175/),[ml] / [gram·min],1.54,101717,DB00762,Irinotecan
,11357175,area under the curve (AUC),The area under the curve (AUC) ratio lactone/total drug was 0.212 +/- 0.098 and the half-life of interconversion was 5.02 +/- 0.10 min.,"Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11357175/),,0.212,101718,DB00762,Irinotecan
,11357175,half-life of interconversion,The area under the curve (AUC) ratio lactone/total drug was 0.212 +/- 0.098 and the half-life of interconversion was 5.02 +/- 0.10 min.,"Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11357175/),min,5.02,101719,DB00762,Irinotecan
,1788984,cumulative,"3. The cumulative biliary and urinary excretion of radioactivity after dosage of rats with irinotecan were 62.2% and 33.3% dose, respectively, and 9.0% of the radioactivity was excreted in the faeces.","Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788984/),%,62.2,101777,DB00762,Irinotecan
,1788984,biliary,"3. The cumulative biliary and urinary excretion of radioactivity after dosage of rats with irinotecan were 62.2% and 33.3% dose, respectively, and 9.0% of the radioactivity was excreted in the faeces.","Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788984/),%,62.2,101778,DB00762,Irinotecan
,1788984,urinary excretion,"3. The cumulative biliary and urinary excretion of radioactivity after dosage of rats with irinotecan were 62.2% and 33.3% dose, respectively, and 9.0% of the radioactivity was excreted in the faeces.","Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788984/),%,33.3,101779,DB00762,Irinotecan
,25687989,clearance,"The estimated clearance of bevacizumab was 0.18 L/day, the free VEGF165 levels at baseline were 212 ng/L, and the elimination rate constant of free VEGF165 was 0.401 day(-1).",A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687989/),[l] / [d],0.18,102885,DB00762,Irinotecan
,25687989,elimination rate constant,"The estimated clearance of bevacizumab was 0.18 L/day, the free VEGF165 levels at baseline were 212 ng/L, and the elimination rate constant of free VEGF165 was 0.401 day(-1).",A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687989/),1/[day],0.401,102886,DB00762,Irinotecan
,23984532,elimination half-life,"Compared with CPT-11 solution, the elimination half-life of CPT-11 was prolonged from 2.28 h to 3.95 h after the intravenous injection of CPT-11 NPs, and its AUC was 1.47 times than that of CPT-11 solution.",[Pharmacokinetics and tissue distribution of irinotecan hydrochloride nanoparticles]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23984532/),h,2.28,103704,DB00762,Irinotecan
,23984532,elimination half-life,"Compared with CPT-11 solution, the elimination half-life of CPT-11 was prolonged from 2.28 h to 3.95 h after the intravenous injection of CPT-11 NPs, and its AUC was 1.47 times than that of CPT-11 solution.",[Pharmacokinetics and tissue distribution of irinotecan hydrochloride nanoparticles]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23984532/),h,3.95,103705,DB00762,Irinotecan
,21630281,systemic clearance,Mean systemic clearance of SN2310 ranged between 1.91 and 2.02 L/h/m(2) .,"Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21630281/),[h·l] / [m(2],1.91 and 2.02,105223,DB00762,Irinotecan
,21630281,t1/2,Mean t1/2 values of SN-38 across the 20-30 mg/m(2) dose levels (131-199 h) were 33-55-fold longer than those observed for SN2310.,"Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21630281/),h,131-199,105224,DB00762,Irinotecan
,16003560,mass ratio,"Pharmacokinetic results revealed a mass ratio of plasma SN-38G/SN-38, which was very similar to historical controls (7.15 +/- 5.67, n = 18).","A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003560/),,7.15,106007,DB00762,Irinotecan
,31482519,AUC0-24H,Pharmacokinetic studies demonstrated that the copper-quercetin formulations had an AUC0-24H of 8382.1 μg h/mL when administered to mice at 50 mg/kg.,Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31482519/),[h·μg] / [ml],8382.1,106057,DB00762,Irinotecan
>,31482519,IC50,"Given that quercetin exhibits an IC50 of >10 μM when tested against cancer cell lines, we believe that the utility of this novel quercetin formulation for cancer indications will ultimately be as a component of a combination product.",Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31482519/),μM,10,106058,DB00762,Irinotecan
,12496745,CL,Estimated irinotecan CL (25.2 L/h) was similar to that determined in other studies.,"Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496745/),[l] / [h],25.2,107173,DB00762,Irinotecan
,17652269,Tissue half-life,Tissue half-life was 16.7 days for nLs-CPT-11 and 10.9 days for Doxil.,Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17652269/),d,16.7,107365,DB00762,Irinotecan
,17652269,Tissue half-life,Tissue half-life was 16.7 days for nLs-CPT-11 and 10.9 days for Doxil.,Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17652269/),d,10.9,107366,DB00762,Irinotecan
,31370815,overall response rate,The overall response rate was 55.6%.,Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31370815/),%,55.6,107632,DB00762,Irinotecan
,31370815,progression free,"The median progression free and overall survival were 8.1 and 18.2 months, respectively.",Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31370815/),month,8.1,107633,DB00762,Irinotecan
,31370815,overall survival,"The median progression free and overall survival were 8.1 and 18.2 months, respectively.",Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31370815/),month,18.2,107634,DB00762,Irinotecan
,22201120,Overall response rate,"Overall response rate and median progression-free survival in a total of 61 patients were 43% and 7.5 months, respectively.",Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201120/),%,43,108550,DB00762,Irinotecan
,22201120,progression-free survival,"Overall response rate and median progression-free survival in a total of 61 patients were 43% and 7.5 months, respectively.",Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201120/),month,7.5,108551,DB00762,Irinotecan
,30262136,progression-free survival,"Objective response (35 [49%] of 71 vs 40 [56%] of 71), clinical benefit (62 [87%] vs 65 [92%]), and progression-free survival (median 10·8 months [95% CI 7·4-11·5] vs 11·1 months [95% CI 8·0-12·8]) were similar in the BEVZ92 and reference bevacizumab groups.","Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30262136/),month,10·8,109658,DB00762,Irinotecan
,30262136,progression-free survival,"Objective response (35 [49%] of 71 vs 40 [56%] of 71), clinical benefit (62 [87%] vs 65 [92%]), and progression-free survival (median 10·8 months [95% CI 7·4-11·5] vs 11·1 months [95% CI 8·0-12·8]) were similar in the BEVZ92 and reference bevacizumab groups.","Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30262136/),month,11·1,109659,DB00762,Irinotecan
,18619980,absolute bioavailability (F),"The absolute bioavailability (F) of irinotecan control was 33%, which was increased to 43% (1.3 fold) by quercetin administration.",Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18619980/),%,33,110540,DB00762,Irinotecan
,18619980,absolute bioavailability (F),"The absolute bioavailability (F) of irinotecan control was 33%, which was increased to 43% (1.3 fold) by quercetin administration.",Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18619980/),%,43,110541,DB00762,Irinotecan
,24114122,AUCs,"UGT1A1 *1/*28 and *1/*1 patients treated with IRIN (150) had similar AUCs for the active irinotecan metabolite, SN38 (366 +/- 278 and 350 +/- 159 ng/ml*hr, respectively).","UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24114122/),[ng] / [h·ml],366,111241,DB00762,Irinotecan
,24114122,AUCs,"UGT1A1 *1/*28 and *1/*1 patients treated with IRIN (150) had similar AUCs for the active irinotecan metabolite, SN38 (366 +/- 278 and 350 +/- 159 ng/ml*hr, respectively).","UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24114122/),[ng] / [h·ml],350,111242,DB00762,Irinotecan
,24114122,exposures,"UGT1A1 *28/*28 patients (n = 3) treated with a lower IRIN dose (100) had non-significantly higher mean SN38 exposures (604 +/- 289 ng/ml*hr, p = 0.14).","UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24114122/),[ng] / [h·ml],604,111243,DB00762,Irinotecan
,29785106,IC50,The IC50 for the SN38-loaded targeted liposomes (0.11 μM) was significantly lower than for the SN38 solution (0.37 μM) in the MCF7 cell line (P<0.01).,SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29785106/),μM,0.11,111651,DB00762,Irinotecan
,29785106,IC50,The IC50 for the SN38-loaded targeted liposomes (0.11 μM) was significantly lower than for the SN38 solution (0.37 μM) in the MCF7 cell line (P<0.01).,SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29785106/),μM,0.37,111652,DB00762,Irinotecan
,10821401,flow-rate,"Mobile phase consists of potassium dihydrogenphosphate (0.1 M)-acetonitrile (67:33), at a flow-rate of 1 ml/min.",Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10821401/),[ml] / [min],1,112800,DB00762,Irinotecan
,10821401,peak plasma concentration,The peak plasma concentration of CPT-11 at the end of the infusion is 3800 ng/ml.,Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10821401/),[ng] / [ml],3800,112801,DB00762,Irinotecan
,10821401,terminal half-life,Plasma decay is biphasic with a terminal half-life of 11.6 h.,Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10821401/),h,11.6,112802,DB00762,Irinotecan
,10821401,volume of distribution at steady state (Vss),"The volume of distribution at steady state (Vss) is 203 l/m2, and the total body clearance (Cl) is 14.8 l/h x m2.",Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10821401/),[l] / [m2],203,112803,DB00762,Irinotecan
,10821401,total body clearance (Cl),"The volume of distribution at steady state (Vss) is 203 l/m2, and the total body clearance (Cl) is 14.8 l/h x m2.",Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10821401/),[l] / [h·m2],14.8,112804,DB00762,Irinotecan
,10821401,maximum concentrations,"The maximum concentrations of SN-38 and SN-38G reach 28.9 and 151 ng/ml, respectively.",Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10821401/),[ng] / [ml],28.9,112805,DB00762,Irinotecan
,10821401,maximum concentrations,"The maximum concentrations of SN-38 and SN-38G reach 28.9 and 151 ng/ml, respectively.",Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10821401/),[ng] / [ml],151,112806,DB00762,Irinotecan
,9815787,Max,3.76+/-0.68 4.10+/-0.86 7.86+/-1.43 Range 2.01-5.03 2. 29-5.72 4.30-10.68 Max/min 2.50 2.45 2.48 High interpatient variability was observed in the AUC.,Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815787/),,2.50,113003,DB00762,Irinotecan
,12044505,time to progression (TTP),"The median time to progression (TTP) was 9.6 months (range 2.5-21.8 months), median survival was 14.8 months (range 0.3-27+ months) and actuarial 1-year survival time was 55%.","Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12044505/),month,9.6,113160,DB00762,Irinotecan
,12044505,survival,"The median time to progression (TTP) was 9.6 months (range 2.5-21.8 months), median survival was 14.8 months (range 0.3-27+ months) and actuarial 1-year survival time was 55%.","Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12044505/),month,14,113161,DB00762,Irinotecan
,28102464,PFS,"Six patients achieved a partial response, and in 15 patients with CRC median PFS was 5.95 months (95% CI: 5.29-8.77).",A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102464/),month,5.95,113620,DB00762,Irinotecan
,28102464,Cmax,"The mean free aflibercept values for Cmax (64.8 μg/mL) AUC (291 μg.day/mL), CL (0.92 L/day) and Vss (5.9 L) were similar to those measured in Caucasian patients.",A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102464/),[μg] / [ml],64.8,113621,DB00762,Irinotecan
,28102464,AUC,"The mean free aflibercept values for Cmax (64.8 μg/mL) AUC (291 μg.day/mL), CL (0.92 L/day) and Vss (5.9 L) were similar to those measured in Caucasian patients.",A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102464/),[d·μg] / [ml],291,113622,DB00762,Irinotecan
,28102464,CL,"The mean free aflibercept values for Cmax (64.8 μg/mL) AUC (291 μg.day/mL), CL (0.92 L/day) and Vss (5.9 L) were similar to those measured in Caucasian patients.",A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102464/),[l] / [d],0.92,113623,DB00762,Irinotecan
,28102464,Vss,"The mean free aflibercept values for Cmax (64.8 μg/mL) AUC (291 μg.day/mL), CL (0.92 L/day) and Vss (5.9 L) were similar to those measured in Caucasian patients.",A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102464/),l,5.9,113624,DB00762,Irinotecan
,8535406,terminal half-life,The plasma radioactivity showed bi-exponential decay with a terminal half-life of 9.91 h.,"Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H- pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8535406/),h,9.91,114996,DB00762,Irinotecan
,8535406,half-life,"The half-life of unchanged SN-38 after dosing with SN-38 was about 7 min, which was much shorter than that after dosing with CPT-11 (2.8 h) as reported previously.","Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H- pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8535406/),min,7,114997,DB00762,Irinotecan
,8535406,half-life,"The half-life of unchanged SN-38 after dosing with SN-38 was about 7 min, which was much shorter than that after dosing with CPT-11 (2.8 h) as reported previously.","Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H- pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8535406/),h,2.8,114998,DB00762,Irinotecan
,27208903,progression-free survival,"The median progression-free survival and OS were 2.9 months (95% CI, 1.1-5.3 months) and 8.7 months (95% CI, 5.7-14.9 months), respectively.",A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27208903/),month,2.9,115319,DB00762,Irinotecan
,27208903,OS,"The median progression-free survival and OS were 2.9 months (95% CI, 1.1-5.3 months) and 8.7 months (95% CI, 5.7-14.9 months), respectively.",A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27208903/),month,8.7,115320,DB00762,Irinotecan
,10561345,survival duration,"The median survival duration was 9.9 months (range, 1.6 to 30.8 months).",Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561345/),month,9,115808,DB00762,Irinotecan
,16051481,plasma AUC,"Among 14 patients, compartmental model showed no significant differences in mean plasma AUC at week 1 versus week 4 for irinotecan (44,388 versus 39,800 microg/ml/h) and cetuximab (20,441 versus 23,363 microg/ml/h), respectively.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),[μg] / [h·ml],"44,388",115941,DB00762,Irinotecan
,16051481,plasma AUC,"Among 14 patients, compartmental model showed no significant differences in mean plasma AUC at week 1 versus week 4 for irinotecan (44,388 versus 39,800 microg/ml/h) and cetuximab (20,441 versus 23,363 microg/ml/h), respectively.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),[μg] / [h·ml],"39,800",115942,DB00762,Irinotecan
,16051481,plasma AUC,"Among 14 patients, compartmental model showed no significant differences in mean plasma AUC at week 1 versus week 4 for irinotecan (44,388 versus 39,800 microg/ml/h) and cetuximab (20,441 versus 23,363 microg/ml/h), respectively.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),[μg] / [h·ml],"20,441",115943,DB00762,Irinotecan
,16051481,plasma AUC,"Among 14 patients, compartmental model showed no significant differences in mean plasma AUC at week 1 versus week 4 for irinotecan (44,388 versus 39,800 microg/ml/h) and cetuximab (20,441 versus 23,363 microg/ml/h), respectively.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),[μg] / [h·ml],"23,363",115944,DB00762,Irinotecan
,16051481,Half-lifes,"Half-lifes (standard deviations) for irinotecan were 16.02 (+/-8.41) h at week 1 and 13.99 (+/-2.14) h at week 4, and for cetuximab 106 (+/-32) at week 3 and 111 (+/-30) h at week 4.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),h,16.02,115945,DB00762,Irinotecan
,16051481,Half-lifes,"Half-lifes (standard deviations) for irinotecan were 16.02 (+/-8.41) h at week 1 and 13.99 (+/-2.14) h at week 4, and for cetuximab 106 (+/-32) at week 3 and 111 (+/-30) h at week 4.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),h,13.99,115946,DB00762,Irinotecan
,16051481,Half-lifes,"Half-lifes (standard deviations) for irinotecan were 16.02 (+/-8.41) h at week 1 and 13.99 (+/-2.14) h at week 4, and for cetuximab 106 (+/-32) at week 3 and 111 (+/-30) h at week 4.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),h,106,115947,DB00762,Irinotecan
,16051481,Half-lifes,"Half-lifes (standard deviations) for irinotecan were 16.02 (+/-8.41) h at week 1 and 13.99 (+/-2.14) h at week 4, and for cetuximab 106 (+/-32) at week 3 and 111 (+/-30) h at week 4.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),h,111,115948,DB00762,Irinotecan
,32795876,objective response rates,The objective response rates were 10.3% (arm A) and 25% (arm B).,A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32795876/),%,10.3,116842,DB00762,Irinotecan
,32795876,objective response rates,The objective response rates were 10.3% (arm A) and 25% (arm B).,A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32795876/),%,25,116843,DB00762,Irinotecan
,16510602,tissue half-life (t(1/2)),"Tissue residence was dose dependent, with doses of 60 microg (3 mg/mL), 0.8 mg (40 mg/mL), and 1.6 mg (80 mg/mL) resulting in tissue half-life (t(1/2)) of 6.7, 10.7, and 19.7 days, respectively.",Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510602/),d,6.7,117857,DB00762,Irinotecan
,16510602,tissue half-life (t(1/2)),"Tissue residence was dose dependent, with doses of 60 microg (3 mg/mL), 0.8 mg (40 mg/mL), and 1.6 mg (80 mg/mL) resulting in tissue half-life (t(1/2)) of 6.7, 10.7, and 19.7 days, respectively.",Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510602/),d,10.7,117858,DB00762,Irinotecan
,16510602,tissue half-life (t(1/2)),"Tissue residence was dose dependent, with doses of 60 microg (3 mg/mL), 0.8 mg (40 mg/mL), and 1.6 mg (80 mg/mL) resulting in tissue half-life (t(1/2)) of 6.7, 10.7, and 19.7 days, respectively.",Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510602/),d,19.7,117859,DB00762,Irinotecan
,16510602,tissue t(1/2),"In contrast, CED of free CPT-11 resulted in rapid drug clearance (tissue t(1/2) = 0.3 day).",Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510602/),d,0.3,117860,DB00762,Irinotecan
,16510602,tissue t(1/2),"At equivalent CED doses, nanoliposomal CPT-11 increased area under the time-concentration curve by 25-fold and tissue t(1/2) by 22-fold over free CPT-11; CED in intracranial U87 glioma xenografts showed even longer tumor retention (tissue t(1/2) = 43 days).",Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510602/),d,43,117861,DB00762,Irinotecan
,21617725,peak serum concentrations (Cmax),"The peak serum concentrations (Cmax) of irinotecan and SN-38 in this patient were 1,480 and 17.8 ng/mL, respectively, which were similar to the reported values in patients with normal renal function after a similar dose of irinotecan (75 mg/m2).",Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617725/),[ng] / [ml],"1,480",117884,DB00762,Irinotecan
,21617725,peak serum concentrations (Cmax),"The peak serum concentrations (Cmax) of irinotecan and SN-38 in this patient were 1,480 and 17.8 ng/mL, respectively, which were similar to the reported values in patients with normal renal function after a similar dose of irinotecan (75 mg/m2).",Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617725/),[ng] / [ml],17.8,117885,DB00762,Irinotecan
,21617725,area under the serum concentration-time curve (AUC0-∞),"The area under the serum concentration-time curve (AUC0-∞) was 8,240 ng×h/mL for irinotecan and 619 ng×h/mL for SN-38.",Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617725/),[h·ng] / [ml],"8,240",117886,DB00762,Irinotecan
,21617725,area under the serum concentration-time curve (AUC0-∞),"The area under the serum concentration-time curve (AUC0-∞) was 8,240 ng×h/mL for irinotecan and 619 ng×h/mL for SN-38.",Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617725/),[h·ng] / [ml],619,117887,DB00762,Irinotecan
,17216531,progression-free,"Median progression-free and overall survivals were 12.2 and 26.6 months, respectively.","Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216531/),month,12.2,119214,DB00762,Irinotecan
,17216531,overall survivals,"Median progression-free and overall survivals were 12.2 and 26.6 months, respectively.","Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216531/),month,26.6,119215,DB00762,Irinotecan
,30406838,MTD,MTD was established at 21 mg/m2.,"Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30406838/),[mg] / [m2],21,119448,DB00762,Irinotecan
,20213078,progression-free survival,"Median progression-free survival was 8.6 months (95% CI, 5.9,11.2), and median overall survival was 15.6 months (95% CI, 8.4,22.8).",Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20213078/),month,8.6,120431,DB00762,Irinotecan
,20213078,overall survival,"Median progression-free survival was 8.6 months (95% CI, 5.9,11.2), and median overall survival was 15.6 months (95% CI, 8.4,22.8).",Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20213078/),month,15.6,120432,DB00762,Irinotecan
,7775263,maximum tolerated dose,The maximum tolerated dose of CPT-11 was 90 mg/m2 in both phase I trials.,Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7775263/),[mg] / [m2],90,122982,DB00762,Irinotecan
,8874328,clearance,"The mean CPT-11 clearance and area under the concentration-time curve (AUC) were 15.2 L/h. m2 and 24,769ng.",Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874328/),[l] / [h·m2],15.2,124641,DB00762,Irinotecan
,8874328,area under the concentration-time curve (AUC),"The mean CPT-11 clearance and area under the concentration-time curve (AUC) were 15.2 L/h. m2 and 24,769ng.",Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874328/),ng,"24,769",124642,DB00762,Irinotecan
,8874328,AUCs,"The large difference in SN-38 and SN-38G AUCs (559 v 2,283 ng.",Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874328/),ng,559,124643,DB00762,Irinotecan
,8874328,AUCs,"The large difference in SN-38 and SN-38G AUCs (559 v 2,283 ng.",Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874328/),ng,"2,283",124644,DB00762,Irinotecan
,17925558,overall response rate,"Of 161 patients assessable for response, one patient with hepatoblastoma had a complete response, with partial responses observed in patients with medulloblastoma (n = 4), rhabdomyosarcoma (n = 1), neuroblastoma (n = 1), and germinoma (n = 1), for an overall response rate of 5%.",Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17925558/),%,5,125275,DB00762,Irinotecan
,17925558,plasma clearance,"The mean +/- standard deviation IRN plasma clearance was 374 +/- 148 mL/min/m2, with median relative extent of conversion and relative extent of glucuronidation of 0.05 (range, 0.01 to 0.25) and 2.24 (range, 0.39 to 9.6), respectively.",Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17925558/),[ml] / [m2·min],374,125276,DB00762,Irinotecan
,17713471,clearance,"Coadministration of LPV/RTV reduces the clearance of CPT11 by 47% (11.3+/-3.5 vs 21.3+/-6.3 l/h/m(2), P=0.0008).",Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713471/),[h·l] / [m(2],11.3,126949,DB00762,Irinotecan
,17713471,clearance,"Coadministration of LPV/RTV reduces the clearance of CPT11 by 47% (11.3+/-3.5 vs 21.3+/-6.3 l/h/m(2), P=0.0008).",Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713471/),[h·l] / [m(2],21.3,126950,DB00762,Irinotecan
,17713471,AUCs ratio,"The LPV/RTV treatment also inhibited the formation of SN38 glucuronide (SN38G), as shown by the 36% decrease in the SN38G/SN38 AUCs ratio (5.9+/-1.6 vs 9.2+/-2.6, P=0.002) consistent with UGT1A1 inhibition by LPV/RTV.",Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713471/),,5.9,126951,DB00762,Irinotecan
,17713471,AUCs ratio,"The LPV/RTV treatment also inhibited the formation of SN38 glucuronide (SN38G), as shown by the 36% decrease in the SN38G/SN38 AUCs ratio (5.9+/-1.6 vs 9.2+/-2.6, P=0.002) consistent with UGT1A1 inhibition by LPV/RTV.",Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713471/),,9.2,126952,DB00762,Irinotecan
,7786821,maximum plasma concentrations,CPT-11 mean maximum plasma concentrations reached 2034 ng/ml at the MTD (115 mg/m2).,Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786821/),[ng] / [ml],2034,126987,DB00762,Irinotecan
,7786821,terminal-phase half-life,The terminal-phase half-life was 8.3 h and the mean residence time 10.2 h.,Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786821/),h,8.3,126988,DB00762,Irinotecan
,7786821,mean residence time,The terminal-phase half-life was 8.3 h and the mean residence time 10.2 h.,Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786821/),h,10.2,126989,DB00762,Irinotecan
,7786821,volume of distribution at steady state,The mean volume of distribution at steady state was 141 l/m2/h.,Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786821/),[l] / [h·m2],141,126990,DB00762,Irinotecan
,7786821,Total body clearance,"Total body clearance did not vary with increased dosage (mean = 14.3 l/h/m2), indicating linear pharmacokinetics within the dose range administered in this trial.",Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786821/),[l] / [h·m2],14.3,126991,DB00762,Irinotecan
,7786821,peak levels,Mean metabolite SN-38 peak levels reached 41 ng/ml at the MTD.,Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786821/),[ng] / [ml],41,126992,DB00762,Irinotecan
,7786821,MTD,The MTD for CPT-11 administered in a 3 consecutive-days-every-3 weeks schedule in this patient population is 115 mg/m2/day.,Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786821/),[mg] / [d·m2],115,126993,DB00762,Irinotecan
,10357408,response rate,Four partial responses (response rate of 26.7%) with a median response duration of 25.9 weeks and 2 regressions of evaluable disease (overall response rate of 40%) were observed.,Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10357408/),%,26.7,132134,DB00762,Irinotecan
,10357408,overall response rate,Four partial responses (response rate of 26.7%) with a median response duration of 25.9 weeks and 2 regressions of evaluable disease (overall response rate of 40%) were observed.,Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10357408/),%,40,132135,DB00762,Irinotecan
,10357408,survival time,"The median survival time after chemotherapy was 28.3 weeks, and the median time to treatment failure was 22.1 weeks.",Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10357408/),weeks,28.3,132136,DB00762,Irinotecan
,10357408,time to treatment failure,"The median survival time after chemotherapy was 28.3 weeks, and the median time to treatment failure was 22.1 weeks.",Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10357408/),weeks,22.1,132137,DB00762,Irinotecan
,11193899,elimination half-lives,Pharmacokinetic analysis demonstrates a second-order kinetics with elimination half-lives of 0.49 and 2.7 hours.,Alternative administration of camptothecin analogues. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193899/),h,0.49,133092,DB00762,Irinotecan
,11193899,elimination half-lives,Pharmacokinetic analysis demonstrates a second-order kinetics with elimination half-lives of 0.49 and 2.7 hours.,Alternative administration of camptothecin analogues. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193899/),h,2.7,133093,DB00762,Irinotecan
,11193899,peritoneal to plasma AUC ratio,The peritoneal to plasma AUC ratio was 31.2.,Alternative administration of camptothecin analogues. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193899/),,31.2,133094,DB00762,Irinotecan
,22490854,plasma concentrations,"The average plasma concentrations of fluorouracil of the three groups were (23.48 ± 1.95) ng/ml, (31.47 ± 2.33) ng/ml and (39.89 ± 3.87) ng/ml, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),[ng] / [ml],23.48,133672,DB00762,Irinotecan
,22490854,plasma concentrations,"The average plasma concentrations of fluorouracil of the three groups were (23.48 ± 1.95) ng/ml, (31.47 ± 2.33) ng/ml and (39.89 ± 3.87) ng/ml, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),[ng] / [ml],31.47,133673,DB00762,Irinotecan
,22490854,plasma concentrations,"The average plasma concentrations of fluorouracil of the three groups were (23.48 ± 1.95) ng/ml, (31.47 ± 2.33) ng/ml and (39.89 ± 3.87) ng/ml, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),[ng] / [ml],39.89,133674,DB00762,Irinotecan
,22490854,OS,"As for therapeutic efficacy, the median OS of the groups 2 and 3 were 18.0 and 17.5 months, significantly higher than that in the group 1 (13.0 months, P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,18.0,133675,DB00762,Irinotecan
,22490854,OS,"As for therapeutic efficacy, the median OS of the groups 2 and 3 were 18.0 and 17.5 months, significantly higher than that in the group 1 (13.0 months, P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,17.5,133676,DB00762,Irinotecan
,22490854,OS,"As for therapeutic efficacy, the median OS of the groups 2 and 3 were 18.0 and 17.5 months, significantly higher than that in the group 1 (13.0 months, P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,13.0,133677,DB00762,Irinotecan
,22490854,PFS,"The PFS were 4.5, 7.5 and 8.0 months, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,4.5,133678,DB00762,Irinotecan
,22490854,PFS,"The PFS were 4.5, 7.5 and 8.0 months, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,7.5,133679,DB00762,Irinotecan
,22490854,PFS,"The PFS were 4.5, 7.5 and 8.0 months, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,8.0,133680,DB00762,Irinotecan
,15041715,clearance,Mean +/- SD docetaxel clearance values were similar with weekly and 3-weekly schedules (25.2 +/- 7.7 versus 23.7 +/- 7.9 liter/h/m(2)); half-lives were also similar with both schedules of administration (16.5 +/- 11.2 versus 17.6 +/- 7.4 h).,Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041715/),[h·l] / [m(2],25.2,133703,DB00762,Irinotecan
,15041715,clearance,Mean +/- SD docetaxel clearance values were similar with weekly and 3-weekly schedules (25.2 +/- 7.7 versus 23.7 +/- 7.9 liter/h/m(2)); half-lives were also similar with both schedules of administration (16.5 +/- 11.2 versus 17.6 +/- 7.4 h).,Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041715/),[h·l] / [m(2],23.7,133704,DB00762,Irinotecan
,15041715,half-lives,Mean +/- SD docetaxel clearance values were similar with weekly and 3-weekly schedules (25.2 +/- 7.7 versus 23.7 +/- 7.9 liter/h/m(2)); half-lives were also similar with both schedules of administration (16.5 +/- 11.2 versus 17.6 +/- 7.4 h).,Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041715/),h,16.5,133705,DB00762,Irinotecan
,15041715,half-lives,Mean +/- SD docetaxel clearance values were similar with weekly and 3-weekly schedules (25.2 +/- 7.7 versus 23.7 +/- 7.9 liter/h/m(2)); half-lives were also similar with both schedules of administration (16.5 +/- 11.2 versus 17.6 +/- 7.4 h).,Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041715/),h,17.6,133706,DB00762,Irinotecan
,16411223,overall response rate,"The overall response rate was 47%, and there was a trend in favor of P-I (54%) compared with I-P (39%).",Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411223/),%,47,134208,DB00762,Irinotecan
,16411223,overall response rate,"The overall response rate was 47%, and there was a trend in favor of P-I (54%) compared with I-P (39%).",Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411223/),%,54,134209,DB00762,Irinotecan
,16411223,overall response rate,"The overall response rate was 47%, and there was a trend in favor of P-I (54%) compared with I-P (39%).",Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411223/),%,39,134210,DB00762,Irinotecan
,19940007,Response rates,"Response rates in the cetuximab monotherapy and combination therapy phases were 15% and 42%, respectively.",Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940007/),%,15,137032,DB00762,Irinotecan
,19940007,Response rates,"Response rates in the cetuximab monotherapy and combination therapy phases were 15% and 42%, respectively.",Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940007/),%,42,137033,DB00762,Irinotecan
>,15897584,Peak flavopiridol concentrations,Peak flavopiridol concentrations of >/=2 mumol/L were achieved above flavopiridol 50 mg/m(2).,A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15897584/),[μM] / [l],2,137237,DB00762,Irinotecan
,14988754,terminal half-life,"The pharmacokinetics of irinotecan are characterized by a 2- or 3-compartment decay, with a terminal half-life of about 10 h, a total volume of distribution of 150 l/m(2) and a total plasma clearance of 15 l/h/m(2).",Pharmacology of irinotecan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14988754/),h,10,138344,DB00762,Irinotecan
,14988754,total volume of distribution,"The pharmacokinetics of irinotecan are characterized by a 2- or 3-compartment decay, with a terminal half-life of about 10 h, a total volume of distribution of 150 l/m(2) and a total plasma clearance of 15 l/h/m(2).",Pharmacology of irinotecan. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14988754/),[l] / [m(2],150,138345,DB00762,Irinotecan
,14988754,total plasma clearance,"The pharmacokinetics of irinotecan are characterized by a 2- or 3-compartment decay, with a terminal half-life of about 10 h, a total volume of distribution of 150 l/m(2) and a total plasma clearance of 15 l/h/m(2).",Pharmacology of irinotecan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14988754/),[h·l] / [m(2],15,138346,DB00762,Irinotecan
,14988754,half-life,SN-38 AUC is only a small fraction of that of irinotecan (2-4%) and SN-38 is eliminated from plasma with a half-life of about 12 h.,Pharmacology of irinotecan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14988754/),h,12,138347,DB00762,Irinotecan
,17429623,half-life,"The long half-life (292.0 +/- 135.7 h), low clearance (0.045 +/- 0.038 l/h), and volume of distribution (14.3 +/- 5.9 l) observed for UCN-01 are consistent with prior UCN-01 data.",Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429623/),h,292.0,138759,DB00762,Irinotecan
,17429623,clearance,"The long half-life (292.0 +/- 135.7 h), low clearance (0.045 +/- 0.038 l/h), and volume of distribution (14.3 +/- 5.9 l) observed for UCN-01 are consistent with prior UCN-01 data.",Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429623/),[l] / [h],0.045,138760,DB00762,Irinotecan
,17429623,volume of distribution,"The long half-life (292.0 +/- 135.7 h), low clearance (0.045 +/- 0.038 l/h), and volume of distribution (14.3 +/- 5.9 l) observed for UCN-01 are consistent with prior UCN-01 data.",Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429623/),l,14.3,138761,DB00762,Irinotecan
,29527010,objective response rate,"Fifteen patients had a partial response (objective response rate, 17.6%).",A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29527010/),%,17.6,143147,DB00762,Irinotecan
,22358992,peak,"Normalized serum irinotecan reached a peak of 333 ng/ml (range 198.8-502.5) for IV, 327.1 ng/ml (range 277.1-495.6) for IA, and 189.7 ng/ml (range 111.1-261.9) for DEBIRI (P < 0.001) delivery.",Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358992/),[ng] / [ml],333,143674,DB00762,Irinotecan
,22358992,peak,"Normalized serum irinotecan reached a peak of 333 ng/ml (range 198.8-502.5) for IV, 327.1 ng/ml (range 277.1-495.6) for IA, and 189.7 ng/ml (range 111.1-261.9) for DEBIRI (P < 0.001) delivery.",Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358992/),[ng] / [ml],327.1,143675,DB00762,Irinotecan
,22358992,peak,"Normalized serum irinotecan reached a peak of 333 ng/ml (range 198.8-502.5) for IV, 327.1 ng/ml (range 277.1-495.6) for IA, and 189.7 ng/ml (range 111.1-261.9) for DEBIRI (P < 0.001) delivery.",Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358992/),[ng] / [ml],189.7,143676,DB00762,Irinotecan
,22358992,tumor necrosis,"At 24 h, tumor necrosis was 25% (10-30), 60% (40-91.25), and 95% (76.25-95) for IV, IA, and DEBIRI, respectively (P = 0.03).",Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358992/),%,25,143677,DB00762,Irinotecan
,22358992,tumor necrosis,"At 24 h, tumor necrosis was 25% (10-30), 60% (40-91.25), and 95% (76.25-95) for IV, IA, and DEBIRI, respectively (P = 0.03).",Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358992/),%,60,143678,DB00762,Irinotecan
,22358992,tumor necrosis,"At 24 h, tumor necrosis was 25% (10-30), 60% (40-91.25), and 95% (76.25-95) for IV, IA, and DEBIRI, respectively (P = 0.03).",Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358992/),%,95,143679,DB00762,Irinotecan
,22842404,Cmax,"Average Cmax for irinotecan and SN-38 was 194 ng/ml and 16.7 ng/ml, respectively, with average t½ of 4.6 h and 12.4 h following administration of DEBIRI.",First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22842404/),[ng] / [ml],194,144283,DB00762,Irinotecan
,22842404,Cmax,"Average Cmax for irinotecan and SN-38 was 194 ng/ml and 16.7 ng/ml, respectively, with average t½ of 4.6 h and 12.4 h following administration of DEBIRI.",First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22842404/),[ng] / [ml],16.7,144284,DB00762,Irinotecan
,22842404,t½,"Average Cmax for irinotecan and SN-38 was 194 ng/ml and 16.7 ng/ml, respectively, with average t½ of 4.6 h and 12.4 h following administration of DEBIRI.",First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22842404/),h,4.6,144285,DB00762,Irinotecan
,22842404,t½,"Average Cmax for irinotecan and SN-38 was 194 ng/ml and 16.7 ng/ml, respectively, with average t½ of 4.6 h and 12.4 h following administration of DEBIRI.",First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22842404/),h,12.4,144286,DB00762,Irinotecan
,22842404,overall response rate,"Best overall response during the study showed disease control in 9 patients (2 patients with partial response and 7 with stable disease, overall response rate of 18%).",First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22842404/),%,18,144287,DB00762,Irinotecan
,12751911,C,"There were no differences in the mean (+/- SD) C, (15.8 +/- 7.5 vs 12.1 +/- 3.3 microg/ml), t1/2 (2.2 +/- 0.7 vs 2.2 +/- 0.5 h), CL (5.7 +/- 2.1 vs 6.8 +/- 1.2 l/h/kg), Vd (1798 +/- 958 vs 2280 +/- 731 l/kg) or AUC0-infinity (11.8 +/- 3.9 vs 9.1 +/- 1.7 microg x h/ml) of CPT-11 after dosing with or without activated charcoal.",Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12751911/),[μg] / [ml],15.8,144718,DB00762,Irinotecan
,12751911,C,"There were no differences in the mean (+/- SD) C, (15.8 +/- 7.5 vs 12.1 +/- 3.3 microg/ml), t1/2 (2.2 +/- 0.7 vs 2.2 +/- 0.5 h), CL (5.7 +/- 2.1 vs 6.8 +/- 1.2 l/h/kg), Vd (1798 +/- 958 vs 2280 +/- 731 l/kg) or AUC0-infinity (11.8 +/- 3.9 vs 9.1 +/- 1.7 microg x h/ml) of CPT-11 after dosing with or without activated charcoal.",Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12751911/),[μg] / [ml],12.1,144719,DB00762,Irinotecan
,12751911,t1/2,"There were no differences in the mean (+/- SD) C, (15.8 +/- 7.5 vs 12.1 +/- 3.3 microg/ml), t1/2 (2.2 +/- 0.7 vs 2.2 +/- 0.5 h), CL (5.7 +/- 2.1 vs 6.8 +/- 1.2 l/h/kg), Vd (1798 +/- 958 vs 2280 +/- 731 l/kg) or AUC0-infinity (11.8 +/- 3.9 vs 9.1 +/- 1.7 microg x h/ml) of CPT-11 after dosing with or without activated charcoal.",Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12751911/),h,2.2,144720,DB00762,Irinotecan
,12751911,t1/2,"There were no differences in the mean (+/- SD) C, (15.8 +/- 7.5 vs 12.1 +/- 3.3 microg/ml), t1/2 (2.2 +/- 0.7 vs 2.2 +/- 0.5 h), CL (5.7 +/- 2.1 vs 6.8 +/- 1.2 l/h/kg), Vd (1798 +/- 958 vs 2280 +/- 731 l/kg) or AUC0-infinity (11.8 +/- 3.9 vs 9.1 +/- 1.7 microg x h/ml) of CPT-11 after dosing with or without activated charcoal.",Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12751911/),h,2.2,144721,DB00762,Irinotecan
,12751911,CL,"There were no differences in the mean (+/- SD) C, (15.8 +/- 7.5 vs 12.1 +/- 3.3 microg/ml), t1/2 (2.2 +/- 0.7 vs 2.2 +/- 0.5 h), CL (5.7 +/- 2.1 vs 6.8 +/- 1.2 l/h/kg), Vd (1798 +/- 958 vs 2280 +/- 731 l/kg) or AUC0-infinity (11.8 +/- 3.9 vs 9.1 +/- 1.7 microg x h/ml) of CPT-11 after dosing with or without activated charcoal.",Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12751911/),[l] / [h·kg],5.7,144722,DB00762,Irinotecan
,12751911,CL,"There were no differences in the mean (+/- SD) C, (15.8 +/- 7.5 vs 12.1 +/- 3.3 microg/ml), t1/2 (2.2 +/- 0.7 vs 2.2 +/- 0.5 h), CL (5.7 +/- 2.1 vs 6.8 +/- 1.2 l/h/kg), Vd (1798 +/- 958 vs 2280 +/- 731 l/kg) or AUC0-infinity (11.8 +/- 3.9 vs 9.1 +/- 1.7 microg x h/ml) of CPT-11 after dosing with or without activated charcoal.",Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12751911/),[l] / [h·kg],6.8,144723,DB00762,Irinotecan
,12751911,Vd,"There were no differences in the mean (+/- SD) C, (15.8 +/- 7.5 vs 12.1 +/- 3.3 microg/ml), t1/2 (2.2 +/- 0.7 vs 2.2 +/- 0.5 h), CL (5.7 +/- 2.1 vs 6.8 +/- 1.2 l/h/kg), Vd (1798 +/- 958 vs 2280 +/- 731 l/kg) or AUC0-infinity (11.8 +/- 3.9 vs 9.1 +/- 1.7 microg x h/ml) of CPT-11 after dosing with or without activated charcoal.",Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12751911/),[l] / [kg],1798,144724,DB00762,Irinotecan
,12751911,Vd,"There were no differences in the mean (+/- SD) C, (15.8 +/- 7.5 vs 12.1 +/- 3.3 microg/ml), t1/2 (2.2 +/- 0.7 vs 2.2 +/- 0.5 h), CL (5.7 +/- 2.1 vs 6.8 +/- 1.2 l/h/kg), Vd (1798 +/- 958 vs 2280 +/- 731 l/kg) or AUC0-infinity (11.8 +/- 3.9 vs 9.1 +/- 1.7 microg x h/ml) of CPT-11 after dosing with or without activated charcoal.",Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12751911/),[l] / [kg],2280,144725,DB00762,Irinotecan
,12751911,AUC0-infinity,"There were no differences in the mean (+/- SD) C, (15.8 +/- 7.5 vs 12.1 +/- 3.3 microg/ml), t1/2 (2.2 +/- 0.7 vs 2.2 +/- 0.5 h), CL (5.7 +/- 2.1 vs 6.8 +/- 1.2 l/h/kg), Vd (1798 +/- 958 vs 2280 +/- 731 l/kg) or AUC0-infinity (11.8 +/- 3.9 vs 9.1 +/- 1.7 microg x h/ml) of CPT-11 after dosing with or without activated charcoal.",Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12751911/),[h·μg] / [ml],11.8,144726,DB00762,Irinotecan
,12751911,AUC0-infinity,"There were no differences in the mean (+/- SD) C, (15.8 +/- 7.5 vs 12.1 +/- 3.3 microg/ml), t1/2 (2.2 +/- 0.7 vs 2.2 +/- 0.5 h), CL (5.7 +/- 2.1 vs 6.8 +/- 1.2 l/h/kg), Vd (1798 +/- 958 vs 2280 +/- 731 l/kg) or AUC0-infinity (11.8 +/- 3.9 vs 9.1 +/- 1.7 microg x h/ml) of CPT-11 after dosing with or without activated charcoal.",Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12751911/),[h·μg] / [ml],9.1,144727,DB00762,Irinotecan
,12738720,maximum tolerated dose,"For the 21-day cycle, the maximum tolerated dose was 75 mg/m(2) for i.v. etoposide and 85 mg/m(2) for oral etoposide.",Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12738720/),[mg] / [m(2],75,144785,DB00762,Irinotecan
,12738720,maximum tolerated dose,"For the 21-day cycle, the maximum tolerated dose was 75 mg/m(2) for i.v. etoposide and 85 mg/m(2) for oral etoposide.",Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12738720/),[mg] / [m],85,144786,DB00762,Irinotecan
,15313923,IC50,"In Sf9-BCRP vesicles, pantoprazole and omeprazole inhibited MTX transport (IC50 13 microm and 36 microm, respectively).",Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15313923/),μm,13,145395,DB00762,Irinotecan
,15313923,IC50,"In Sf9-BCRP vesicles, pantoprazole and omeprazole inhibited MTX transport (IC50 13 microm and 36 microm, respectively).",Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15313923/),μm,36,145396,DB00762,Irinotecan
,16141295,MTD,"The MTD of CPT-11 was considered to be 100 mg/m(2), because 50% of the patients (3/6) developed DLTs, diarrhea and rash.",Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16141295/),,100,148323,DB00762,Irinotecan
,27920527,area under the plasma concentration-time curve to infinity,"At a dose of 313 mg/m2, mean DTS-108, SN-38, and SN-38G area under the plasma concentration-time curve to infinity (coefficients of variation %) were 439,293 (24%), 1,992 (34%), and 4,538 (46%) h·ng/mL.","Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27920527/),[h·ng] / [ml],"439,293",149184,DB00762,Irinotecan
,27920527,area under the plasma concentration-time curve to infinity,"At a dose of 313 mg/m2, mean DTS-108, SN-38, and SN-38G area under the plasma concentration-time curve to infinity (coefficients of variation %) were 439,293 (24%), 1,992 (34%), and 4,538 (46%) h·ng/mL.","Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27920527/),[h·ng] / [ml],"1,992",149185,DB00762,Irinotecan
,27920527,area under the plasma concentration-time curve to infinity,"At a dose of 313 mg/m2, mean DTS-108, SN-38, and SN-38G area under the plasma concentration-time curve to infinity (coefficients of variation %) were 439,293 (24%), 1,992 (34%), and 4,538 (46%) h·ng/mL.","Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27920527/),[h·ng] / [ml],"4,538",149186,DB00762,Irinotecan
,27920527,coefficients,"At a dose of 313 mg/m2, mean DTS-108, SN-38, and SN-38G area under the plasma concentration-time curve to infinity (coefficients of variation %) were 439,293 (24%), 1,992 (34%), and 4,538 (46%) h·ng/mL.","Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27920527/),[h·ng] / [ml],"439,293",149187,DB00762,Irinotecan
,27920527,coefficients,"At a dose of 313 mg/m2, mean DTS-108, SN-38, and SN-38G area under the plasma concentration-time curve to infinity (coefficients of variation %) were 439,293 (24%), 1,992 (34%), and 4,538 (46%) h·ng/mL.","Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27920527/),[h·ng] / [ml],"1,992",149188,DB00762,Irinotecan
,27920527,coefficients,"At a dose of 313 mg/m2, mean DTS-108, SN-38, and SN-38G area under the plasma concentration-time curve to infinity (coefficients of variation %) were 439,293 (24%), 1,992 (34%), and 4,538 (46%) h·ng/mL.","Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27920527/),[h·ng] / [ml],"4,538",149189,DB00762,Irinotecan
,27920527,maximum tolerated dose,The maximum tolerated dose of DTS-108 was 416 mg/m2.,"Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27920527/),[mg] / [m2],416,149190,DB00762,Irinotecan
>,28278081,progression free survival,"Of the *1/*1 -*1/*1 genotype combination, the median progression free survival of the CSN-38 1.5 h > 50.24 ng/ml subset was remarkably longer than that of the CSN-38 1.5 h ≤ 50.24 ng/ml subset.",Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28278081/),[ng] / [ml],50.24,152655,DB00762,Irinotecan
,28278081,progression free survival,"Of the *1/*1 -*1/*1 genotype combination, the median progression free survival of the CSN-38 1.5 h > 50.24 ng/ml subset was remarkably longer than that of the CSN-38 1.5 h ≤ 50.24 ng/ml subset.",Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28278081/),,1,152656,DB00762,Irinotecan
≤,28278081,progression free survival,"Of the *1/*1 -*1/*1 genotype combination, the median progression free survival of the CSN-38 1.5 h > 50.24 ng/ml subset was remarkably longer than that of the CSN-38 1.5 h ≤ 50.24 ng/ml subset.",Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28278081/),[ng] / [ml],50.24,152657,DB00762,Irinotecan
,24867782,brain/plasma ratios,"Our results show that TMZ, CPT-11 and SN-38 are transported by ABCB1 at the BBB level with brain/plasma ratios of 1.1, 2.1 and 2.3, respectively.",Irinotecan and temozolomide brain distribution: a focus on ABCB1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24867782/),,1.1,153589,DB00762,Irinotecan
,24867782,brain/plasma ratios,"Our results show that TMZ, CPT-11 and SN-38 are transported by ABCB1 at the BBB level with brain/plasma ratios of 1.1, 2.1 and 2.3, respectively.",Irinotecan and temozolomide brain distribution: a focus on ABCB1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24867782/),,2.1,153590,DB00762,Irinotecan
,24867782,brain/plasma ratios,"Our results show that TMZ, CPT-11 and SN-38 are transported by ABCB1 at the BBB level with brain/plasma ratios of 1.1, 2.1 and 2.3, respectively.",Irinotecan and temozolomide brain distribution: a focus on ABCB1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24867782/),,2.3,153591,DB00762,Irinotecan
,9229329,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 115 mg/m2 in the daily schedule and 145 mg/m2 in the weekly schedule.,CPT-11: the European clinical development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229329/),[mg] / [m2],115,154289,DB00762,Irinotecan
,9229329,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 115 mg/m2 in the daily schedule and 145 mg/m2 in the weekly schedule.,CPT-11: the European clinical development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229329/),[mg] / [m2],145,154290,DB00762,Irinotecan
,17322542,MTD,"The MTD and RD of diflomotecan administered according to a dx5 repeated three weekly are 0.15 and 0.125 mg/m(2)/day, respectively.",A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322542/),[mg] / [m],0.15,154713,DB00762,Irinotecan
,17322542,RD,"The MTD and RD of diflomotecan administered according to a dx5 repeated three weekly are 0.15 and 0.125 mg/m(2)/day, respectively.",A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322542/),[mg] / [m],0.125,154714,DB00762,Irinotecan
,10561369,objective response rate,"Antitumor activity was observed at almost all dose levels, with an objective response rate of 22%.","Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561369/),%,22,156071,DB00762,Irinotecan
,10561369,time to progression,Median time to progression was 6.3 months and overall survival was 15 months.,"Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561369/),month,6.3,156072,DB00762,Irinotecan
,10561369,overall survival,Median time to progression was 6.3 months and overall survival was 15 months.,"Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561369/),month,15,156073,DB00762,Irinotecan
,26429709,RPTD,The RPTD of navitoclax in combination with irinotecan 75 mg/m(2) QW during a 21-day cycle was 150 mg in these heavily pretreated patients.,"Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26429709/),mg,150,156907,DB00762,Irinotecan
,16303861,time to progression,"Median time to progression was 9.9 months [lower 95% confidence limit (CL) 7.9, upper 95% CL not reached].",Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303861/),month,9.9,157278,DB00762,Irinotecan
,11990713,clearance,The mean clearance of irinotecan was 14.54 L/h per m2 (range 8.45-20.83 L/h per m2).,Phase I study of irinotecan in pediatric patients with malignant solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11990713/),[l] / [h·m2],14.54,157306,DB00762,Irinotecan
,23789755,clearances,"The typical values (between-subject variability; %) of the irinotecan, SN-38 and SN-38G clearances were 42,9 L/h (56,4%), 1340 L/h (76,8%) and 188 L/h (70,1%), respectively.","[Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23789755/),[l] / [h],"42,9",157712,DB00762,Irinotecan
,23789755,clearances,"The typical values (between-subject variability; %) of the irinotecan, SN-38 and SN-38G clearances were 42,9 L/h (56,4%), 1340 L/h (76,8%) and 188 L/h (70,1%), respectively.","[Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23789755/),[l] / [h],1340,157713,DB00762,Irinotecan
,23789755,clearances,"The typical values (between-subject variability; %) of the irinotecan, SN-38 and SN-38G clearances were 42,9 L/h (56,4%), 1340 L/h (76,8%) and 188 L/h (70,1%), respectively.","[Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23789755/),[l] / [h],188,157714,DB00762,Irinotecan
,9342501,maximum irinotecan plasma concentrations,"Following the intravenous administration of irinotecan at 100 to 350 mg/m2, mean maximum irinotecan plasma concentrations are within the 1 to 10 mg/L range.",Clinical pharmacokinetics of irinotecan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342501/),[mg] / [l],1 to 10,158504,DB00762,Irinotecan
,9342501,terminal half-life,Plasma concentrations can be described using a 2- or 3-compartment model with a mean terminal half-life ranging from 5 to 27 hours.,Clinical pharmacokinetics of irinotecan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342501/),h,5 to 27,158505,DB00762,Irinotecan
,9342501,volume of distribution at steady-state (Vss),"The volume of distribution at steady-state (Vss) ranges from 136 to 255 L/m2, and the total body clearance is 8 to 21 L/h/m2.",Clinical pharmacokinetics of irinotecan. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342501/),[l] / [m2],136 to 255,158506,DB00762,Irinotecan
,9342501,total body clearance,"The volume of distribution at steady-state (Vss) ranges from 136 to 255 L/m2, and the total body clearance is 8 to 21 L/h/m2.",Clinical pharmacokinetics of irinotecan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342501/),[l] / [h·m2],8 to 21,158507,DB00762,Irinotecan
,9342501,apparent terminal half-life,SN-38 plasma decay follows closely that of the parent compound with an apparent terminal half-life ranging from 6 to 30 hours.,Clinical pharmacokinetics of irinotecan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342501/),h,6 to 30,158508,DB00762,Irinotecan
,9342501,Cumulative biliary excretion,"Cumulative biliary excretion is 25% for irinotecan, 2% for SN-38 glucuronide and about 1% for SN-38.",Clinical pharmacokinetics of irinotecan. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342501/),%,25,158509,DB00762,Irinotecan
,9342501,Cumulative biliary excretion,"Cumulative biliary excretion is 25% for irinotecan, 2% for SN-38 glucuronide and about 1% for SN-38.",Clinical pharmacokinetics of irinotecan. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342501/),%,2,158510,DB00762,Irinotecan
,9342501,Cumulative biliary excretion,"Cumulative biliary excretion is 25% for irinotecan, 2% for SN-38 glucuronide and about 1% for SN-38.",Clinical pharmacokinetics of irinotecan. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342501/),%,1,158511,DB00762,Irinotecan
,18823053,response rate,"The response rate was approximately 25% (all partial responses [PRs], 12 patients; 95% confidence interval [95% CI], 13-39).",Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823053/),%,25,159956,DB00762,Irinotecan
,18823053,clinical benefit rate,Six patients had stable disease (SD) for > or =6 months for a clinical benefit rate (PR + SD) of 39%.,Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823053/),,39,159957,DB00762,Irinotecan
,18823053,time to disease progression,"The median time to disease progression was 3.7 months (95% CI, 2.5 months-4.6 months), and median survival was 11.6 months (95% CI, 8.9 months-15 months).",Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823053/),month,3.7,159958,DB00762,Irinotecan
,18823053,survival,"The median time to disease progression was 3.7 months (95% CI, 2.5 months-4.6 months), and median survival was 11.6 months (95% CI, 8.9 months-15 months).",Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823053/),month,11.6,159959,DB00762,Irinotecan
,28043863,plasma release half-lives,"Three conjugates with plasma release half-lives of 2.5h, 21h, and 72h were tested for efficacy and toxicity using a mouse SW620 xenograft model.",Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28043863/),h,2.5,160091,DB00762,Irinotecan
,28043863,plasma release half-lives,"Three conjugates with plasma release half-lives of 2.5h, 21h, and 72h were tested for efficacy and toxicity using a mouse SW620 xenograft model.",Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28043863/),h,21,160092,DB00762,Irinotecan
,28043863,plasma release half-lives,"Three conjugates with plasma release half-lives of 2.5h, 21h, and 72h were tested for efficacy and toxicity using a mouse SW620 xenograft model.",Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28043863/),h,72,160093,DB00762,Irinotecan
,28043863,plasma release half-life,"In this model, the linker with a plasma release half-life of 21h achieved sustained SN-38 exposure in blood, above the target concentration.",Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28043863/),h,21,160094,DB00762,Irinotecan
,7624917,AUC,"The least-bias and most precise sampling times for estimating AUC were 3.5; 3.5 and 9.5; and 0.5, 3.5, and 9.5 h, respectively.",Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): implication for area under the concentration-time curve monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624917/),h,3.5,161964,DB00762,Irinotecan
,7624917,AUC,"The least-bias and most precise sampling times for estimating AUC were 3.5; 3.5 and 9.5; and 0.5, 3.5, and 9.5 h, respectively.",Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): implication for area under the concentration-time curve monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624917/),h,9.5,161965,DB00762,Irinotecan
,7624917,AUC,"The least-bias and most precise sampling times for estimating AUC were 3.5; 3.5 and 9.5; and 0.5, 3.5, and 9.5 h, respectively.",Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): implication for area under the concentration-time curve monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624917/),h,0.5,161966,DB00762,Irinotecan
,11800029,MTD,"The MTD and recommended dose of irinotecan were 60 and 50 mg/m2, respectively.",Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11800029/),mg,60,161979,DB00762,Irinotecan
,11800029,response rates,"In phase II studies, response rates were 81.3% (95% confidence interval 61.8-100%) in 16 patients with small-cell lung cancer and 22.2% (2.7-41.8%) in 18 patients with non-small-cell lung cancer.",Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11800029/),%,81.3,161980,DB00762,Irinotecan
,11800029,response rates,"In phase II studies, response rates were 81.3% (95% confidence interval 61.8-100%) in 16 patients with small-cell lung cancer and 22.2% (2.7-41.8%) in 18 patients with non-small-cell lung cancer.",Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11800029/),%,22.2,161981,DB00762,Irinotecan
,11800029,area under the plasma concentration versus time curve (AUC),"The area under the plasma concentration versus time curve (AUC) of carboplatin ranged from 2.87 to 9.31 mg x min/ml, with a median of 4.66 mg x min/ml.",Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11800029/),[mg·min] / [ml],4.66,161982,DB00762,Irinotecan
,8229134,terminal plasma half-life,"The terminal plasma half-life for CPT-11 (total) was 7.9 +/- 2.8 hours, for CPT-11 (lactone) 6.3 +/- 2.2 hours, for SN-38 (total) 13.0 +/- 5.8 hours, and for SN-38 (lactone) 11.5 +/- 3.8 hours.",Phase I and pharmacokinetic trial of weekly CPT-11. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229134/),h,7.9,163081,DB00762,Irinotecan
,8229134,terminal plasma half-life,"The terminal plasma half-life for CPT-11 (total) was 7.9 +/- 2.8 hours, for CPT-11 (lactone) 6.3 +/- 2.2 hours, for SN-38 (total) 13.0 +/- 5.8 hours, and for SN-38 (lactone) 11.5 +/- 3.8 hours.",Phase I and pharmacokinetic trial of weekly CPT-11. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229134/),h,6.3,163082,DB00762,Irinotecan
,8229134,terminal plasma half-life,"The terminal plasma half-life for CPT-11 (total) was 7.9 +/- 2.8 hours, for CPT-11 (lactone) 6.3 +/- 2.2 hours, for SN-38 (total) 13.0 +/- 5.8 hours, and for SN-38 (lactone) 11.5 +/- 3.8 hours.",Phase I and pharmacokinetic trial of weekly CPT-11. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229134/),h,13.0,163083,DB00762,Irinotecan
,8229134,terminal plasma half-life,"The terminal plasma half-life for CPT-11 (total) was 7.9 +/- 2.8 hours, for CPT-11 (lactone) 6.3 +/- 2.2 hours, for SN-38 (total) 13.0 +/- 5.8 hours, and for SN-38 (lactone) 11.5 +/- 3.8 hours.",Phase I and pharmacokinetic trial of weekly CPT-11. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229134/),h,11.5,163084,DB00762,Irinotecan
,8229134,MTD,The MTD for CPT-11 in this patient population was 150 mg/m2/wk when administered on a weekly-times-four schedule repeated every 6 weeks.,Phase I and pharmacokinetic trial of weekly CPT-11. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229134/),[mg] / [m2·wk],150,163085,DB00762,Irinotecan
,16133526,plasma half-life,The plasma half-life of IT-101 ranges from 17 -20 h and is significantly greater than that of CPT alone (1.3 h).,Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16133526/),h,17 -20,164086,DB00762,Irinotecan
,16133526,plasma half-life,The plasma half-life of IT-101 ranges from 17 -20 h and is significantly greater than that of CPT alone (1.3 h).,Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16133526/),h,1.3,164087,DB00762,Irinotecan
,33501859,area under the curve (AUC0-∞),"Pharmacokinetic profile established through venous sampling in Buffalo rats demonstrate that the area under the curve (AUC0-∞) of IRI was significantly less after PVCE with IRI-lipiodol as compared to IRI alone (131 vs. 316 µg*min/mL, p-value = .023), suggesting significantly higher amounts of IRI retention in the liver with the IRI-lipiodol nanoemulsion via first-pass extraction.",A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33501859/),[min·μg] / [ml],131,164942,DB00762,Irinotecan
,33501859,area under the curve (AUC0-∞),"Pharmacokinetic profile established through venous sampling in Buffalo rats demonstrate that the area under the curve (AUC0-∞) of IRI was significantly less after PVCE with IRI-lipiodol as compared to IRI alone (131 vs. 316 µg*min/mL, p-value = .023), suggesting significantly higher amounts of IRI retention in the liver with the IRI-lipiodol nanoemulsion via first-pass extraction.",A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33501859/),[min·μg] / [ml],316,164943,DB00762,Irinotecan
,33501859,IRI,Subseqent biodistribution studies in tumor-bearing WAG/Rjj rats revealed more IRI present in the tumor following TACE versus PVCE (29.19 ± 12.33 µg/g versus 3.42 ± 1.62; p-value = .0033) or IV (29.19 ± 12.33 µg/g versus 1.05 ± 0.47; p-value = .0035).,A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33501859/),[μg] / [g],29.19,164944,DB00762,Irinotecan
,33501859,IRI,Subseqent biodistribution studies in tumor-bearing WAG/Rjj rats revealed more IRI present in the tumor following TACE versus PVCE (29.19 ± 12.33 µg/g versus 3.42 ± 1.62; p-value = .0033) or IV (29.19 ± 12.33 µg/g versus 1.05 ± 0.47; p-value = .0035).,A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33501859/),[μg] / [g],3.42,164945,DB00762,Irinotecan
,33501859,IRI,Subseqent biodistribution studies in tumor-bearing WAG/Rjj rats revealed more IRI present in the tumor following TACE versus PVCE (29.19 ± 12.33 µg/g versus 3.42 ± 1.62; p-value = .0033) or IV (29.19 ± 12.33 µg/g versus 1.05 ± 0.47; p-value = .0035).,A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33501859/),,1.05,164946,DB00762,Irinotecan
,18525298,MTD,The MTD of epirubicin was 50 mg/m2.,"Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18525298/),[mg] / [m2],50,165644,DB00762,Irinotecan
,17289892,Maximum tolerated dose,Maximum tolerated dose of irinotecan in FOLFIRI schedule with celecoxib is 200 mg/m2.,"Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17289892/),mg,200,166306,DB00762,Irinotecan
,32932279,plasma Cmax,Mean plasma Cmax(100 mg) was 254.50 ± 104.17 ng/mL for irinotecan and 46.72 ± 13.75 ng/mL for SN-38.,"LifePearl microspheres loaded with irinotecan in the treatment of Liver-dominant metastatic colorectal carcinoma: feasibility, safety and pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32932279/),[ng] / [ml],254.50,166347,DB00762,Irinotecan
,32932279,plasma Cmax,Mean plasma Cmax(100 mg) was 254.50 ± 104.17 ng/mL for irinotecan and 46.72 ± 13.75 ng/mL for SN-38.,"LifePearl microspheres loaded with irinotecan in the treatment of Liver-dominant metastatic colorectal carcinoma: feasibility, safety and pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32932279/),[ng] / [ml],46.72,166348,DB00762,Irinotecan
,32932279,Cmax,Mean Cmax(200 mg) was 970.09 ± 353.75 ng/mL for irinotecan and 118.45 ± 25.11 ng/mL for SN-38.,"LifePearl microspheres loaded with irinotecan in the treatment of Liver-dominant metastatic colorectal carcinoma: feasibility, safety and pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32932279/),[ng] / [ml],970.09,166349,DB00762,Irinotecan
,32932279,Cmax,Mean Cmax(200 mg) was 970.09 ± 353.75 ng/mL for irinotecan and 118.45 ± 25.11 ng/mL for SN-38.,"LifePearl microspheres loaded with irinotecan in the treatment of Liver-dominant metastatic colorectal carcinoma: feasibility, safety and pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32932279/),[ng] / [ml],118.45,166350,DB00762,Irinotecan
,20420789,clearance (CL),CPT-11 exhibited a mean clearance (CL) of 15.31 +/- 5.95 (l/h) (13.06 +/- 3.58 (l/hr/m(2))) and AUC(0-inf) of 3547.0 +/- 1406.5 (ng x h/ml); the AUC ratio of parent CPT-11 to SN-38 was 5.0%.,Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420789/),[l] / [h],15.31,166712,DB00762,Irinotecan
,20420789,clearance (CL),CPT-11 exhibited a mean clearance (CL) of 15.31 +/- 5.95 (l/h) (13.06 +/- 3.58 (l/hr/m(2))) and AUC(0-inf) of 3547.0 +/- 1406.5 (ng x h/ml); the AUC ratio of parent CPT-11 to SN-38 was 5.0%.,Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420789/),[h·l] / [m(2],13.06,166713,DB00762,Irinotecan
,20420789,AUC(0-inf),CPT-11 exhibited a mean clearance (CL) of 15.31 +/- 5.95 (l/h) (13.06 +/- 3.58 (l/hr/m(2))) and AUC(0-inf) of 3547.0 +/- 1406.5 (ng x h/ml); the AUC ratio of parent CPT-11 to SN-38 was 5.0%.,Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420789/),[h·ng] / [ml],3547.0,166714,DB00762,Irinotecan
,20420789,AUC ratio,CPT-11 exhibited a mean clearance (CL) of 15.31 +/- 5.95 (l/h) (13.06 +/- 3.58 (l/hr/m(2))) and AUC(0-inf) of 3547.0 +/- 1406.5 (ng x h/ml); the AUC ratio of parent CPT-11 to SN-38 was 5.0%.,Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420789/),%,5.0,166715,DB00762,Irinotecan
,20420789,V,"The final model for CPT-11 are as follows: CL (l/h) = 1.31 x CBW(0.75) (omegaCL = 21.7%), Vss (l) = 2.66 x CBW (omegaVss = 21.2%), Vc (l) = 1.13 x CBW, inter-compartment CL (l/h) = 0.257 x CBW(0.75).",Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420789/),,2,166716,DB00762,Irinotecan
,20420789,Vc (l),"The final model for CPT-11 are as follows: CL (l/h) = 1.31 x CBW(0.75) (omegaCL = 21.7%), Vss (l) = 2.66 x CBW (omegaVss = 21.2%), Vc (l) = 1.13 x CBW, inter-compartment CL (l/h) = 0.257 x CBW(0.75).",Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420789/),,1.13,166717,DB00762,Irinotecan
,24494810,survival time,"As a therapy for orthotopic brain tumors, nanoliposomal irinotecan showed a mean survival time of 54.2 versus 29.5 days for free irinotecan.","Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24494810/),d,54.2,167495,DB00762,Irinotecan
,24494810,survival time,"As a therapy for orthotopic brain tumors, nanoliposomal irinotecan showed a mean survival time of 54.2 versus 29.5 days for free irinotecan.","Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24494810/),d,29.5,167496,DB00762,Irinotecan
,24962521,maximum tolerated dose,The maximum tolerated dose was identified as 24 mg/m(2) due to dose-limiting thrombocytopenia in two patients receiving 30 mg/m(2) .,"Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962521/),[mg] / [m(2],24,168431,DB00762,Irinotecan
,10561231,area under the curve/irinotecan area under the curve ratio,The mean metabolic SN-38 area under the curve/irinotecan area under the curve ratio was 16% +/- 6% compared with 3% to 5% after short infusion schedules involving therapeutic dosages.,"Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561231/),%,16,168934,DB00762,Irinotecan
,10653882,steady-state plasma concentration (Css),"At this dose, the steady-state plasma concentration (Css) of total SN-38 (the active metabolite of irinotecan) was 6.42 +/- 1.10 nmol/L, and the Css of total irinotecan was 28.60 +/- 17.78 nmol/L.",Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653882/),[nM] / [l],6.42,169914,DB00762,Irinotecan
,10653882,Css,"At this dose, the steady-state plasma concentration (Css) of total SN-38 (the active metabolite of irinotecan) was 6.42 +/- 1.10 nmol/L, and the Css of total irinotecan was 28.60 +/- 17.78 nmol/L.",Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653882/),[nM] / [l],28.60,169915,DB00762,Irinotecan
,10653882,molar ratio of the area under the concentration curve (AUC),"The systemic exposure to SN-38 relative to irinotecan was greater than anticipated, with a molar ratio of the area under the concentration curve (AUC) of SN-38 to irinotecan of 0.24 +/- 0.08.",Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653882/),,0.24,169916,DB00762,Irinotecan
,28804517,progression-free survival,"It is the first, second-line treatment approved by the US Food and Drug Administration to treat patients with MPC based on results of the NAnoliPOsomaL Irinotecan (NAPOLI-1) study, which showed that this regimen significantly prolonged progression-free survival (3.1 months versus 1.5 months) and overall survival (6.2 months versus 4.1 months) compared with 5-FU/folinic acid alone.",Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28804517/),month,3.1,170253,DB00762,Irinotecan
,28804517,progression-free survival,"It is the first, second-line treatment approved by the US Food and Drug Administration to treat patients with MPC based on results of the NAnoliPOsomaL Irinotecan (NAPOLI-1) study, which showed that this regimen significantly prolonged progression-free survival (3.1 months versus 1.5 months) and overall survival (6.2 months versus 4.1 months) compared with 5-FU/folinic acid alone.",Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28804517/),month,1.5,170254,DB00762,Irinotecan
,28804517,overall survival,"It is the first, second-line treatment approved by the US Food and Drug Administration to treat patients with MPC based on results of the NAnoliPOsomaL Irinotecan (NAPOLI-1) study, which showed that this regimen significantly prolonged progression-free survival (3.1 months versus 1.5 months) and overall survival (6.2 months versus 4.1 months) compared with 5-FU/folinic acid alone.",Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28804517/),month,6.2,170255,DB00762,Irinotecan
,28804517,overall survival,"It is the first, second-line treatment approved by the US Food and Drug Administration to treat patients with MPC based on results of the NAnoliPOsomaL Irinotecan (NAPOLI-1) study, which showed that this regimen significantly prolonged progression-free survival (3.1 months versus 1.5 months) and overall survival (6.2 months versus 4.1 months) compared with 5-FU/folinic acid alone.",Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28804517/),month,4.1,170256,DB00762,Irinotecan
,16536473,T(1/2),TAB2.5 also showed prolonged retention (T(1/2) = 36.9 h) in tumor-bearing mice with tumor/plasma ratios of up to 1000.,Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16536473/),h,36.9,170969,DB00762,Irinotecan
up to,16536473,tumor/plasma ratios,TAB2.5 also showed prolonged retention (T(1/2) = 36.9 h) in tumor-bearing mice with tumor/plasma ratios of up to 1000.,Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16536473/),,1000,170970,DB00762,Irinotecan
,20943763,terminal-phase half-life,"Polymer-bound SN-38 (NK012) and SN-38 released from NK012 were slowly eliminated from the plasma, with a terminal-phase half-life of approximately 140 and 210 hours, respectively.","Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20943763/),h,140,171618,DB00762,Irinotecan
,20943763,terminal-phase half-life,"Polymer-bound SN-38 (NK012) and SN-38 released from NK012 were slowly eliminated from the plasma, with a terminal-phase half-life of approximately 140 and 210 hours, respectively.","Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20943763/),h,210,171619,DB00762,Irinotecan
,19066728,OS,"PFS at 6 months was 6.25% (2/32 patients) on schedule A and 18.75% (6/32 patients) on schedule B but median OS (5.1 versus 5.5 months), and survival at one year (19%) was similar for both arms.",Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19066728/),month,5,171812,DB00762,Irinotecan
,8398707,beta half-life,Elimination of CPT-11 was biphasic with a mean (+/- s.d.) beta half-life of 11.36 +/- 7.26 h.,Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398707/),h,11.36,172661,DB00762,Irinotecan
,8398707,terminal half-life,"The mean terminal half-life of the major metabolite (7-ethyl-10-hydroxycamptothecin; SN-38) was 22.13 +/- 13.28 (s.d.) h, and modest escalation of the CPT-11 dose from 80 mg m-2 to 90 mg m-2 resulted in a statistically significant apparent increase in the plasma concentrations of SN-38.",Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398707/),h,22.13,172662,DB00762,Irinotecan
,8398707,overall response rate,There were one complete response (7%) and five partial responses (36%) among the 14 patients for an overall response rate of 43%.,Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398707/),%,43,172663,DB00762,Irinotecan
,26884555,MTD,"The MTD for alisertib was 60 mg/m(2), with mandatory myeloid growth factor support and cephalosporin prophylaxis for diarrhea.",Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26884555/),[mg] / [m],60,174301,DB00762,Irinotecan
,26884555,overall response rate,"The overall response rate was 31.8%, with a 50% response rate observed at the MTD.",Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26884555/),%,31.8,174302,DB00762,Irinotecan
,26884555,Progression-free survival rate,Progression-free survival rate at 2 years was 52.4%.,Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26884555/),%,52.4,174303,DB00762,Irinotecan
,10725311,recovery,"Mean +/- S.D. recovery of radioactivity in urine and feces was 95.8 +/- 2.7% (range 92.2-100.3%, n = 7) of dose.","Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725311/),%,95.8,174530,DB00762,Irinotecan
,22615057,progression free survival (PFS),The median progression free survival (PFS) and overall survival (OS) were 2.5 and 4.7 months respectively.,"Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615057/),month,2.5,175046,DB00762,Irinotecan
,22615057,overall survival (OS),The median progression free survival (PFS) and overall survival (OS) were 2.5 and 4.7 months respectively.,"Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615057/),month,4.7,175047,DB00762,Irinotecan
,19170226,area under the concentration versus time curve (AUC(0-->infinity)),"The median oxaliplatin area under the concentration versus time curve (AUC(0-->infinity)) was 5.9 microg . hour/mL (range, 1.8-7.6 microg . hour/mL).",Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19170226/),[h·μg] / [ml],5.9,175329,DB00762,Irinotecan
,9850031,MTD,The MTD for this regimen was 30 mg/m2/wk of cisplatin plus 50 mg/m2/wk of irinotecan in previously treated patients and 30 mg/m2/wk of cisplatin plus 65 mg/m2/wk of irinotecan in chemotherapy-naive patients.,Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850031/),[mg] / [m2·wk],30,178291,DB00762,Irinotecan
,16085147,flow rate,"Mobile phase consisted of acetonitrile-10 mM ammonium acetate buffer (pH 5.50) (28:72, v/v), at a flow rate of 0.8 ml/min.",Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16085147/),[ml] / [min],0.8,178372,DB00762,Irinotecan
,17992531,AUC ratios,A slight trend toward increasing AUC ratios (20%) was detected in both male and female patients bearing *1G.,Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17992531/),,20,179268,DB00762,Irinotecan
,16291583,response rate,"The response rate was 17% (95% CI 10-23), median time to progression (TTP) was 5.4 months (95% CI 4.6-6.4) and median survival 9.5 months (95% CI 8.5-11.2).",Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291583/),%,17,179683,DB00762,Irinotecan
,16291583,time to progression (TTP),"The response rate was 17% (95% CI 10-23), median time to progression (TTP) was 5.4 months (95% CI 4.6-6.4) and median survival 9.5 months (95% CI 8.5-11.2).",Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291583/),month,5.4,179684,DB00762,Irinotecan
,16291583,survival,"The response rate was 17% (95% CI 10-23), median time to progression (TTP) was 5.4 months (95% CI 4.6-6.4) and median survival 9.5 months (95% CI 8.5-11.2).",Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291583/),month,9.5,179685,DB00762,Irinotecan
,22674635,terminal half-life,PK analysis indicated a mean terminal half-life of 19.4 ± 3.4 hours.,"Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22674635/),h,19.4,181276,DB00762,Irinotecan
,19090012,area under the curve [AUC],"Two of 6 subjects at the first dose level (carboplatin target area under the curve [AUC], 4.0 mg/mL*min; irinotecan, 18 mg/m2/dose) experienced dose-limiting gastrointestinal toxicities requiring a dose de-escalation scheme (carboplatin AUC, 4.0 mg/mL*min; irinotecan, 15 mg/m2/dose).",Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19090012/),[mg] / [min·ml],4.0,181284,DB00762,Irinotecan
,19090012,AUC,"Two of 6 subjects at the first dose level (carboplatin target area under the curve [AUC], 4.0 mg/mL*min; irinotecan, 18 mg/m2/dose) experienced dose-limiting gastrointestinal toxicities requiring a dose de-escalation scheme (carboplatin AUC, 4.0 mg/mL*min; irinotecan, 15 mg/m2/dose).",Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19090012/),[mg] / [min·ml],4.0,181285,DB00762,Irinotecan
,19090012,AUC,"A further dose de-escalation to carboplatin AUC of 4.0 mg/mL*min and irinotecan of 12 mg/m2/dose resulted in dose-limiting bone marrow suppression in 1 of 13 patients treated at that dose, and therefore was determined to be the MTD.",Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19090012/),[mg] / [min·ml],4.0,181286,DB00762,Irinotecan
,19090012,AUC,"The recommended phase 2 dose in heavily pretreated pediatric patients is carboplatin (AUC, 4 mg/mL*min on Day 1) and irinotecan (12 mg/m2/dayx10 days) given every 21 days.",Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19090012/),[mg] / [min·ml],4,181287,DB00762,Irinotecan
,12649109,overall response rate,This resulted in an overall response rate of only 2.2% (95% confidence interval 0.2% to 6.5%).,Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),%,2.2,181628,DB00762,Irinotecan
,12649109,time to tumour progression,The median time to tumour progression was 9 weeks in group A and 14.4 weeks in group B.,Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),weeks,9,181629,DB00762,Irinotecan
,12649109,time to tumour progression,The median time to tumour progression was 9 weeks in group A and 14.4 weeks in group B.,Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),weeks,14.4,181630,DB00762,Irinotecan
,12649109,progression-free survival rates,"Six-month progression-free survival rates were 26% in group A and 43% in group B. Grade 3-4 toxicities (percentage of patients in groups A and B) consisted of neutropenia (12.5% and 25.9%), diarrhoea (8.3% and 7.4%), asthenia (12.5% and 7.4%) and vomiting (0% and 7.4%).",Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),%,26,181631,DB00762,Irinotecan
,12649109,progression-free survival rates,"Six-month progression-free survival rates were 26% in group A and 43% in group B. Grade 3-4 toxicities (percentage of patients in groups A and B) consisted of neutropenia (12.5% and 25.9%), diarrhoea (8.3% and 7.4%), asthenia (12.5% and 7.4%) and vomiting (0% and 7.4%).",Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),%,43,181632,DB00762,Irinotecan
,12649109,clearance,The clearance of irinotecan was 12.4 and 14.4 l/h/m(2) in two patients who received no anticonvulsant.,Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),[h·l] / [m(2],12.4,181633,DB00762,Irinotecan
,12649109,clearance,The clearance of irinotecan was 12.4 and 14.4 l/h/m(2) in two patients who received no anticonvulsant.,Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),[h·l] / [m(2],14.4,181634,DB00762,Irinotecan
,12649109,clearance,"In patients receiving valproic acid, the clearance of irinotecan was 17.2 +/- 4.4 l/h/m(2).",Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),[h·l] / [m(2],17.2,181635,DB00762,Irinotecan
,12149304,half-life,"The interconversion between the lactone and carboxylate forms of CPT-11 was relatively rapid, with an equilibration half-life of 14 minutes in the central compartment and hydrolysis occurring at a rate five times faster than lactonization.",Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12149304/),min,14,181718,DB00762,Irinotecan
,12149304,steady-state volume of distribution [Vss],"CPT-11 lactone had extensive tissue distribution (steady-state volume of distribution [Vss], 445 L) compared with the carboxylate form (Vss, 78 L, excluding peripherally formed CPT-11 carboxylate).",Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12149304/),l,445,181719,DB00762,Irinotecan
,12149304,Vss,"CPT-11 lactone had extensive tissue distribution (steady-state volume of distribution [Vss], 445 L) compared with the carboxylate form (Vss, 78 L, excluding peripherally formed CPT-11 carboxylate).",Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12149304/),l,78,181720,DB00762,Irinotecan
,12149304,Clearance (CL),Clearance (CL) was higher for the lactone form (74.3 L/h) compared with the carboxylate form (12.3 L/h).,Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12149304/),[l] / [h],74.3,181721,DB00762,Irinotecan
,12149304,Clearance (CL),Clearance (CL) was higher for the lactone form (74.3 L/h) compared with the carboxylate form (12.3 L/h).,Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12149304/),[l] / [h],12.3,181722,DB00762,Irinotecan
,33125824,limits of detection,"The limits of detection for the lactone and carboxylate forms in plasma were found to be 0.44 ng·ml-1 and 0.28 ng·ml-1 , respectively.",Mechanism and optimization of supramolecular complexation-enhanced fluorescence spectroscopy for the determination of SN-38 in plasma and cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33125824/),[ng] / [ml],0.44,184107,DB00762,Irinotecan
,33125824,limits of detection,"The limits of detection for the lactone and carboxylate forms in plasma were found to be 0.44 ng·ml-1 and 0.28 ng·ml-1 , respectively.",Mechanism and optimization of supramolecular complexation-enhanced fluorescence spectroscopy for the determination of SN-38 in plasma and cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33125824/),[ng] / [ml],0.28,184108,DB00762,Irinotecan
,30284603,progression-free survival,"In group A, the RR was 3.8%, and the median progression-free survival and overall survival were 3.30 months and 15.03 months, respectively.","A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30284603/),month,3.30,184228,DB00762,Irinotecan
,30284603,overall survival,"In group A, the RR was 3.8%, and the median progression-free survival and overall survival were 3.30 months and 15.03 months, respectively.","A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30284603/),month,15,184229,DB00762,Irinotecan
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,4.3,188010,DB00762,Irinotecan
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,3.6,188011,DB00762,Irinotecan
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,1.9,188012,DB00762,Irinotecan
,16010591,half-lives,"The AUC and Cmax of both irinotecan and its active metabolite SN38 increased linearly in proportion to dose, and the mean half-lives of irinotecan conversion to SN38 and SN38 elimination were 6.2 h (CV 171%) and 7.2 h (CV 48%).",Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16010591/),h,6.2,188040,DB00762,Irinotecan
,16010591,half-lives,"The AUC and Cmax of both irinotecan and its active metabolite SN38 increased linearly in proportion to dose, and the mean half-lives of irinotecan conversion to SN38 and SN38 elimination were 6.2 h (CV 171%) and 7.2 h (CV 48%).",Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16010591/),h,7.2,188041,DB00762,Irinotecan
,16288302,time to progression,"Median time to progression was 19 weeks (95% CI, 15-22 weeks), and median survival was 52 weeks (95% CI, 39-64 weeks).",A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16288302/),weeks,19,188256,DB00762,Irinotecan
,16288302,survival,"Median time to progression was 19 weeks (95% CI, 15-22 weeks), and median survival was 52 weeks (95% CI, 39-64 weeks).",A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16288302/),weeks,52,188257,DB00762,Irinotecan
,14769140,AUC,"At the 750-mg/m(2) dose, the AUC for CPT-11 (21.6 microg x h/ml) matched the AUC (21.6 microg x h/ml) in the non-EIAED group treated with 350 mg/m(2) of CPT-11.",Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14769140/),[h·μg] / [ml],21.6,189632,DB00762,Irinotecan
,28558150,half-life,"IMMU-132 cleared with a half-life of approximately 11 to 14 hours, reflecting the release of SN-38 from the conjugate; IgG cleared more slowly (half-life, approximately 103-114 hours).","Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28558150/),h,11 to 14,190567,DB00762,Irinotecan
,28558150,half-life,"IMMU-132 cleared with a half-life of approximately 11 to 14 hours, reflecting the release of SN-38 from the conjugate; IgG cleared more slowly (half-life, approximately 103-114 hours).","Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28558150/),h,103-114,190568,DB00762,Irinotecan
,10981288,area-under-curve (AUC),"Of the 32 patients in phase I portion of the trial, six received irinotecan 40 mg/m2 plus carboplatin at an area-under-curve (AUC) of 6 and paclitaxel 225 mg/m2 on an every-3-week schedule (regimen A).","Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10981288/),[mg] / [m2],6,191117,DB00762,Irinotecan
,10981288,objective response rate,"The unconfirmed objective response rate in phase I was 64.5%; median time to progression and median survival were 7.1 months and 11.6 months, respectively, and 1-year survival was 46.9%.","Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10981288/),%,64.5,191118,DB00762,Irinotecan
,10981288,time to progression,"The unconfirmed objective response rate in phase I was 64.5%; median time to progression and median survival were 7.1 months and 11.6 months, respectively, and 1-year survival was 46.9%.","Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10981288/),month,7.1,191119,DB00762,Irinotecan
,10981288,survival,"The unconfirmed objective response rate in phase I was 64.5%; median time to progression and median survival were 7.1 months and 11.6 months, respectively, and 1-year survival was 46.9%.","Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10981288/),month,11.6,191120,DB00762,Irinotecan
,10981288,objective response rate,"The unconfirmed objective response rate in phase II was 60.6%, including one complete response (CR) and 19 partial responses (PRs); one CR and 16 PRs were subsequently confirmed.","Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10981288/),%,60.6,191121,DB00762,Irinotecan
,7961128,Vc,"The population mean values (CV%) of Vc, CL, K12, and K21 were, respectively, 31.8 (15.7%) liter/m2, 14.1 (27.8%) liter/h/m2, 1.1 (8.4%)/h, and 0.41 (30.3%)/h.",CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7961128/),,31.8,191376,DB00762,Irinotecan
,7961128,CL,"The population mean values (CV%) of Vc, CL, K12, and K21 were, respectively, 31.8 (15.7%) liter/m2, 14.1 (27.8%) liter/h/m2, 1.1 (8.4%)/h, and 0.41 (30.3%)/h.",CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7961128/),,14.1,191377,DB00762,Irinotecan
,7961128,K12,"The population mean values (CV%) of Vc, CL, K12, and K21 were, respectively, 31.8 (15.7%) liter/m2, 14.1 (27.8%) liter/h/m2, 1.1 (8.4%)/h, and 0.41 (30.3%)/h.",CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7961128/),,14.1,191378,DB00762,Irinotecan
,7961128,K21,"The population mean values (CV%) of Vc, CL, K12, and K21 were, respectively, 31.8 (15.7%) liter/m2, 14.1 (27.8%) liter/h/m2, 1.1 (8.4%)/h, and 0.41 (30.3%)/h.",CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7961128/),,0.41,191379,DB00762,Irinotecan
,26489552,in,"Since the levels of tumor markers increased, the 5-FU dose was increased from 2,700 to 3,000 mg/m2 using a Jackson-type pump and an extended infusion time of 53 hours.",[Improved Response to 5-FU Using Dose Adjustment and Elastomeric Pump Selection Based on Monitoring of the 5-FU Level--A Case Report]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26489552/),,53,191430,DB00762,Irinotecan
,26489552,areas under the concentration vs. time curve (AUC mg,"The areas under the concentration vs. time curve (AUC mg・h/L)were 21 and 44 mg・h/L for the Jackson- and bottle-type pumps, respectively.",[Improved Response to 5-FU Using Dose Adjustment and Elastomeric Pump Selection Based on Monitoring of the 5-FU Level--A Case Report]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26489552/),[mg・h] / [l],21,191431,DB00762,Irinotecan
,26489552,areas under the concentration vs. time curve (AUC mg,"The areas under the concentration vs. time curve (AUC mg・h/L)were 21 and 44 mg・h/L for the Jackson- and bottle-type pumps, respectively.",[Improved Response to 5-FU Using Dose Adjustment and Elastomeric Pump Selection Based on Monitoring of the 5-FU Level--A Case Report]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26489552/),[mg・h] / [l],44,191432,DB00762,Irinotecan
,26489552,AUC,"The AUC decreased to 27 mg・h/L, but the liver metastases were reduced and the adverse effects subsided to Grade 1.",[Improved Response to 5-FU Using Dose Adjustment and Elastomeric Pump Selection Based on Monitoring of the 5-FU Level--A Case Report]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26489552/),[mg・h] / [l],27,191433,DB00762,Irinotecan
,16404360,progression-free survival,"Of patients with radiologically evaluable disease at baseline, 50 and 48% responded to therapy in arms A and B, respectively; at median 17.1 months' follow-up, median progression-free survival was 17.1 and 15.9 months, respectively.",SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404360/),month,17.1,191815,DB00762,Irinotecan
,16404360,progression-free survival,"Of patients with radiologically evaluable disease at baseline, 50 and 48% responded to therapy in arms A and B, respectively; at median 17.1 months' follow-up, median progression-free survival was 17.1 and 15.9 months, respectively.",SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404360/),month,15.9,191816,DB00762,Irinotecan
,21918903,AUC,The observed AUC of NDP ranged from 4 to 14 (μg h(-1) ml(-1)) with large variation.,Evaluation of a formula for individual dosage of nedaplatin based on renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21918903/),[μg] / [h·ml],4 to 14,196968,DB00762,Irinotecan
,23850745,oil carrying capacity,"The SMEDDS were developed using Capmul MCM-C8, Cremophor EL and Pluronic L-121 as oil, surfactant and co-surfactant respectively and has good oil carrying capacity (30%) with competence to produce nano-scale oil droplets (130 ± 2.13 nm) on spontaneous emulsification.",Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23850745/),%,30,197426,DB00762,Irinotecan
,16446328,MTD,The MTD was 40 mg/m2/d without cefixime but 60 mg/m2/d with cefixime.,Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446328/),[mg] / [d·m2],40,199730,DB00762,Irinotecan
,16446328,MTD,The MTD was 40 mg/m2/d without cefixime but 60 mg/m2/d with cefixime.,Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446328/),[mg] / [d·m2],60,199731,DB00762,Irinotecan
,16446328,area under the curve,"Systemic exposure to SN-38 at the MTD was significantly higher with cefixime than without cefixime (mean SN-38 area under the curve: 19.5 ng x h/mL; standard deviation [SD], 6.8 ng x h/mL v 10.4 ng x h/mL; SD, 4.3 ng x h/mL, respectively; P = .030).",Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446328/),[h·ng] / [ml],19.5,199732,DB00762,Irinotecan
,16446328,area under the curve,"Systemic exposure to SN-38 at the MTD was significantly higher with cefixime than without cefixime (mean SN-38 area under the curve: 19.5 ng x h/mL; standard deviation [SD], 6.8 ng x h/mL v 10.4 ng x h/mL; SD, 4.3 ng x h/mL, respectively; P = .030).",Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446328/),[h·ng] / [ml],10.4,199733,DB00762,Irinotecan
,16278402,clearance,"Short-term (4 days) or more prolonged intake of milk thistle (12 days) had no significant effect on irinotecan clearance (mean, 31.2 versus 25.4 versus 25.6 L/h; P = 0.16).",Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278402/),[l] / [h],31.2,200371,DB00762,Irinotecan
,16278402,clearance,"Short-term (4 days) or more prolonged intake of milk thistle (12 days) had no significant effect on irinotecan clearance (mean, 31.2 versus 25.4 versus 25.6 L/h; P = 0.16).",Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278402/),[l] / [h],25.4,200372,DB00762,Irinotecan
,16278402,clearance,"Short-term (4 days) or more prolonged intake of milk thistle (12 days) had no significant effect on irinotecan clearance (mean, 31.2 versus 25.4 versus 25.6 L/h; P = 0.16).",Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278402/),[l] / [h],25.6,200373,DB00762,Irinotecan
,16278402,maximum plasma concentrations,The maximum plasma concentrations of silybin ranged between 0.0249 and 0.257 micromol/L.,Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278402/),[μM] / [l],0.0249 and 0.257,200374,DB00762,Irinotecan
,8275479,mean residence times,"The Cmax for the active metabolite of CPT-11, 7-ethyl-10-hydroxycamptothecin (SN-38), was achieved at 2.2 +/- 0.1 h after treatment, and mean residence times for both CPT-11 and SN-38 were long, 9.1 and 10.0 h, respectively.",Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8275479/),h,9.1,202531,DB00762,Irinotecan
,8275479,mean residence times,"The Cmax for the active metabolite of CPT-11, 7-ethyl-10-hydroxycamptothecin (SN-38), was achieved at 2.2 +/- 0.1 h after treatment, and mean residence times for both CPT-11 and SN-38 were long, 9.1 and 10.0 h, respectively.",Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8275479/),h,10.0,202532,DB00762,Irinotecan
,19620803,conversion,"The median conversion and conjugation ratios were 0.0155 and 2.812, respectively (n=48).",Individual differences in rate-limiting reactions during metabolism of irinotecan hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620803/),,0.0155,202789,DB00762,Irinotecan
,19620803,conjugation ratios,"The median conversion and conjugation ratios were 0.0155 and 2.812, respectively (n=48).",Individual differences in rate-limiting reactions during metabolism of irinotecan hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620803/),,2.812,202790,DB00762,Irinotecan
,15196737,MTD,"The MTD of irinotecan and paclitaxel were 40 and 50 mg/m2, respectively.",A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15196737/),[mg] / [m2],40,203626,DB00762,Irinotecan
,15196737,MTD,"The MTD of irinotecan and paclitaxel were 40 and 50 mg/m2, respectively.",A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15196737/),[mg] / [m2],50,203627,DB00762,Irinotecan
,27883280,MTD,The MTD of irinotecan for previously treated lung cancer patients that are heterozygous for the UGT1A1 * 28 or UGT1A1 * 6 gene polymorphism is 60 mg/m2 .,Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27883280/),[mg] / [m2],60,205118,DB00762,Irinotecan
,15939714,Response rate,Response rate in the phase II cohort was 42% [95% confidence interval (CI) 29% to 56%].,A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15939714/),%,42,206007,DB00762,Irinotecan
,15939714,duration of response,Median duration of response was 7.7 months (95% CI 7.5-8.9).,A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15939714/),month,7.7,206008,DB00762,Irinotecan
,15939714,time to progression,Median time to progression was 8.3 months (95% CI 5.8-10).,A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15939714/),month,8.3,206009,DB00762,Irinotecan
,22305081,Precision,"Precision of the three analytes in the same order ranged from 0.8 to 2.8%, 2.4 to 5.7%, and 2.4 to 2.8%.","Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305081/),%,0.8 to 2.8,207749,DB00762,Irinotecan
,22305081,Precision,"Precision of the three analytes in the same order ranged from 0.8 to 2.8%, 2.4 to 5.7%, and 2.4 to 2.8%.","Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305081/),%,2.4 to 5.7,207750,DB00762,Irinotecan
,22305081,Precision,"Precision of the three analytes in the same order ranged from 0.8 to 2.8%, 2.4 to 5.7%, and 2.4 to 2.8%.","Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305081/),%,2.4 to 2.8,207751,DB00762,Irinotecan
,25228368,t 1/2,"Etirinotecan pegol was eliminated very slowly from the tumor (t 1/2 = 17 days), achieving higher and more sustained tumor exposure when compared with conventional irinotecan.","Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25228368/),d,17,208432,DB00762,Irinotecan
,22528576,minimal detectable levels,"Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18.6, 21, and 18.6 ng/ml) and SN-38 (1.06, 1.47, and 1.55 ng/ml) after the first, second, and third DEBIRI treatments, respectively.",Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),[ng] / [ml],18.6,209363,DB00762,Irinotecan
,22528576,minimal detectable levels,"Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18.6, 21, and 18.6 ng/ml) and SN-38 (1.06, 1.47, and 1.55 ng/ml) after the first, second, and third DEBIRI treatments, respectively.",Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),[ng] / [ml],21,209364,DB00762,Irinotecan
,22528576,minimal detectable levels,"Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18.6, 21, and 18.6 ng/ml) and SN-38 (1.06, 1.47, and 1.55 ng/ml) after the first, second, and third DEBIRI treatments, respectively.",Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),[ng] / [ml],1.06,209365,DB00762,Irinotecan
,22528576,minimal detectable levels,"Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18.6, 21, and 18.6 ng/ml) and SN-38 (1.06, 1.47, and 1.55 ng/ml) after the first, second, and third DEBIRI treatments, respectively.",Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),[ng] / [ml],1.47,209366,DB00762,Irinotecan
,22528576,minimal detectable levels,"Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18.6, 21, and 18.6 ng/ml) and SN-38 (1.06, 1.47, and 1.55 ng/ml) after the first, second, and third DEBIRI treatments, respectively.",Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),[ng] / [ml],1.55,209367,DB00762,Irinotecan
,22528576,overall survival,Four (40 %) patients were successfully downstaged to resection and/or ablation with a median overall survival of 15.2 months.,Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),month,15.2,209368,DB00762,Irinotecan
,10741701,Systemic clearance rate,Systemic clearance rate for IRN was 58.7 +/- 18.8 liters/h/m2 (mean +/- SD).,Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741701/),[l] / [h·m2],58.7,209531,DB00762,Irinotecan
,10741701,area under the concentration-time curve (AUC(0-->6),"The mean +/- SD ng/ml x h single-day lactone SN-38 area under the concentration-time curve (AUC(0-->6) was 90.9 +/- 96.4, 103.7 +/- 62.4, and 95.3 +/- 63.9 at IRN doses of 20, 24, and 29 mg/m2, respectively.",Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741701/),[ng] / [h·ml],90.9,209532,DB00762,Irinotecan
,10741701,area under the concentration-time curve (AUC(0-->6),"The mean +/- SD ng/ml x h single-day lactone SN-38 area under the concentration-time curve (AUC(0-->6) was 90.9 +/- 96.4, 103.7 +/- 62.4, and 95.3 +/- 63.9 at IRN doses of 20, 24, and 29 mg/m2, respectively.",Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741701/),[ng] / [h·ml],103.7,209533,DB00762,Irinotecan
,10741701,area under the concentration-time curve (AUC(0-->6),"The mean +/- SD ng/ml x h single-day lactone SN-38 area under the concentration-time curve (AUC(0-->6) was 90.9 +/- 96.4, 103.7 +/- 62.4, and 95.3 +/- 63.9 at IRN doses of 20, 24, and 29 mg/m2, respectively.",Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741701/),[ng] / [h·ml],95.3,209534,DB00762,Irinotecan
,15816556,maximum tolerated dose (MTD),"Multiple dose administration (i.v. x 5) of LE-SN38 indicated a maximum tolerated dose (MTD) of 5.0 and 7.5 mg/kg/day for male and female mice, respectively.","Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15816556/),[mg] / [d·kg],5.0,210226,DB00762,Irinotecan
,15816556,maximum tolerated dose (MTD),"Multiple dose administration (i.v. x 5) of LE-SN38 indicated a maximum tolerated dose (MTD) of 5.0 and 7.5 mg/kg/day for male and female mice, respectively.","Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15816556/),[mg] / [d·kg],7.5,210227,DB00762,Irinotecan
,15816556,MTD,The MTD of LE-SN38 in dogs was 1.2 mg/kg.,"Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15816556/),[mg] / [kg],1.2,210228,DB00762,Irinotecan
,15816556,elimination half-life (t1/2),The elimination half-life (t1/2) of SN-38 in mouse plasma was 6.38 h with volume of distribution (VdSS) 2.55 L/kg.,"Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15816556/),h,6.38,210229,DB00762,Irinotecan
,15816556,volume of distribution (VdSS),The elimination half-life (t1/2) of SN-38 in mouse plasma was 6.38 h with volume of distribution (VdSS) 2.55 L/kg.,"Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15816556/),[l] / [kg],2.55,210230,DB00762,Irinotecan
,15816556,t1/2,"In dogs, t1/2 and VdSS were 1.38-6.42 h and 1.69-5.01 L/kg; respectively.","Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15816556/),h,1.38-6.42,210231,DB00762,Irinotecan
,15816556,VdSS,"In dogs, t1/2 and VdSS were 1.38-6.42 h and 1.69-5.01 L/kg; respectively.","Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15816556/),[l] / [kg],1.69-5.01,210232,DB00762,Irinotecan
,9533544,complete response,SN-38 systemic exposure associated with the lowest oral dose (25 mg/kg) achieving complete response for HC1 was 942.6 ng/ml x h.,Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533544/),[ng] / [h·ml],94,210595,DB00762,Irinotecan
,21174225,objective response rate,"The objective response rate was 30.0% (95% confidence interval [CI], 14.7%-49.4%) and the disease control rate (complete response, partial response, or stable disease) was 76.7% (95% CI, 57.7%-90.0%).","Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21174225/),%,30.,210925,DB00762,Irinotecan
,21174225,progression-free survival,The median progression-free survival was 5.3 months and median overall survival was 10.8 months.,"Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21174225/),month,5.3,210926,DB00762,Irinotecan
,21174225,overall survival,The median progression-free survival was 5.3 months and median overall survival was 10.8 months.,"Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21174225/),month,10.8,210927,DB00762,Irinotecan
,28041782,serum area under the concentration-time curve (0-24 h),"There were no significant differences in the serum area under the concentration-time curve (0-24 h) for free SN-38, at 1,500 and 1,310 μg∙min/mL in the IA and IV groups, respectively (P = .152).",Intraarterial Therapy Using Micellar Nanoparticles Incorporating SN-38 in a Rabbit Liver Tumor Model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28041782/),[μg∙min] / [ml],"1,500",210974,DB00762,Irinotecan
,28041782,serum area under the concentration-time curve (0-24 h),"There were no significant differences in the serum area under the concentration-time curve (0-24 h) for free SN-38, at 1,500 and 1,310 μg∙min/mL in the IA and IV groups, respectively (P = .152).",Intraarterial Therapy Using Micellar Nanoparticles Incorporating SN-38 in a Rabbit Liver Tumor Model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28041782/),[μg∙min] / [ml],"1,310",210975,DB00762,Irinotecan
,12915867,overall response rate,"Of 34 patients with evaluable disease, one patient had a complete response and nine patients had partial response, yielding an overall response rate of 29.4%.","Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915867/),%,29.4,212168,DB00762,Irinotecan
,27871319,MTD,The MTD of PEP02 was determined as 80 mg/m2.,A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27871319/),[mg] / [m2],80,212352,DB00762,Irinotecan
,27871319,MTD,"The MTD of PEP02 on day 1 in combination with 24-h infusion of 5-FU and LV on days 1 and 8, every 3 weeks was 80 mg/m2, which will be the recommended dose for future studies.",A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27871319/),mg,80,212353,DB00762,Irinotecan
,27904955,C max,"Neutropenia occurred in approximately 80% of dogs receiving irinotecan (mean SN38 C max of 13.5 and 26.3 ng/mL for 20 and 25 mg/kg, respectively).",Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27904955/),[ng] / [ml],13.5,212719,DB00762,Irinotecan
,27904955,C max,"Neutropenia occurred in approximately 80% of dogs receiving irinotecan (mean SN38 C max of 13.5 and 26.3 ng/mL for 20 and 25 mg/kg, respectively).",Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27904955/),[ng] / [ml],26.3,212720,DB00762,Irinotecan
,27904955,C max,"No neutropenia occurred in dogs receiving EP at doses up to and including 25 mg/kg (mean SN38 C max of 3.4 and 4.9 ng/mL for 20 and 25 mg/kg, respectively), despite 2.5-3.6 times greater SN38 AUC after EP compared to irinotecan at equivalent doses.",Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27904955/),[ng] / [ml],3.4,212721,DB00762,Irinotecan
,27904955,C max,"No neutropenia occurred in dogs receiving EP at doses up to and including 25 mg/kg (mean SN38 C max of 3.4 and 4.9 ng/mL for 20 and 25 mg/kg, respectively), despite 2.5-3.6 times greater SN38 AUC after EP compared to irinotecan at equivalent doses.",Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27904955/),[ng] / [ml],4.9,212722,DB00762,Irinotecan
,10668856,distribution half-life,The distribution half-life of ultrafiltrated plasma platinum ranges from 10 to 25 minutes and its terminal elimination half-life is 26 hours (determined with FAAS) or 270 hours (ICP-MS).,Oxaliplatin: pharmacokinetics and chronopharmacological aspects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668856/),min,10 to 25,213128,DB00762,Irinotecan
,10668856,terminal elimination half-life,The distribution half-life of ultrafiltrated plasma platinum ranges from 10 to 25 minutes and its terminal elimination half-life is 26 hours (determined with FAAS) or 270 hours (ICP-MS).,Oxaliplatin: pharmacokinetics and chronopharmacological aspects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668856/),h,26,213129,DB00762,Irinotecan
,10668856,terminal elimination half-life,The distribution half-life of ultrafiltrated plasma platinum ranges from 10 to 25 minutes and its terminal elimination half-life is 26 hours (determined with FAAS) or 270 hours (ICP-MS).,Oxaliplatin: pharmacokinetics and chronopharmacological aspects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668856/),h,270,213130,DB00762,Irinotecan
,10668856,elimination half-life,"The elimination half-life of erythrocytic platinum is 12 to 50 days, close to that of erythrocytes.",Oxaliplatin: pharmacokinetics and chronopharmacological aspects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668856/),d,12 to 50,213131,DB00762,Irinotecan
,8044782,terminal half-life,CPT-11 plasma disposition was bi- or triphasic with a terminal half-life of 9.3 h.,"Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8044782/),h,9.3,213758,DB00762,Irinotecan
,16832665,overall response rate,There were five partial responses among 11 patients for an overall response rate of 45%.,Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832665/),%,45,214503,DB00762,Irinotecan
,29067643,progression-free survival,"Gedatolisib plus irinotecan produced a response rate of ~5% and clinical benefit in 16% of patients with advanced colorectal cancer (progression-free survival, 2.8 months).",A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067643/),month,2.8,217514,DB00762,Irinotecan
,20827550,steady-state volume of distribution (Vss),"The typical values of steady-state volume of distribution (Vss) (46.6 L/m(2)), inter-compartment clearance (6.70 L/h/m(2)) and clearance (16.0 L/h/m(2)) for plasma CPT-11 were estimated in a two-compartment PK model.",Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20827550/),[l] / [m(2],46.6,218132,DB00762,Irinotecan
,20827550,inter-compartment clearance,"The typical values of steady-state volume of distribution (Vss) (46.6 L/m(2)), inter-compartment clearance (6.70 L/h/m(2)) and clearance (16.0 L/h/m(2)) for plasma CPT-11 were estimated in a two-compartment PK model.",Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20827550/),[h·l] / [m(2],6.70,218133,DB00762,Irinotecan
,20827550,clearance,"The typical values of steady-state volume of distribution (Vss) (46.6 L/m(2)), inter-compartment clearance (6.70 L/h/m(2)) and clearance (16.0 L/h/m(2)) for plasma CPT-11 were estimated in a two-compartment PK model.",Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20827550/),[h·l] / [m(2],16.0,218134,DB00762,Irinotecan
,23835420,transport,Morphine showed low transporter-independent membrane permeability (0.5 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],0.5 × 10⁻⁶,218864,DB00762,Irinotecan
,23835420,membrane permeability,Morphine showed low transporter-independent membrane permeability (0.5 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],0.5 × 10⁻⁶,218865,DB00762,Irinotecan
,23835420,KM,"The increase was concentration-dependent and followed Michaelis-Menten kinetics (KM = 3.4 μM, VMAX = 27 pmol/min/mg protein).",Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),μM,3.4,218866,DB00762,Irinotecan
,23835420,VMAX,"The increase was concentration-dependent and followed Michaelis-Menten kinetics (KM = 3.4 μM, VMAX = 27 pmol/min/mg protein).",Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[pM] / [mg·min],27,218867,DB00762,Irinotecan
,23835420,transporter-independent,Codeine itself had high transporter-independent membrane permeability (8.2 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],8.2 × 10⁻⁶,218868,DB00762,Irinotecan
,23835420,membrane permeability,Codeine itself had high transporter-independent membrane permeability (8.2 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],8.2 × 10⁻⁶,218869,DB00762,Irinotecan
,26163340,duration of response,2 patients (22 %) achieved partial response with the duration of response were 112 and 799 days.,Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26163340/),d,112,219831,DB00762,Irinotecan
,26163340,duration of response,2 patients (22 %) achieved partial response with the duration of response were 112 and 799 days.,Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26163340/),d,799,219832,DB00762,Irinotecan
,20039040,MTD,The MTD was defined as 80 mg/day lomeguatrib with 300 mg/m(2) irinotecan.,A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20039040/),mg,80,221359,DB00762,Irinotecan
,21161529,f(CSF),"The estimate of f(CSF) (% and RSE) was 0.165 (73.5) for the control group and 0.265 (66.5) for radiation-treated groups, respectively (P < 0.05).",Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21161529/),%,0.165,221591,DB00762,Irinotecan
,21161529,f(CSF),"The estimate of f(CSF) (% and RSE) was 0.165 (73.5) for the control group and 0.265 (66.5) for radiation-treated groups, respectively (P < 0.05).",Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21161529/),,0.265,221592,DB00762,Irinotecan
,20653675,AUC ratio,"The median AUC ratio of patients having three or four functional CES1 genes (diplotypes A/B, A/D or B/C, C/D, B/B and B/D; n= 35) was 1.24-fold of that in patients with two functional CES1 genes (diplotypes A/A, A/C and C/C; n= 23) [median (25th-75th percentiles): 0.31 (0.25-0.38) vs. 0.25 (0.20-0.32), P= 0.0134].",Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20653675/),,0.31,222062,DB00762,Irinotecan
,20653675,AUC ratio,"The median AUC ratio of patients having three or four functional CES1 genes (diplotypes A/B, A/D or B/C, C/D, B/B and B/D; n= 35) was 1.24-fold of that in patients with two functional CES1 genes (diplotypes A/A, A/C and C/C; n= 23) [median (25th-75th percentiles): 0.31 (0.25-0.38) vs. 0.25 (0.20-0.32), P= 0.0134].",Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20653675/),,0.25,222063,DB00762,Irinotecan
,16328416,MTD,"Daily oral administration of irinotecan as the PFC formulation for 5 days every 3 weeks can safely deliver protracted exposure to SN-38, with the MTD of 50 mg/m(2)/d.",A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16328416/),[mg] / [m],50,222120,DB00762,Irinotecan
,23982118,objective tumor response rate,"In 22 efficacy-evaluable patients, the objective tumor response rate was 59.1 % (75 % for both MCRC and MGC in the first-line setting) and the disease control rate was 100 %.",Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982118/),%,59.1,223209,DB00762,Irinotecan
,23982118,objective tumor response rate,"In 22 efficacy-evaluable patients, the objective tumor response rate was 59.1 % (75 % for both MCRC and MGC in the first-line setting) and the disease control rate was 100 %.",Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982118/),%,75,223210,DB00762,Irinotecan
,11345644,Vmax,"The irinotecan carboxylesterase-converting enzyme in human plasma had a Vmax of 89.9 +/- 22.7 pmol/h per ml plasma and a Km of 207 +/- 56 microM (mean +/- SD, n = 3).",Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345644/),[pM] / [h·ml·plasma],89.9,223721,DB00762,Irinotecan
,11345644,Km,"The irinotecan carboxylesterase-converting enzyme in human plasma had a Vmax of 89.9 +/- 22.7 pmol/h per ml plasma and a Km of 207 +/- 56 microM (mean +/- SD, n = 3).",Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345644/),μM,207,223722,DB00762,Irinotecan
,11345644,specific activity,The mean value of the specific activity of this enzyme in 20 adult cancer patients was 10.08 +/- 2.96 pmol/h per ml plasma ranging from 5.43 to 15.39 pmol/h per ml.,Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345644/),[pM] / [h·ml],10.08,223723,DB00762,Irinotecan
,11345644,specific activity,The mean value of the specific activity of this enzyme in 20 adult cancer patients was 10.08 +/- 2.96 pmol/h per ml plasma ranging from 5.43 to 15.39 pmol/h per ml.,Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345644/),[pM] / [h·ml],5.43 to 15.39,223724,DB00762,Irinotecan
,19687340,MTD,The MTD of the combination regimen was 15 mg/m(2)/d of IV irinotecan for 5 days of 2 consecutive weeks and 112.5 mg/m(2)/d of gefitinib given for 12 days.,Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19687340/),[mg] / [d·m(2)],15,225785,DB00762,Irinotecan
,19687340,MTD,The MTD of the combination regimen was 15 mg/m(2)/d of IV irinotecan for 5 days of 2 consecutive weeks and 112.5 mg/m(2)/d of gefitinib given for 12 days.,Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19687340/),[mg] / [d·m(2)],112.5,225786,DB00762,Irinotecan
,19687340,bioavailability,"Gefitinib increased the bioavailability of oral irinotecan by four-fold over that observed in historical controls (median, 0.09 v 0.42; P < .000001), reducing the apparent clearance (an inverse measure of exposure) of irinotecan and SN-38 by 37% and 38%, respectively (P < .0001).",Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19687340/),,0.09,225787,DB00762,Irinotecan
,19687340,bioavailability,"Gefitinib increased the bioavailability of oral irinotecan by four-fold over that observed in historical controls (median, 0.09 v 0.42; P < .000001), reducing the apparent clearance (an inverse measure of exposure) of irinotecan and SN-38 by 37% and 38%, respectively (P < .0001).",Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19687340/),,0.42,225788,DB00762,Irinotecan
,29564497,clearance,"With the model developed based on total dose of EP, the population estimates of EP clearance and central volume were 0.237 L/h and 5.5 L, respectively.",Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29564497/),[l] / [h],0.237,226450,DB00762,Irinotecan
,29564497,central volume,"With the model developed based on total dose of EP, the population estimates of EP clearance and central volume were 0.237 L/h and 5.5 L, respectively.",Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29564497/),l,5.5,226451,DB00762,Irinotecan
,9554590,clearance (CL),"9-AC lactone had a clearance (CL) of 2.1 +/- 0.9 l/kg per h, a volume of distribution at steady state (Vd[ss]) of 1.6 +/- 0.7 l/kg and a half-life (t1/2) of 3.2 +/- 0.8 h.","Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),[l] / [h·kg],2.1,226844,DB00762,Irinotecan
,9554590,volume of distribution at steady state (Vd[ss]),"9-AC lactone had a clearance (CL) of 2.1 +/- 0.9 l/kg per h, a volume of distribution at steady state (Vd[ss]) of 1.6 +/- 0.7 l/kg and a half-life (t1/2) of 3.2 +/- 0.8 h.","Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),[l] / [kg],1.6,226845,DB00762,Irinotecan
,9554590,half-life (t1/2),"9-AC lactone had a clearance (CL) of 2.1 +/- 0.9 l/kg per h, a volume of distribution at steady state (Vd[ss]) of 1.6 +/- 0.7 l/kg and a half-life (t1/2) of 3.2 +/- 0.8 h.","Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),h,3.2,226846,DB00762,Irinotecan
,9554590,CL,"For irinotecan, the CL was 3.4 +/- 0.4 l/kg per h, the Vd(ss) was 7.1 +/- 1.3 l/kg, and the t1/2 was 4.9 +/- 2.2 h.","Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),[l] / [h·kg],3.4,226847,DB00762,Irinotecan
,9554590,Vd(ss),"For irinotecan, the CL was 3.4 +/- 0.4 l/kg per h, the Vd(ss) was 7.1 +/- 1.3 l/kg, and the t1/2 was 4.9 +/- 2.2 h.","Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),[l] / [kg],7.1,226848,DB00762,Irinotecan
,9554590,t1/2,"For irinotecan, the CL was 3.4 +/- 0.4 l/kg per h, the Vd(ss) was 7.1 +/- 1.3 l/kg, and the t1/2 was 4.9 +/- 2.2 h.","Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),h,4.9,226849,DB00762,Irinotecan
,9554590,AUC(CSF):AUC(P) ratio,The AUC(CSF):AUC(P) ratio for irinotecan lactone was 14 +/- 3%.,"Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),%,14,226850,DB00762,Irinotecan
<,9554590,AUC(CSF):AUC(P) ratio,The AUC(CSF):AUC(P) ratio for SN-38 lactone was estimated to be < or = 8%.,"Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),%,8,226851,DB00762,Irinotecan
,9554590,AUC(CSF):AUC(P) ratio,"Despite their structural similarity, the CSF penetration of 9-AC and SN-38 is substantially less than that of topotecan which we previously found to have an AUC(CSF):AUC(P) ratio of 32%.","Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),%,32,226852,DB00762,Irinotecan
,23242585,overall response (complete response (CR) + partial response (PR)) rate,The overall response (complete response (CR) + partial response (PR)) rate was 4 %.,A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23242585/),%,4,227378,DB00762,Irinotecan
,23242585,overall survival,"Median overall survival in patients with TP53 mutant tumors was poor compared to wild type (5.5 vs. 20.3 months, p = 0.004).",A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23242585/),month,5.5,227379,DB00762,Irinotecan
,23242585,overall survival,"Median overall survival in patients with TP53 mutant tumors was poor compared to wild type (5.5 vs. 20.3 months, p = 0.004).",A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23242585/),month,20.3,227380,DB00762,Irinotecan
,14586557,time to tumor progression,The median time to tumor progression was 43 days (95% CI 37-92 days).,"A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586557/),d,43,227622,DB00762,Irinotecan
,14586557,overall survival,The median overall survival was 117 days (95% CI 90-279 days).,"A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586557/),d,117,227623,DB00762,Irinotecan
,14586557,plasma clearance,"The average plasma clearance, total volume of distribution, and terminal elimination half-life were 2.1 l/h per m(2), 20 l/m(2) and 9.5 h, respectively.","A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586557/),[h·l] / [m(2],2.1,227624,DB00762,Irinotecan
,14586557,total volume of distribution,"The average plasma clearance, total volume of distribution, and terminal elimination half-life were 2.1 l/h per m(2), 20 l/m(2) and 9.5 h, respectively.","A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586557/),[l] / [m(2],20,227625,DB00762,Irinotecan
,14586557,terminal elimination half-life,"The average plasma clearance, total volume of distribution, and terminal elimination half-life were 2.1 l/h per m(2), 20 l/m(2) and 9.5 h, respectively.","A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586557/),h,9.5,227626,DB00762,Irinotecan
,20479404,time to progression,Median time to progression for all 34 eligible patients enrolled was 127 days for MG and 71 days for BSG.,Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20479404/),d,127,230153,DB00762,Irinotecan
,20479404,Progression-free survival rates,"Progression-free survival rates at 6 months were 41.8% and 9.7% for MG and BSG, respectively.",Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20479404/),%,41.8,230154,DB00762,Irinotecan
,20479404,Progression-free survival rates,"Progression-free survival rates at 6 months were 41.8% and 9.7% for MG and BSG, respectively.",Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20479404/),%,9.7,230155,DB00762,Irinotecan
,25233635,elimination half-life,"Compared with irinotecan solution, the elimination half-life of SN-38 was prolonged from 2.17 h to 2.67 h after the intravenous injection of CPT-11 NPs, but its AUC had little change.",[Pharmacokinetics of SN-38 in rats and tissue distribution of 7-ethyl-10-hydroxycamptothecin in mice after intravenous injection of irinotecan hydrochloride nanoparticles]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25233635/),h,2.17,232211,DB00762,Irinotecan
,25233635,elimination half-life,"Compared with irinotecan solution, the elimination half-life of SN-38 was prolonged from 2.17 h to 2.67 h after the intravenous injection of CPT-11 NPs, but its AUC had little change.",[Pharmacokinetics of SN-38 in rats and tissue distribution of 7-ethyl-10-hydroxycamptothecin in mice after intravenous injection of irinotecan hydrochloride nanoparticles]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25233635/),h,2.67,232212,DB00762,Irinotecan
,23179335,response rate,"The response rate and progression-free survival at 4.0 mg/kg was 8.3 % and 7.59 months, respectively.",A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179335/),%,8.3,232228,DB00762,Irinotecan
,23179335,progression-free survival,"The response rate and progression-free survival at 4.0 mg/kg was 8.3 % and 7.59 months, respectively.",A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179335/),month,7.59,232229,DB00762,Irinotecan
,23179335,RPTD,The RPTD of aflibercept in combination with FOLFIRI for Japanese patients with mCRC was determined to be 4.0 mg/kg every 2 weeks.,A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179335/),[mg] / [kg],4.0,232230,DB00762,Irinotecan
,20461774,AUC ratio,Mean peritoneal SN-38: CPT-11 AUC ratio was 0.043.,Pharmacokinetics of intraperitoneal irinotecan in a pig model. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20461774/),,0.043,232709,DB00762,Irinotecan
,32393425,IC50,"In the liver microsome incubation system, the IC50 of CsA for UGT1A1 enzyme was 9.4 μM.",Effects of cyclosporin A on the pharmacokinetics and toxicities of irinotecan mediated by UGT1A1 in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32393425/),μM,9.4,235530,DB00762,Irinotecan
>,17015056,half-life [t(1/2 beta)],"Of 188 patients, 3 (1.6%) had marked alterations of 5-FU/5-FDHU pharmacokinetics (ie, 5-FU half-life [t(1/2 beta)] >5 hours, 5-FU total body clearance [CL(TB)] <1 L x h(-1) x m(-2), and 5-FDHU time to reach maximum plasma concentration [t max] > or = 45 minutes); they were excluded from 5-FU treatments and treated with irinotecan, which was well tolerated.",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),h,5,237401,DB00762,Irinotecan
<,17015056,total body clearance [CL(TB)],"Of 188 patients, 3 (1.6%) had marked alterations of 5-FU/5-FDHU pharmacokinetics (ie, 5-FU half-life [t(1/2 beta)] >5 hours, 5-FU total body clearance [CL(TB)] <1 L x h(-1) x m(-2), and 5-FDHU time to reach maximum plasma concentration [t max] > or = 45 minutes); they were excluded from 5-FU treatments and treated with irinotecan, which was well tolerated.",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),[l] / [(m)^2·h],1,237402,DB00762,Irinotecan
> or =,17015056,time to reach maximum plasma concentration [t max],"Of 188 patients, 3 (1.6%) had marked alterations of 5-FU/5-FDHU pharmacokinetics (ie, 5-FU half-life [t(1/2 beta)] >5 hours, 5-FU total body clearance [CL(TB)] <1 L x h(-1) x m(-2), and 5-FDHU time to reach maximum plasma concentration [t max] > or = 45 minutes); they were excluded from 5-FU treatments and treated with irinotecan, which was well tolerated.",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),min,45,237403,DB00762,Irinotecan
,17015056,area under the curve (AUC),"The plasma disposition of 5-FU in the remaining 185 patients revealed an area under the curve (AUC) of 3.73 +/- 2.18 h x microg/mL (mean +/- SD), maximum plasma concentration (Cmax) of 16.78 +/- 8.61 microg/mL, and t(1/2 beta) of 0.16 +/- 0.15 hour, whereas the CL(TB) was 65.67 +/- 31.86 L x h(-1) x m(-2).",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),[h·μg] / [ml],3.73,237404,DB00762,Irinotecan
,17015056,maximum plasma concentration (Cmax),"The plasma disposition of 5-FU in the remaining 185 patients revealed an area under the curve (AUC) of 3.73 +/- 2.18 h x microg/mL (mean +/- SD), maximum plasma concentration (Cmax) of 16.78 +/- 8.61 microg/mL, and t(1/2 beta) of 0.16 +/- 0.15 hour, whereas the CL(TB) was 65.67 +/- 31.86 L x h(-1) x m(-2).",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),[μg] / [ml],16.78,237405,DB00762,Irinotecan
,17015056,t(1/2 beta),"The plasma disposition of 5-FU in the remaining 185 patients revealed an area under the curve (AUC) of 3.73 +/- 2.18 h x microg/mL (mean +/- SD), maximum plasma concentration (Cmax) of 16.78 +/- 8.61 microg/mL, and t(1/2 beta) of 0.16 +/- 0.15 hour, whereas the CL(TB) was 65.67 +/- 31.86 L x h(-1) x m(-2).",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),h,0.16,237406,DB00762,Irinotecan
,17015056,CL(TB),"The plasma disposition of 5-FU in the remaining 185 patients revealed an area under the curve (AUC) of 3.73 +/- 2.18 h x microg/mL (mean +/- SD), maximum plasma concentration (Cmax) of 16.78 +/- 8.61 microg/mL, and t(1/2 beta) of 0.16 +/- 0.15 hour, whereas the CL(TB) was 65.67 +/- 31.86 L x h(-1) x m(-2).",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),[l] / [(m)^2·h],65.67,237407,DB00762,Irinotecan
,17015056,Cmax,"The 5-FDHU plasma profile showed a Cmax value of 3.64 +/- 1.94 microg/mL, whereas the t max value was 26.63 +/- 10.06 minutes, with an AUC value of 3.71 +/- 1.90 h x microg/mL.",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),[μg] / [ml],3.64,237408,DB00762,Irinotecan
,17015056,t max,"The 5-FDHU plasma profile showed a Cmax value of 3.64 +/- 1.94 microg/mL, whereas the t max value was 26.63 +/- 10.06 minutes, with an AUC value of 3.71 +/- 1.90 h x microg/mL.",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),min,26.63,237409,DB00762,Irinotecan
,17015056,AUC,"The 5-FDHU plasma profile showed a Cmax value of 3.64 +/- 1.94 microg/mL, whereas the t max value was 26.63 +/- 10.06 minutes, with an AUC value of 3.71 +/- 1.90 h x microg/mL.",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),[h·μg] / [ml],3.71,237410,DB00762,Irinotecan
,17015056,activity,"The PBMC DPD activity was 202.15 +/- 141.14 pmol 5-FDHU x min(-1) x mg(-1) protein (95% confidence interval, 165-239.3 pmol 5-FDHU x min(-1) x mg(-1) protein).",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),[5-fdhu·pM] / [mg·min],202.15,237411,DB00762,Irinotecan
greater,17015056,t max,"Interestingly, no relationships between PBMC DPD activity and common toxicities were found, whereas 5-FDHU t max values greater than 30 minutes were associated with the risk of moderate to severe neutropenia and diarrhea (P = .0323 and P = .0138, respectively; chi-square test).",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),min,30,237412,DB00762,Irinotecan
,23921573,C max,"The co-administration of MK-0646 with cetuximab and irinotecan did not affect the PK of cetuximab and irinotecan, but reduced the C max (from 16.8 to 13.0 ng/mL) and the AUC0-24h (by 13 %) of SN-38, the active metabolite of irinotecan.","Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23921573/),[ng] / [ml],16.8,240172,DB00762,Irinotecan
,23921573,C max,"The co-administration of MK-0646 with cetuximab and irinotecan did not affect the PK of cetuximab and irinotecan, but reduced the C max (from 16.8 to 13.0 ng/mL) and the AUC0-24h (by 13 %) of SN-38, the active metabolite of irinotecan.","Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23921573/),[ng] / [ml],13.0,240173,DB00762,Irinotecan
,21585373,half-life,"Pegylated liposomal irinotecan loaded with sbe-CD/triethylammonium gradient had irinotecan half-life values ranging from 9.4 to 13.1 h, surpassing vesicles prepared by the triethylammonium sulfate method (∼4.5 h).",Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21585373/),h,9.4 to 13.1,240977,DB00762,Irinotecan
,21585373,half-life,"Pegylated liposomal irinotecan loaded with sbe-CD/triethylammonium gradient had irinotecan half-life values ranging from 9.4 to 13.1 h, surpassing vesicles prepared by the triethylammonium sulfate method (∼4.5 h).",Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21585373/),h,∼4.5,240978,DB00762,Irinotecan
,31924737,progression-free survival,"The median progression-free survival was 7.9 months (95% confidence interval, 5.1-13.4 months).",Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31924737/),month,7.9,241197,DB00762,Irinotecan
,15936253,total body clearance (CL),"Accordingly, the value of total body clearance (CL) of CPT-11 lactone was significantly lower in combination group compared to the control (1.329 versus 1.837 L/h/kg, P = 0.0002).",Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15936253/),[l] / [h·kg],1.329,241595,DB00762,Irinotecan
,15936253,total body clearance (CL),"Accordingly, the value of total body clearance (CL) of CPT-11 lactone was significantly lower in combination group compared to the control (1.329 versus 1.837 L/h/kg, P = 0.0002).",Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15936253/),[l] / [h·kg],1.837,241596,DB00762,Irinotecan
,14551303,MTD,MTD was 600 mg/m2 in both cohorts.,A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551303/),[mg] / [m2],600,247143,DB00762,Irinotecan
,14551303,plasma clearance,"The mean +/- standard deviation (SD) CPT-11 plasma clearance was 20.7 +/- 9.5 L/h/m2 (range, 5 to 54).",A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551303/),[l] / [h·m2],20.7,247144,DB00762,Irinotecan
,14551303,metabolic ratio,"The mean +/- SD SN-38 metabolic ratio was 1.5% +/- 1.1% (range, 0.15% to 5.55%).",A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551303/),%,1.5,247145,DB00762,Irinotecan
,15909526,run time,"Fast separation of SN-38, CPT-11 and CPT was carried out isocratically on a C18, 2 mm x 50 mm, 5 microm HPLC column with a mobile phase containing acetonitrile and 20 mM ammonium acetate (pH 3.5) and a 2.5 min chromatographic run time.",Liquid chromatographic-tandem mass spectrometric assay for the simultaneous quantification of Camptosar and its metabolite SN-38 in mouse plasma and tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909526/),min,2.5,249694,DB00762,Irinotecan
,24596626,Cmax,"Cmax, t1/2, AUC0-30h and AUC0-∞ were 16.1 ± 2.7 g/ml, 7.6 ± 1.2 h, 71.3 ± 8.8 μg·h/ml and 82.3 ± 9.5 μg·h/ml, respectively.",Formulation and evaluation of irinotecan suppository for rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24596626/),[g] / [ml],16.1,249703,DB00762,Irinotecan
,24596626,t1/2,"Cmax, t1/2, AUC0-30h and AUC0-∞ were 16.1 ± 2.7 g/ml, 7.6 ± 1.2 h, 71.3 ± 8.8 μg·h/ml and 82.3 ± 9.5 μg·h/ml, respectively.",Formulation and evaluation of irinotecan suppository for rectal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24596626/),h,7.6,249704,DB00762,Irinotecan
,24596626,t1/2,"Cmax, t1/2, AUC0-30h and AUC0-∞ were 16.1 ± 2.7 g/ml, 7.6 ± 1.2 h, 71.3 ± 8.8 μg·h/ml and 82.3 ± 9.5 μg·h/ml, respectively.",Formulation and evaluation of irinotecan suppository for rectal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24596626/),[h·μg] / [ml],71.3,249705,DB00762,Irinotecan
,24596626,AUC0-30h,"Cmax, t1/2, AUC0-30h and AUC0-∞ were 16.1 ± 2.7 g/ml, 7.6 ± 1.2 h, 71.3 ± 8.8 μg·h/ml and 82.3 ± 9.5 μg·h/ml, respectively.",Formulation and evaluation of irinotecan suppository for rectal administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24596626/),h,7.6,249706,DB00762,Irinotecan
,24596626,AUC0-30h,"Cmax, t1/2, AUC0-30h and AUC0-∞ were 16.1 ± 2.7 g/ml, 7.6 ± 1.2 h, 71.3 ± 8.8 μg·h/ml and 82.3 ± 9.5 μg·h/ml, respectively.",Formulation and evaluation of irinotecan suppository for rectal administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24596626/),[h·μg] / [ml],71.3,249707,DB00762,Irinotecan
,24596626,AUC0-∞,"Cmax, t1/2, AUC0-30h and AUC0-∞ were 16.1 ± 2.7 g/ml, 7.6 ± 1.2 h, 71.3 ± 8.8 μg·h/ml and 82.3 ± 9.5 μg·h/ml, respectively.",Formulation and evaluation of irinotecan suppository for rectal administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24596626/),[h·μg] / [ml],82.3,249708,DB00762,Irinotecan
,24596626,AUC0-30h,"The AUC0-30h and AUC0-∞ were 32.2 ± 6.2 μg·h/ml and 41.6 ± 7.2 μg·h/ml, respectively.",Formulation and evaluation of irinotecan suppository for rectal administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24596626/),[h·μg] / [ml],32.2,249709,DB00762,Irinotecan
,24596626,AUC0-∞,"The AUC0-30h and AUC0-∞ were 32.2 ± 6.2 μg·h/ml and 41.6 ± 7.2 μg·h/ml, respectively.",Formulation and evaluation of irinotecan suppository for rectal administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24596626/),[h·μg] / [ml],41.6,249710,DB00762,Irinotecan
,24596626,absolute bioavailability,It representing ∼50.6% of the absolute bioavailability.,Formulation and evaluation of irinotecan suppository for rectal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24596626/),%,∼50.6,249711,DB00762,Irinotecan
,22610355,AUC,The dose of CPT-11 was administered at a fixed dose of 60 mg/m(2) and that of NDP was gradually increased from 8 to 12 μg h/mL (AUC).,Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22610355/),[h·μg] / [ml],8,250162,DB00762,Irinotecan
,22610355,AUC,The dose of CPT-11 was administered at a fixed dose of 60 mg/m(2) and that of NDP was gradually increased from 8 to 12 μg h/mL (AUC).,Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22610355/),[h·μg] / [ml],12,250163,DB00762,Irinotecan
,12351598,objective response rate,"In five patients (11.9%) a complete and in 25 (59.5%) a partial response was demonstrated, for an objective response rate of 71.4% (95% confidence interval, 47% to 83%).","Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12351598/),%,71.4,253135,DB00762,Irinotecan
,12351598,progression-free,"Median progression-free and overall survival times were 10.4 and 26.5 months, respectively.","Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12351598/),month,10.4,253136,DB00762,Irinotecan
,12351598,overall survival times,"Median progression-free and overall survival times were 10.4 and 26.5 months, respectively.","Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12351598/),month,26.5,253137,DB00762,Irinotecan
,11839656,MTD,The MTD was 25 mg/m(2)/day and the dose-limiting toxicities were neutropenia and diarrhea.,Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839656/),mg,25,253651,DB00762,Irinotecan
,11839656,MTD,The MTD of CPT-11 given by hepatic 5-day continuous infusion was 25 mg/m(2)/day.,Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839656/),[mg] / [m],25,253652,DB00762,Irinotecan
,10473080,la,CPT-11 lactone clearance was similar to single agent data and not significantly different between study courses (60.4 +/- 17.1 versus 65.5 +/- 16.3 liter/h/m2; P = 0.66).,Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10473080/),[l] / [h·m2],60.4,255185,DB00762,Irinotecan
,10473080,la,CPT-11 lactone clearance was similar to single agent data and not significantly different between study courses (60.4 +/- 17.1 versus 65.5 +/- 16.3 liter/h/m2; P = 0.66).,Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10473080/),[l] / [h·m2],65.5,255186,DB00762,Irinotecan
,10473080,clearance,CPT-11 lactone clearance was similar to single agent data and not significantly different between study courses (60.4 +/- 17.1 versus 65.5 +/- 16.3 liter/h/m2; P = 0.66).,Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10473080/),[l] / [h·m2],60.4,255187,DB00762,Irinotecan
,10473080,clearance,CPT-11 lactone clearance was similar to single agent data and not significantly different between study courses (60.4 +/- 17.1 versus 65.5 +/- 16.3 liter/h/m2; P = 0.66).,Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10473080/),[l] / [h·m2],65.5,255188,DB00762,Irinotecan
,10473080,clearance,"In addition, CPT-11 had no influence on the clearance of nonprotein-bound CDDP (40.8 +/- 16.7 versus 50.3 +/- 18.6 liter/h/m2; P = 0.08) and the platinum DNA-adduct formation in peripheral leukocytes in either sequence (1.94 +/- 2.20 versus 2.42 +/- 1.62 pg Pt/microg DNA; P = 0.41).",Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10473080/),[l] / [h·m2],40.8,255189,DB00762,Irinotecan
,10473080,clearance,"In addition, CPT-11 had no influence on the clearance of nonprotein-bound CDDP (40.8 +/- 16.7 versus 50.3 +/- 18.6 liter/h/m2; P = 0.08) and the platinum DNA-adduct formation in peripheral leukocytes in either sequence (1.94 +/- 2.20 versus 2.42 +/- 1.62 pg Pt/microg DNA; P = 0.41).",Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10473080/),[l] / [h·m2],50.3,255190,DB00762,Irinotecan
,10473080,DNA-adduct formation,"In addition, CPT-11 had no influence on the clearance of nonprotein-bound CDDP (40.8 +/- 16.7 versus 50.3 +/- 18.6 liter/h/m2; P = 0.08) and the platinum DNA-adduct formation in peripheral leukocytes in either sequence (1.94 +/- 2.20 versus 2.42 +/- 1.62 pg Pt/microg DNA; P = 0.41).",Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10473080/),pg,1.94,255191,DB00762,Irinotecan
,10473080,DNA-adduct formation,"In addition, CPT-11 had no influence on the clearance of nonprotein-bound CDDP (40.8 +/- 16.7 versus 50.3 +/- 18.6 liter/h/m2; P = 0.08) and the platinum DNA-adduct formation in peripheral leukocytes in either sequence (1.94 +/- 2.20 versus 2.42 +/- 1.62 pg Pt/microg DNA; P = 0.41).",Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10473080/),pg,2.42,255192,DB00762,Irinotecan
,23046546,survival time,"The median survival time were 22, 37 and 54 days in the control, CPT-11-treated, and IHL-305-treated mice, respectively.",PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23046546/),d,22,255869,DB00762,Irinotecan
,23046546,survival time,"The median survival time were 22, 37 and 54 days in the control, CPT-11-treated, and IHL-305-treated mice, respectively.",PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23046546/),d,37,255870,DB00762,Irinotecan
,23046546,survival time,"The median survival time were 22, 37 and 54 days in the control, CPT-11-treated, and IHL-305-treated mice, respectively.",PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23046546/),d,54,255871,DB00762,Irinotecan
,23328499,50% inhibition concentration (IC50),"SN-38 glucuronidation in human and rat liver microsomes was inhibited dose-dependently by the presence of tacrolimus and the 50% inhibition concentration (IC50) values of tacrolimus in rat and human liver microsomes were 10.33 μM and 3.58 μM, respectively.","[Effect of tacrolimus on the pharmacokinetics and glucuronidation of SN-38, an active metabolite of irinotecan]. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328499/),μM,10.33,256392,DB00762,Irinotecan
,23328499,50% inhibition concentration (IC50),"SN-38 glucuronidation in human and rat liver microsomes was inhibited dose-dependently by the presence of tacrolimus and the 50% inhibition concentration (IC50) values of tacrolimus in rat and human liver microsomes were 10.33 μM and 3.58 μM, respectively.","[Effect of tacrolimus on the pharmacokinetics and glucuronidation of SN-38, an active metabolite of irinotecan]. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328499/),μM,3.58,256393,DB00762,Irinotecan
,23328499,inhibition constant (Ki),"When the inhibition type was determined by Lineweaver-Burk and Dixon plots, the inhibition was noncompetitive and the calculated inhibition constant (Ki) values for rat and human liver microsomes were 12.57 μM and 3.88 μM, respectively.","[Effect of tacrolimus on the pharmacokinetics and glucuronidation of SN-38, an active metabolite of irinotecan]. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328499/),μM,12.57,256394,DB00762,Irinotecan
,23328499,inhibition constant (Ki),"When the inhibition type was determined by Lineweaver-Burk and Dixon plots, the inhibition was noncompetitive and the calculated inhibition constant (Ki) values for rat and human liver microsomes were 12.57 μM and 3.88 μM, respectively.","[Effect of tacrolimus on the pharmacokinetics and glucuronidation of SN-38, an active metabolite of irinotecan]. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328499/),μM,3.88,256395,DB00762,Irinotecan
,19171709,area under the plasma concentration versus time curve,The median SN-38 lactone area under the plasma concentration versus time curve at this dose was 72 ng . hr/mL.,Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19171709/),[h·ng] / [ml],72,256758,DB00762,Irinotecan
,23505115,flow rate,"The concentrations of SN-38 were measured by LC-MS/MS method with Agilent Eclipse Plus C18 (2.1 mm ×100 mm, 1.8 μm) reversed phase column using acetonitrile-0.1% methanoic acid as mobile phase with gradient elution at a flow rate of 0.3 ml/min and temperature at 35 degree.",[Determination of 7-ethyl-10-hydroxycamptothecin in microdialysates from rat brain with LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23505115/),[ml] / [min],0.3,257350,DB00762,Irinotecan
,23505115,recovery of,The recovery of assay for SN-38 ranged from 97.54%-100.60%.,[Determination of 7-ethyl-10-hydroxycamptothecin in microdialysates from rat brain with LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23505115/),%,97.54,257351,DB00762,Irinotecan
,23505115,recovery of,The recovery of assay for SN-38 ranged from 97.54%-100.60%.,[Determination of 7-ethyl-10-hydroxycamptothecin in microdialysates from rat brain with LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23505115/),%,100.60,257352,DB00762,Irinotecan
,17195945,T(max),"However, SN-38 T(max) was longer on Day 8 (0.88 h vs. 1.23 h, p = 0.012).",Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17195945/),h,0.88,257590,DB00762,Irinotecan
,17195945,T(max),"However, SN-38 T(max) was longer on Day 8 (0.88 h vs. 1.23 h, p = 0.012).",Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17195945/),h,1.23,257591,DB00762,Irinotecan
,11533095,plasma clearance of unbound cisplatin (CL(free)),"The mean plasma clearance of unbound cisplatin (CL(free)) was 57.1 +/- 14.7 L/h (range, 31.0 to 116 L/h), with an interpatient variability of 25.6%.",Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11533095/),[l] / [h],57.1,262601,DB00762,Irinotecan
,11533095,BSA,"BSA varied between 1.43 and 2.40 m(2) (mean, 1.86 +/- 0.19 m(2)), with an interpatient variability of 10.4%.",Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11533095/),m(2),1.86,262602,DB00762,Irinotecan
>,21796439,response rate,A response rate >55% was sought.,A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796439/),%,55,262719,DB00762,Irinotecan
,21796439,exposure (,"Median (range) systemic irinotecan exposure (AUC) was 283 ng/ml*hr (range, 163-890 ng/ml*hr) and 28 ng/ml*hr (3.6-297 ng/ml*hr) for the active metabolite, SN-38.",A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796439/),[ng] / [h·ml],283,262720,DB00762,Irinotecan
,21796439,AUC),"Median (range) systemic irinotecan exposure (AUC) was 283 ng/ml*hr (range, 163-890 ng/ml*hr) and 28 ng/ml*hr (3.6-297 ng/ml*hr) for the active metabolite, SN-38.",A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796439/),[ng] / [h·ml],283,262721,DB00762,Irinotecan
,21796439,AUC),"Median (range) systemic irinotecan exposure (AUC) was 283 ng/ml*hr (range, 163-890 ng/ml*hr) and 28 ng/ml*hr (3.6-297 ng/ml*hr) for the active metabolite, SN-38.",A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796439/),[ng] / [h·ml],28,262722,DB00762,Irinotecan
,30199708,IC50,"Antitumor activity screening assay indicated that BGC0222 exhibited better in vitro antiproliferation activity than irinotecan and NKTR-102 against HT29, MIA PaCa-2 and MCF-7 tumor cell lines, with IC50 of 1.83 ± 0.09 μM, 3.95 ± 0.16 μM and 0.68 ± 0.04 μM, respectively, while it displayed better in vivo antiproliferation activity than irinotecan and NKTR-102 in HT-29, MIA PaCa-2, NCI-H446, U-87 MG and MDA-MB-231 xenograft models.","Design, synthesis and pharmacological evaluation of a novel PEG-cRGD-conjugated irinotecan derivative as potential antitumor agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30199708/),μM,1.83,266037,DB00762,Irinotecan
,30199708,IC50,"Antitumor activity screening assay indicated that BGC0222 exhibited better in vitro antiproliferation activity than irinotecan and NKTR-102 against HT29, MIA PaCa-2 and MCF-7 tumor cell lines, with IC50 of 1.83 ± 0.09 μM, 3.95 ± 0.16 μM and 0.68 ± 0.04 μM, respectively, while it displayed better in vivo antiproliferation activity than irinotecan and NKTR-102 in HT-29, MIA PaCa-2, NCI-H446, U-87 MG and MDA-MB-231 xenograft models.","Design, synthesis and pharmacological evaluation of a novel PEG-cRGD-conjugated irinotecan derivative as potential antitumor agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30199708/),μM,3.95,266038,DB00762,Irinotecan
,30199708,IC50,"Antitumor activity screening assay indicated that BGC0222 exhibited better in vitro antiproliferation activity than irinotecan and NKTR-102 against HT29, MIA PaCa-2 and MCF-7 tumor cell lines, with IC50 of 1.83 ± 0.09 μM, 3.95 ± 0.16 μM and 0.68 ± 0.04 μM, respectively, while it displayed better in vivo antiproliferation activity than irinotecan and NKTR-102 in HT-29, MIA PaCa-2, NCI-H446, U-87 MG and MDA-MB-231 xenograft models.","Design, synthesis and pharmacological evaluation of a novel PEG-cRGD-conjugated irinotecan derivative as potential antitumor agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30199708/),μM,0.68,266039,DB00762,Irinotecan
,17237473,objective tumour response rate,"For the patients treated at RDL, the objective tumour response rate was 11.1% (95% confidence interval 2.4% to 29.2%) and median survival was 9.3 months.","Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17237473/),%,11.1,268674,DB00762,Irinotecan
,22134116,vesi,"Mean vesicle size was 45-65 nm for liposome preparations downsized by homogenization, and 80-100 nm when downsized by extrusion, the latter displaying narrower polydispersity.",Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22134116/),nm,45-65,269030,DB00762,Irinotecan
,22134116,vesi,"Mean vesicle size was 45-65 nm for liposome preparations downsized by homogenization, and 80-100 nm when downsized by extrusion, the latter displaying narrower polydispersity.",Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22134116/),,80-100,269031,DB00762,Irinotecan
,22134116,to,MLP to phospholipid mole ratio was 5% (~20 μg MMC-equivalents/μmol).,Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22134116/),%,5,269032,DB00762,Irinotecan
,22134116,mole ratio,MLP to phospholipid mole ratio was 5% (~20 μg MMC-equivalents/μmol).,Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22134116/),%,5,269033,DB00762,Irinotecan
,22134116,mole ratio,MLP to phospholipid mole ratio was 5% (~20 μg MMC-equivalents/μmol).,Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22134116/),μg,20,269034,DB00762,Irinotecan
,28744667,OS,"Median OS was 11.5, 12.9, 16.4, and 16.7, and 12.4 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,11.5,269160,DB00762,Irinotecan
,28744667,OS,"Median OS was 11.5, 12.9, 16.4, and 16.7, and 12.4 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,12.9,269161,DB00762,Irinotecan
,28744667,OS,"Median OS was 11.5, 12.9, 16.4, and 16.7, and 12.4 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,16.4,269162,DB00762,Irinotecan
,28744667,OS,"Median OS was 11.5, 12.9, 16.4, and 16.7, and 12.4 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,16.7,269163,DB00762,Irinotecan
,28744667,OS,"Median OS was 11.5, 12.9, 16.4, and 16.7, and 12.4 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,12.4,269164,DB00762,Irinotecan
,28744667,PFS,"Median PFS was 5.4, 4.6, 6.8, 8.5, and 5.2 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,5.4,269165,DB00762,Irinotecan
,28744667,PFS,"Median PFS was 5.4, 4.6, 6.8, 8.5, and 5.2 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,4.6,269166,DB00762,Irinotecan
,28744667,PFS,"Median PFS was 5.4, 4.6, 6.8, 8.5, and 5.2 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,6.8,269167,DB00762,Irinotecan
,28744667,PFS,"Median PFS was 5.4, 4.6, 6.8, 8.5, and 5.2 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,8.5,269168,DB00762,Irinotecan
,28744667,PFS,"Median PFS was 5.4, 4.6, 6.8, 8.5, and 5.2 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,5.2,269169,DB00762,Irinotecan
,17982652,terminal half-life (t(1/2)),"The estimated pharmacokinetic parameters of irinotecan [terminal half-life (t(1/2)), 11.5 h; total clearance (CL), 25.0 l h(-1); area under curve (AUC), 14.9 mg x h l(-1)] and SN-38 (terminal t(1/2), 32.2 h; AUC, 0.42 mg x h l(-1)) were similar to those determined in other studies.","A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982652/),h,11.5,269647,DB00762,Irinotecan
,17982652,total clearance (CL),"The estimated pharmacokinetic parameters of irinotecan [terminal half-life (t(1/2)), 11.5 h; total clearance (CL), 25.0 l h(-1); area under curve (AUC), 14.9 mg x h l(-1)] and SN-38 (terminal t(1/2), 32.2 h; AUC, 0.42 mg x h l(-1)) were similar to those determined in other studies.","A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982652/),[l] / [h],25.0,269648,DB00762,Irinotecan
,17982652,area under curve (AUC),"The estimated pharmacokinetic parameters of irinotecan [terminal half-life (t(1/2)), 11.5 h; total clearance (CL), 25.0 l h(-1); area under curve (AUC), 14.9 mg x h l(-1)] and SN-38 (terminal t(1/2), 32.2 h; AUC, 0.42 mg x h l(-1)) were similar to those determined in other studies.","A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982652/),[h·mg] / [l],14.9,269649,DB00762,Irinotecan
,17982652,terminal t(1/2),"The estimated pharmacokinetic parameters of irinotecan [terminal half-life (t(1/2)), 11.5 h; total clearance (CL), 25.0 l h(-1); area under curve (AUC), 14.9 mg x h l(-1)] and SN-38 (terminal t(1/2), 32.2 h; AUC, 0.42 mg x h l(-1)) were similar to those determined in other studies.","A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982652/),h,32.2,269650,DB00762,Irinotecan
,17982652,AUC,"The estimated pharmacokinetic parameters of irinotecan [terminal half-life (t(1/2)), 11.5 h; total clearance (CL), 25.0 l h(-1); area under curve (AUC), 14.9 mg x h l(-1)] and SN-38 (terminal t(1/2), 32.2 h; AUC, 0.42 mg x h l(-1)) were similar to those determined in other studies.","A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982652/),[h·mg] / [l],0.42,269651,DB00762,Irinotecan
,9193346,elimination half-life (t1/2),"CPT-11 exhibited a mean elimination half-life (t1/2) of 8.8 hours, an average clearance (CL) of 14.6 L/h/m2, and a mean volume of distribution at steady-state (Vdss) of 136 L/m2.",Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193346/),h,8.8,269712,DB00762,Irinotecan
,9193346,clearance (CL),"CPT-11 exhibited a mean elimination half-life (t1/2) of 8.8 hours, an average clearance (CL) of 14.6 L/h/m2, and a mean volume of distribution at steady-state (Vdss) of 136 L/m2.",Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193346/),[l] / [h·m2],14.6,269713,DB00762,Irinotecan
,9193346,volume of distribution at steady-state (Vdss),"CPT-11 exhibited a mean elimination half-life (t1/2) of 8.8 hours, an average clearance (CL) of 14.6 L/h/m2, and a mean volume of distribution at steady-state (Vdss) of 136 L/m2.",Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193346/),[l] / [m2],136,269714,DB00762,Irinotecan
,9193346,plasma availabilities,"SN-38 and SN-38G had low plasma availabilities (3% and 10% relative to CPT-11), with mean t1/2 values of 11.6 and 10.5 hours, respectively.",Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193346/),%,3,269715,DB00762,Irinotecan
,9193346,plasma availabilities,"SN-38 and SN-38G had low plasma availabilities (3% and 10% relative to CPT-11), with mean t1/2 values of 11.6 and 10.5 hours, respectively.",Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193346/),%,10,269716,DB00762,Irinotecan
,9193346,t1/2,"SN-38 and SN-38G had low plasma availabilities (3% and 10% relative to CPT-11), with mean t1/2 values of 11.6 and 10.5 hours, respectively.",Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193346/),h,11.6,269717,DB00762,Irinotecan
,9193346,t1/2,"SN-38 and SN-38G had low plasma availabilities (3% and 10% relative to CPT-11), with mean t1/2 values of 11.6 and 10.5 hours, respectively.",Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193346/),h,10.5,269718,DB00762,Irinotecan
,7786822,terminal half-life,"Model-independent analysis yielded the following mean population pharmacokinetic parameters for CPT-11: a terminal half-life of 10.8 h, a mean residence time (MRT) of 10.7 h, a volume of distribution at steady state (Vdss) of 150 L/m2, and a total body clearance of 14.3 L/m2/h.",Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786822/),h,10.8,269789,DB00762,Irinotecan
,7786822,mean residence time (MRT),"Model-independent analysis yielded the following mean population pharmacokinetic parameters for CPT-11: a terminal half-life of 10.8 h, a mean residence time (MRT) of 10.7 h, a volume of distribution at steady state (Vdss) of 150 L/m2, and a total body clearance of 14.3 L/m2/h.",Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786822/),h,10.7,269790,DB00762,Irinotecan
,7786822,volume of distribution at steady state (Vdss),"Model-independent analysis yielded the following mean population pharmacokinetic parameters for CPT-11: a terminal half-life of 10.8 h, a mean residence time (MRT) of 10.7 h, a volume of distribution at steady state (Vdss) of 150 L/m2, and a total body clearance of 14.3 L/m2/h.",Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786822/),[l] / [m2],150,269791,DB00762,Irinotecan
,7786822,total body clearance,"Model-independent analysis yielded the following mean population pharmacokinetic parameters for CPT-11: a terminal half-life of 10.8 h, a mean residence time (MRT) of 10.7 h, a volume of distribution at steady state (Vdss) of 150 L/m2, and a total body clearance of 14.3 L/m2/h.",Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786822/),[l] / [h·m2],14.3,269792,DB00762,Irinotecan
,7786822,terminal half-life,Model-dependent analysis disclosed a CPT-11 plasma disposition as either biphasic or triphasic with a mean terminal half-life of 12.0 h.,Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786822/),h,12.0,269793,DB00762,Irinotecan
,7786822,volume of distribution Vdss,The volume of distribution Vdss (150 L/m2) and total body clearance (14.8 L/m2/h) yielded almost identical values to the above model-independent analysis.,Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786822/),[l] / [m2],150,269794,DB00762,Irinotecan
,7786822,total body clearance,The volume of distribution Vdss (150 L/m2) and total body clearance (14.8 L/m2/h) yielded almost identical values to the above model-independent analysis.,Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786822/),[l] / [h·m2],14.8,269795,DB00762,Irinotecan
,7786822,apparent terminal half-life,SN-38 plasma decay followed closely that of the parent compound with a mean apparent terminal half-life of 10.6 h.,Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786822/),h,10.6,269796,DB00762,Irinotecan
,31509102,fecal,"PK studies revealed that the fecal concentrations of irinotecan and SN-38 were significantly decreased from 818.35 ± 120.2 to 411.74 ± 138.83 µg/g or from 423.95 ± 76.44 to 245.63 ± 56.72 µg/g (p<0.05) by XCHT, respectively, suggesting the colonic exposure of SN-38 is significantly decreased by XCHT.",Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan's Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31509102/),µ,818.35,269988,DB00762,Irinotecan
,31509102,fecal,"PK studies revealed that the fecal concentrations of irinotecan and SN-38 were significantly decreased from 818.35 ± 120.2 to 411.74 ± 138.83 µg/g or from 423.95 ± 76.44 to 245.63 ± 56.72 µg/g (p<0.05) by XCHT, respectively, suggesting the colonic exposure of SN-38 is significantly decreased by XCHT.",Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan's Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31509102/),µ,411.74,269989,DB00762,Irinotecan
,31509102,fecal,"PK studies revealed that the fecal concentrations of irinotecan and SN-38 were significantly decreased from 818.35 ± 120.2 to 411.74 ± 138.83 µg/g or from 423.95 ± 76.44 to 245.63 ± 56.72 µg/g (p<0.05) by XCHT, respectively, suggesting the colonic exposure of SN-38 is significantly decreased by XCHT.",Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan's Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31509102/),[μg] / [g],423.95,269990,DB00762,Irinotecan
,31509102,fecal,"PK studies revealed that the fecal concentrations of irinotecan and SN-38 were significantly decreased from 818.35 ± 120.2 to 411.74 ± 138.83 µg/g or from 423.95 ± 76.44 to 245.63 ± 56.72 µg/g (p<0.05) by XCHT, respectively, suggesting the colonic exposure of SN-38 is significantly decreased by XCHT.",Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan's Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31509102/),[μg] / [g],245.63,269991,DB00762,Irinotecan
,1629304,recoveries,"Plasma samples were processed using a solid-phase (C18) extraction step allowing mean recoveries of I, II and the internal standard camptothecin (III) of 84, 99 and 72%, respectively.",Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629304/),%,84,271483,DB00762,Irinotecan
,1629304,recoveries,"Plasma samples were processed using a solid-phase (C18) extraction step allowing mean recoveries of I, II and the internal standard camptothecin (III) of 84, 99 and 72%, respectively.",Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629304/),%,99,271484,DB00762,Irinotecan
,1629304,recoveries,"Plasma samples were processed using a solid-phase (C18) extraction step allowing mean recoveries of I, II and the internal standard camptothecin (III) of 84, 99 and 72%, respectively.",Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629304/),%,72,271485,DB00762,Irinotecan
,1629304,peak plasma concentration,The mean peak plasma concentration of I at the end of the intravenous infusion was 2400 +/- 285 ng/ml (mean +/- standard error of the mean).,Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629304/),[ng] / [ml],2400,271486,DB00762,Irinotecan
,1629304,half-lives alpha,"Plasma decay was triphasic with half-lives alpha, beta and gamma of 5.4 +/- 1.8 min, 2.5 +/- 0.5 h and 20.2 +/- 4.6 h, respectively.",Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629304/),min,5.4,271487,DB00762,Irinotecan
,1629304,beta,"Plasma decay was triphasic with half-lives alpha, beta and gamma of 5.4 +/- 1.8 min, 2.5 +/- 0.5 h and 20.2 +/- 4.6 h, respectively.",Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629304/),h,2.5,271488,DB00762,Irinotecan
,1629304,beta,"Plasma decay was triphasic with half-lives alpha, beta and gamma of 5.4 +/- 1.8 min, 2.5 +/- 0.5 h and 20.2 +/- 4.6 h, respectively.",Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629304/),h,20.2,271489,DB00762,Irinotecan
,1629304,gamma,"Plasma decay was triphasic with half-lives alpha, beta and gamma of 5.4 +/- 1.8 min, 2.5 +/- 0.5 h and 20.2 +/- 4.6 h, respectively.",Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629304/),h,20.2,271490,DB00762,Irinotecan
,1629304,volume of distribution at steady state,"The volume of distribution at steady state was 105 +/- 15 l/m2, and the total body clearance was 12.5 +/- 1.9 l/h.m2.",Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629304/),[l] / [m2],105,271491,DB00762,Irinotecan
,1629304,total body clearance,"The volume of distribution at steady state was 105 +/- 15 l/m2, and the total body clearance was 12.5 +/- 1.9 l/h.m2.",Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629304/),[l] / [h·m2],12.5,271492,DB00762,Irinotecan
,1629304,maximum concentrations,The maximum concentrations of the active metabolite II reached 36 +/- 11 ng/ml.,Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1629304/),[ng] / [ml],36,271493,DB00762,Irinotecan
,24861663,tumor necrosis ratios,Significantly higher tumor necrosis ratios were observed in groups 1 (86.6%-90.0%) and 3 (90.0%-100%) compared with group 2 (63.3%-70%) (P = .031 and P = .016).,Pharmacokinetics and antitumor efficacy of chemoembolization using 40 µm irinotecan-loaded microspheres in a rabbit liver tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861663/),%,86,272206,DB00762,Irinotecan
,24861663,tumor necrosis ratios,Significantly higher tumor necrosis ratios were observed in groups 1 (86.6%-90.0%) and 3 (90.0%-100%) compared with group 2 (63.3%-70%) (P = .031 and P = .016).,Pharmacokinetics and antitumor efficacy of chemoembolization using 40 µm irinotecan-loaded microspheres in a rabbit liver tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861663/),%,90,272207,DB00762,Irinotecan
,24861663,tumor necrosis ratios,Significantly higher tumor necrosis ratios were observed in groups 1 (86.6%-90.0%) and 3 (90.0%-100%) compared with group 2 (63.3%-70%) (P = .031 and P = .016).,Pharmacokinetics and antitumor efficacy of chemoembolization using 40 µm irinotecan-loaded microspheres in a rabbit liver tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861663/),%,90.0,272208,DB00762,Irinotecan
,24861663,tumor necrosis ratios,Significantly higher tumor necrosis ratios were observed in groups 1 (86.6%-90.0%) and 3 (90.0%-100%) compared with group 2 (63.3%-70%) (P = .031 and P = .016).,Pharmacokinetics and antitumor efficacy of chemoembolization using 40 µm irinotecan-loaded microspheres in a rabbit liver tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861663/),%,100,272209,DB00762,Irinotecan
,24861663,tumor necrosis ratios,Significantly higher tumor necrosis ratios were observed in groups 1 (86.6%-90.0%) and 3 (90.0%-100%) compared with group 2 (63.3%-70%) (P = .031 and P = .016).,Pharmacokinetics and antitumor efficacy of chemoembolization using 40 µm irinotecan-loaded microspheres in a rabbit liver tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861663/),%,63,272210,DB00762,Irinotecan
,24861663,tumor necrosis ratios,Significantly higher tumor necrosis ratios were observed in groups 1 (86.6%-90.0%) and 3 (90.0%-100%) compared with group 2 (63.3%-70%) (P = .031 and P = .016).,Pharmacokinetics and antitumor efficacy of chemoembolization using 40 µm irinotecan-loaded microspheres in a rabbit liver tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861663/),%,70,272211,DB00762,Irinotecan
,15381932,time to treatment failure,"No significant differences in efficacy across the four arms were observed, although a shorter time to treatment failure was noted for arm D (1.7 months; P=0.02).",A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15381932/),month,1.7,272562,DB00762,Irinotecan
,15381932,Overall response rates,Overall response rates were in the range 5-11%.,A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15381932/),%,5-11,272563,DB00762,Irinotecan
,15381932,time to progression,"Secondary end points included median survival (6.4-9.4 months), and time to progression (2.7-3.8 months) and treatment failure (1.7-3.2 months).",A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15381932/),month,2.7-3.8,272564,DB00762,Irinotecan
,15381932,treatment failure,"Secondary end points included median survival (6.4-9.4 months), and time to progression (2.7-3.8 months) and treatment failure (1.7-3.2 months).",A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15381932/),month,1.7-3.2,272565,DB00762,Irinotecan
,15592838,MTD,The MTD was 30 mg/m2 per day.,Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592838/),[mg] / [m2],30,273244,DB00762,Irinotecan
,15592838,metabolic ratio of,The metabolic ratio of SN-38 AUC to irinotecan AUC was 0.17+/-0.10 (mean+/-SD).,Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592838/),,0.17,273245,DB00762,Irinotecan
